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Abstract 
AMP-activated protein kinase (AMPK) has been proposed to be a therapeutic target for 
patients with type 2 diabetes and the metabolic syndrome. In skeletal muscle AMPK 
stimulates glucose uptake and fatty acid oxidation, whereas in liver it inhibits fatty acid 
and cholesterol synthesis. The Rab GTPase activating proteins Akt substrate of 160 kDa 
(AS160) and tre-2/USP6, BUB2, cdc16 domain family member 1 (TBC1C1) have been 
identified as potential targets of both protein kinase B (PKB, also known as Akt) and 
AMPK which mediate glucose transporter 4 (GLUT4) translocation to the plasma 
membrane in response to insulin and 5-aminoimidazole-4-carboxamide riboside (AICAR) 
respectively in muscle. Previous work in our laboratory has demonstrated that AICAR 
modestly stimulates basal glucose transport, yet inhibits insulin-stimulated glucose 
transport in 3T3-L1 adipocytes, which is in contrast to the effect of AICAR in skeletal 
muscle.  Currently the role of AMPK in adipocytes remains poorly characterised despite 
the importance of fat tissue in energy homeostasis.  
To address this, the molecular mechanism of AMPK activation by known stimuli, the acute 
effect of various AMPK activators on glucose transport, the effect of AMPK inhibition and 
knockdown on AICAR mediated inhibition of insulin-stimulated glucose transport and the 
effect of acute AICAR treatment on PKB substrate phosphorylation in 3T3-L1 adipocytes 
was investigated. In addition the effect of sustained AMPK activation on glucose transport 
and insulin signaling in 3T3-L1 adipocytes, and the effect of sustained AMPK activation 
on insulin signaling in human adipose tissue was also investigated. 
The AMPK activators; sorbitol, metformin, rosiglitazone, arsenite, azide, hydrogen 
peroxide and isoproterenol were all shown to stimulate AMPK activity in the presence of 
the Ca2+/Calmodulin dependent protein kinase kinase (CaMKK) inhibitor STO-609, 
suggesting that these activators activate AMPK via a CaMKK-independent pathway in 
3T3-L1 adipocytes. However, A23187-stimulated AMPK activity was abrogated in the 
presence of STO-609. Isoproterenol, sodium azide and rosiglitazone, were all shown to 
cause an increase in the ADP/ATP ratio in 3T3-L1 adipocytes compared to control as 
assessed by high performance liquid chromatography, suggesting that they stimulate 
AMPK activity in an LKB1-dependent manner. These results suggest a possible role for 
CaMKK as an upstream AMPK kinase in 3T3-L1 adipocytes, in addition to LKB1. There 
may also exist other upstream AMPK kinases in 3T3-L1 adipocytes that are both 
nucleotide and calcium independent since sorbitol, metformin, arsenite, hydrogen peroxide 
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and leptin were found to activate AMPK independently of CaMKK and also showed no 
significant effect on adenine nucleotide ratios. 
Sorbitol, rosiglitazone, AICAR, isoproterenol and A769662 all significantly inhibited 
insulin-stimulated glucose transport. Furthermore, in the presence of the AMPK inhibitor, 
Compound C, the inhibitory effect of AICAR on insulin-stimulated glucose transport was 
no longer apparent. However, AICAR still displayed a tendency to inhibit insulin-
stimulated glucose transport in 3T3-L1 adipocytes infected with adenoviruses expressing a 
dominant negative AMPK mutant. 
The effect of AICAR on basal and insulin-stimulated AS160/TBC1D1 phosphorylation at 
phospho-Akt substrate (PAS) sites, was assessed. AICAR did not alter AS160/TBC1D1 
phosphorylation compared to basal levels, nor perturb insulin-stimulated AS160/TBC1D1 
phosphorylation at PAS sites. In addition, AICAR did not appear to alter the 
phosphorylation of any other proteins at PAS sites.   
Prolonged AMPK activation by AICAR in 3T3-L1 adipocytes also significantly inhibited 
insulin-stimulated glucose transport and was not associated with altered PKB protein 
expression or insulin-stimulated PKB Ser473 phosphorylation. In addition, chronic AMPK 
activation by metformin in adipose tissue of type 2 diabetic subjects was not associated 
with altered expression of three key insulin signalling molecules; PKB, the 
phosphoinositide 3-kinase (PI3K) p85 subunit and insulin receptor substrate 1 (IRS-1).  
Overall these results suggest a prominent role for LKB1 as an AMPK kinase and a 
potential role for CaMKK as an AMPK kinase in adipocytes. This study also suggests that 
both acute and prolonged AMPK activation in adipocytes inhibits insulin-stimulated 
glucose uptake, however the precise mechanism of inhibition has yet to be elucidated. 
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NCS                Newborn calf serum 
NEFA  Non-esterified fatty acid 
NHE-1  Na+/H+ exchanger-1 
NPY  Neuropeptide Y  
OCT  Organic cation transporter  
PAS  Phospho Akt/PKB substrate 
PBS  Phosphate buffered saline 
PD  pleckstrin-homology 
PDE3B Phosphodiesterase 3B 
PDK-1            Protein dependent kinase-1 
PEPCK Phosphoenolpyruvate carboxykinase 
PFK-1  Phospho-fructose kinase-1 
PFK-2  Phospho-fructose kinase-2 
PGC1a  Peroxisome-proliferator-activated receptor (PPAR)γ co-activator 1a  
PHK  Phosphorylase kinase 
PI3K  Phosphoinositide 3-kinase 
PKA  Protein kinase A 
PKB  Protein kinase B 
PKC  Protein kinase C 
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PLD  Phospholipase D 
POMC  Proopiomrlanocortin 
PPARγ            Peroxisome proliferator-activated receptor gamma  
PTB  Phospho tyrosine binding 
PtdIns  Phosphatidylinositol 
PtdInsP2 Phosphatidylinositol 4,5 bisphosphate 
PtdInsP3 Phosphatidylinositol 3,4,5-trisphosphate 
PVN  Paraventricular nucleus 
PYK2  Proline-rich tyrosine kinase 2 
RICTOR rapamycin insensitive companion of mTOR 
S6K1  Ribosomal protein S6 kinase 
SBTI  Soybean trypsin inhibitor 
SDS  Sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
Ser  Serine 
SNARE    Soluble N-ethylmaleimide-sensitive-factor attachment protein receptor       
SNS  Sympathetic nervous system 
SDS  Sodium dodecyl sulphate 
SOCS-3 Suppressor of cytokine signalling-3 
Src  Sarcoma kinase 
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SREBP-1 Sterol regulatory element binding protein-1 
TG  Triglyceride 
TAK-1  Transforming growth factor-beta activated kinase 
TBC1D1          tre-2/USP6, BUB2, cdc16 domain family member 1 
TBS  Tris buffered saline 
TBST  Tris buffered saline + Tween 20 
TC10  GTP-binding protein TC10 
TEA  Triethylamine 
TEMED N, N, N’, N’-tetramethylenediamine 
Thr  Threonine 
TNF  Tumour necrosis factor 
TOR  Target of rapamycin 
Tris  Tris(hydroxymethyl)aminoethane 
TSC  Tuberous sclerosis complex 
Tye  Tyrosine 
TZD  Thiazolidinedione 
UCP-1/2 Un-coupling protein-1/2 
UMP  Uridine monophosphate 
ZMP  5-Aminoimidazole-4-carboxamide riboside monophosphate 
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Chapter 1  - Introduction 
1.1 Adipose Tissue  
1.1.1 Adipose Tissue Structure 
Adipose tissue is constructed of different components including; adipocytes, connective 
tissue matrix, nerve tissue, stromovascular cells and immune cells (Fig. 1.1). 
 
Figure  1-1: Cellular compartments of the adipose tissue.  
 
One role of adipocytes in adipose tissue is to store triglyceride (TG) during periods of 
caloric excess and to mobilize this reserve when energy expenditure exceeds intake. 
Adipocytes regulate the amount of stored fat in adipose tissue through the mechanisms of 
lipogenesis and lipolysis. 
1.1.2 Lipogenesis 
Lipogenesis is stimulated by insulin during the fed state in adipocytes (Fig. 1.2). Insulin 
increases the uptake of glucose (Fig. 1.2) in the adipose cell via recruitment of glucose 
transporters to the plasma membrane (Saltiel and Kahn 2001). In the cytosol glucose enters 
into glycolysis, where it is converted to pyruvate. Pyruvate is then converted to acetyl-CoA 
in the mitochondria by pyruvate dehydrogenase (Patel and Roche 1990). Acetyl-CoA 
produced in the mitochondria is condensed with oxaloacetate to form citrate, which is then 
transported into the cytosol and broken down to yield acetyl-CoA by citrate lyase (Srere 
1959). Acetyl-CoA carboxylase (ACC), a biotin-dependent enzyme, then catalyses the 
carboxylation of acetyl-CoA to malonyl-CoA (Tong 2005). Fatty acids are synthesized 
from acetyl-CoA and malonyl-CoA by fatty acid synthase (FAS) (Wakil et al 1983, Wakil 
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1989), an enzyme system consisting of a multifunctional polypeptide. The first step in the 
synthesis of TG is the synthesis of phosphatidate which is formed by the addition of two 
fatty acids to glycerol-3-phosphate. Fatty acids must first be activated via esterification, by 
fatty acyl CoA synthetase (Watkins 1997), with Coenzyme A before they can be utilized in 
the synthesis of TG. Glycerol phosphate acyltransferase catalyses the acylation of glycerol 
3-phosphate to lysophoshophatidate, and the subsequent acylation of lysophoshophatidate 
to phosphatidate (Coleman and Lee 2004, Gimeno and Cao 2008). Finally in the synthesis 
of TG, phosphatidate is hydrolysed by a phosphatase to generate diglyceride (DG) which is 
acylated to a TG by diglyceride acyltransferase (Coleman and Lee 2004, Gimeno and Cao 
2008).  
In addition to stimulating glucose uptake, insulin also increases the expression of lipogenic 
enzymes (Assimacopoulos-Jeannet et al 1995) (Fig. 1.2). In liver, insulin is thought to 
increase the expression of genes connected with lipogenesis via the transcription factor 
sterol regulatory element binding protein-1 (SREBP-1) (Horton and Shimomura 1999, 
Kersten 2001). However, currently the regulation of gene expression by insulin via 
SREBP-1 has yet to be clearly defined in adipocytes (Kersten 2001). The nuclear hormone 
receptor, peroxisome proliferator-activated receptor gamma (PPARγ), is an important 
transcription factor in adipocytes involved in the differentiation of preadipocytes into 
mature fat cells. Expression of PPARγ, which regulates the expression of various lipid 
metabolism genes in adipocytes including; adipocyte fatty acid binding protein, lipoprotein 
lipase, fatty acid transport protein and acyl-CoA synthetase (Kersten et al 2000, Yoon et al 
2000), has been shown to be increased by both insulin (Vidal-Puig et al 1997) and SREBP-
1 (Fajas et al 1999). This suggests that in adipocytes insulin may regulate the expression of 
lipogenic enzymes primarily via elevated PPARγ expression. 
Growth hormone (GH) is also involved in the regulation of lipogenesis in adipose tissue. 
GH has been shown to reduce lipogenesis by reducing insulin sensitivity, resulting in 
down-regulation of fatty acid synthase expression in adipose tissue (Yin et al 1998).  
Leptin, synthesised by adipocytes, is another hormone which has been shown to regulate 
lipogenesis. Leptin (Fig. 1.2) has been shown to inhibit lipogenesis (Wang and Sul 1997), 
by down-regulating the expression of genes involved in fatty acid and triglyceride 
synthesis, (Soukas et al 2000). Leptin is thought to mediate these changes in gene 
expression by reducing SREBP-1 expression (Soukas et al 2000). 
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Figure  1-2: Regulation of lipogenesis in adipocytes (adapted from Kersten 2001). 
PPARγ = peroxisome proliferator-activated receptor gamma, SREBP-1 = sterol regulatory element 
binding protein-1. TG = triglyceride 
1.1.3 Lipolysis 
Lipolysis is a catabolic pathway, where by stored TG is hydrolysed to yield non-esterified 
fatty acids (NEFAs), and glycerol. This process is activated in adipose tissue during fasting 
and is regulated by the hormones noradrenaline and insulin. Binding of noradrenaline to β-
adrenergic receptors (Fig. 1.3), coupled to adenylate cyclase via the stimulatory Gs-protein, 
leads to an increased production of cyclic adenosine monophosphate (cAMP) and 
subsequent activation of protein kinase A (PKA) (Holm et al 2000, Holm et al 2003, 
Collins et al 2004). PKA subsequently phosphorylates target proteins including hormone 
sensitive lipase (HSL) and perilipins. Perilipins are characteristic proteins in mature 
adipocytes, which cover lipid droplets in the adipocyte thereby preventing HSL activity 
(Londos et al 1999). However, phosphorylation of perilipins by PKA abolishes their ability 
to inhibit HSL. PKA phosphorylates HSL at three serine residues, Ser563, Ser659 and 
Ser660 (rat HSL) (Anthonsen et al 1998). Once active, HSL migrates to the lipid droplet 
surface where it cleaves the first fatty acid from TG yielding diglyceride (DG) (Fredrikson 
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et al 1986). Diglyceride lipase then cleaves the second fatty acid from DG to yield 
monglyceride (MG) (Fredrikson et al 1986). Finally monoglyceride lipase (MGL) exerts 
its lipase activity and cleaves MG yielding the final fatty acid and glycerol (Fredrikson et 
al 1986). NEFAs and glycerol are exported to muscle and liver respectively. Insulin 
antagonises lipolysis (Fig. 1.3) by reducing PKA activity via a reduction in cAMP levels, 
mediated via activation of phosphodiesterase 3B (PDE3B) (Shakur et al 2001).  
 
Figure  1-3: Hormonal control of adipocyte lipolysis.  
β-AR = beta adrenergic receptor, AC = adenylate cyclase, PKA =  protein kinase A, HSL = 
hormone sensitive lipase, TG = triglyceride, DG = diglyceride, MG = monoglyceride, MGL = 
monoglyceride lipase, NEFA = non-esterified fatty acid, IR =  insulin receptor, PDE3B = 
phosphodiesterase 3B. 
 
1.2 Adipose Tissue Related Disorders 
1.2.1 Obesity 
Adipose tissue has a fundamental role in regulating energy balance and metabolism, thus a 
normal amount of adipose tissue is necessary for maintaining metabolic homeostasis. 
Pamela Jane Logan, 2009   Chapter 1, 24 
Excess or loss of adipose tissue is detrimental to health, and results in obesity and 
lipodystrophy respectively.  
Obesity results from an increase in adipose tissue mass. Currently obesity has reached 
epidemic proportions. The world health organisation projects that by 2015 2.3 billion 
adults will be overweight, and at least 700 million of them will be clinically obese (World 
Health Organisation, 2009). Obesity and overweight increases the risk of chronic diseases 
including; type 2 diabetes, cardiovascular disease, hypertension, stroke, 
hypercholesterolaemia, hypertriglyceridaemia, arthritis, asthma and some cancers (Mokdad 
et al 2003), thereby increasing morbidity and mortality. 
1.2.2 Type 2 diabetes 
1.2.2.1 Insulin secretion  
Insulin, a hormone produced in the pancreas, lowers blood glucose levels by stimulating 
the uptake of glucose into target tissues. Diabetes is a disease in which the body does not 
produce enough insulin, or respond properly to insulin, and is characterized by elevated 
fasting blood glucose levels. Type 1 diabetes is an autoimmune disease that results in the 
destruction of insulin-producing β-cells in the pancreas (Marino and Grey 2008). Type 2 
diabetes is characterized by a fasting hyperglycemia due to the combination of insulin 
resistance in peripheral tissue and an insulin secretory defect of the β-cell. Type 2 diabetes 
is the most common form of diabetes mellitus and is associated with a family history of 
diabetes (American Diabetes Association, 2000), obesity (Sinha et al 2002) and older age 
(Pagano et al 1984). 
After feeding, in the healthy individual, elevated blood glucose levels trigger exocytosis of 
the insulin secretory vesicles and release of insulin into the bloodstream (Fig. 1.4). Glucose 
transporter 2 (GLUT2), facilitates the entry of glucose into the pancreatic β-cells (1). Once 
inside the cell glucose is phosphorylated by glucokinase to glucose 6-phosphate (2), and 
metabolized with a resultant increase in the adenosine triphosphate / adenosine 
diphosphate (ATP/ADP) ratio (3) (Kennedy et al 1999), triggering closure of the ATP-
gated potassium channels (4) in the cellular membrane and depolarization (5) (Cook and 
Hales 1984). Membrane depolarization of the β-cell opens voltage dependent calcium 
channels (VDCC) (6) resulting in an influx of calcium into the β-cell. The increased 
Pamela Jane Logan, 2009   Chapter 1, 25 
intracellular calcium concentration (7) subsequently triggers exocytosis of insulin granules 
into the bloodstream (8) (Rorsman et al 2000) (Fig. 1.4). 
 
Figure  1-4:  The stimulus-secretion coupling pathway of glucose-dependent insulin 
exocytosis. 
VDCC = voltage dependent calcium channels, GLUT2 = glucose transporter 2, PM = plasma 
membrane. 
1.2.2.2 Insulin-stimulated glucose transport 
In normal insulin signalling (Fig. 1.5), insulin stimulates glucose transport in muscle and 
adipocytes via the regulated translocation of vesicles containing the glucose transporter 
GLUT4 to the plasma membrane. The complete mechanism by which insulin regulates the 
translocation of GLUT4 vesicles to the plasma membrane remains currently incompletely 
defined. However, the mechanism established to date is discussed below. 
The initial step in insulin-stimulated GLUT4 translocation to the plasma membrane 
involves the binding of insulin to its receptor. The insulin receptor (IR) is a transmembrane 
receptor, composed of two α-subunits and two β-subunits linked by disulphide bonds. The 
α-subunits are entirely extracellular and contain insulin binding domains, while the linked 
β-subunits penetrate through the plasma membrane into the cytosol (Lee and Pilch 1994). 
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The binding of insulin to its receptor causes a conformational change in the α-subunits. 
This in turn induces a conformational change in the β-subunits which promotes tyrosine 
autophosphorylation of the β-subunits of the insulin receptor (IR). This occurs through an 
intramolecular trans-autophosphorylation mechanism in which one β-subunit tyrosine 
kinase domain phosphorylates the adjacent β-subunit resulting in the activation of the 
intrinsic substrate kinase activity of the insulin receptor (Ullrich and Schlessinger 1990, 
Czech and Corvera 1999, Ward and Lawrence 2009).  
Substrates of the IR are termed insulin receptor substrate (IRS) proteins. IRS proteins are 
characterized by the presence of an NH2-terminal pleckstrin-homology (PH) domain 
adjacent to a phosphotyrosine binding (PTB) domain, followed by a variable-length 
COOH-terminal tail that contains numerous tyrosine and serine phosphorylation sites (Sun 
and Liu 2009). IRS proteins bind to phosphorylated IR Tyr960 via the PTB domain (White 
1998). In addition, the IRS protein PH domain is also thought to mediate specific 
interactions with the IR kinase (Burks et al 1997). Once bound to the IR, IRS is 
phosphorylated on tyrosine residues by the IR (Ward and Lawrence 2009). At least three 
IRS proteins occur in humans, including IRS-1 and IRS-2, which are widely expressed, 
and IRS-4, which is limited to the thymus, brain, and kidney and possibly β-cells (Bernal 
et al 1998, Uchida et al 2000). Both IRS-1 and IRS-2 have key roles in insulin-stimulated 
glucose uptake in fat and muscle, and the independent genetic ablation of either isoform 
leads to peripheral insulin resistance (White 2002). Mechanistically the insulin-dependent 
tyrosine phosphorylation of IRS proteins generates docking sites for the Src homology 2 
(SH2)-domain-containing downstream effector phosphatidylinositol 3’-kinase (PI3K) 
(Whitehead et al 2000). 
PI3Ks are a family of related intracellular signal transduction enzymes which 
phosphorylate the 3 position hydroxyl group of the inositol ring of phosphatidylinositol 
(PtdIns). The PI3K family is divided into three different classes based on their sequence 
homology. Class I PI3Ks are further divided between IA and IB subsets based on their 
structure and mechanism of activation (Vanhaesebroeck et al 1997). Class-1A PI3Ks are 
heterodimers composed of a regulatory p85 subunit and a catalytic p110 subunit. The p85 
subunit contains SH2 domains that bind phosphotyrosine residues in IRS proteins, which 
allosterically regulates the activity of the p110 catalytic subunit (Vanhaesebroeck et al 
1997, Shepherd 2005). Class-1A PI3Ks preferentially phosphorylate phosphatidylinositol 
4,5-bisphosphate (PtdInsP2) to form phosphatidylinositol 3,4,5-trisphosphate (PtdInsP3) at 
the plasma membrane (Vanhaesebroeck et al 1997). Accumulation of this lipid leads to the 
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PH-domain-dependent recruitment of 3-phosphoinositide-dependent protein kinase-1 
(PDK1) and protein kinase B (PKB), two PH-domain-containing enzymes involved in 
GLUT4 translocation to the plasma membrane  (Brazil et al 2004, Currie et al 1999, 
(Calleja et al 2009). 
PKB (also known as Akt) is a serine/threonine kinase, which in mammals comprises three 
highly homologous members known as PKBα, PKBβ, and PKBγ (Scheid and Woodgett 
2003). Activation of PKB requires phosphorylation at two sites. PDK1 phosphorylates 
PKB at Thr308, a residue located in its kinase-domain activation loop (Alessi et al 1997). 
In addition, Ser473 in the C-terminal hydrophobic motif of PKB is also phosphorylated, 
however the identity of the kinase responsible has been controversial, with several 
enzymes having been proposed as candidates to mediate this phosphorylation event 
(Bayascas et al 2005). However, studies by Hresko and co-workers, and Sarbassov and co-
workers have provided evidence that an enzyme complex consisting of mTOR 
(mammalian target of rapamycin) and RICTOR (rapamycin insensitive companion of 
mTOR) mediates the phosphorylation of PKB at Ser473 (Hresko and Mueckler 2005, 
Sarbassov et al 2005). Various studies have strongly linked PKBβ to GLUT4 translocation. 
In 3T3-L1 adipocytes depletion of PKBβ by RNAi was reported to inhibit insulin 
responsiveness in 3T3L1 adipocytes (Jiang et al 2003). In addition knockout of PKBβ in 
mice has been reported to result in impaired glucose uptake in skeletal muscle and hepatic 
insulin resistance (Cho et al 2001). Furthermore, a mutation in PKBβ was recently 
identified in a human family with severe insulin resistance and diabetes (George et al 
2004). 
At the start of this project a Rab GTPase activating protein (GAP), termed Akt substrate of 
160 kDa (AS160), had been identified as a downstream target of PKB (Sano et al 2003). 
More recently another Rab GAP, tre-2/USP6, BUB2, cdc16 domain family member 1 
(TBC1D1), was also identified as a downstream target of PKB (Roach et al 2007). It is 
thought that PKB phosphorylation inhibits Rab-GAP activity, leading to a higher 
proportion of Rabs in the guanosine triphosphate (GTP)-bound state (Sakamoto K, Holman 
GD 2008), which via a currently poorly characterised mechanism, involving SNARE 
(soluble N-ethylmaleimide-sensitive-factor attachment protein receptor) proteins, promotes 
exocytosis of GLUT4 vesicles to the plasma membrane (Bryant et al 2002). 
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Figure  1-5: Insulin receptor signalling. 
IRS = insulin receptor substrate,  PIP2  = phosphatidylinositol 4,5 bisphosphate,  PIP3  =  
phosphatidylinositol 3,4,5-trisphosphate,  PKB = protein kinase B,  PDK1 = protein dependent 
kinase 1, AS160 = Akt substrate of 160 kDa . 
In addition, a parallel insulin-signalling pathway has been reported to contribute to GLUT4 
translocation. Insulin-stimulated phosphorylation of Cbl activates the small GTP-binding 
protein TC10, which functions to stimulate trafficking of GLUT4 vesicles due to actin 
rearrangement (Saltiel and Pessin 2002).   
Current models have proposed that GLUT4 populates two inter-related endosomal cycles 
(the fast cycle 1 and the slow cycle 2) involving the trans-golgi network and a population 
of vesicles called GLUT4-storage vesicles (Fig. 1.6). In the absence of insulin, GLUT4 is 
thought to be sequestered away from the cell surface into the fast cycling endosomal 
system (cycle 1). Once there, unique sequences within GLUT4 direct it into a slowly 
recycling pathway (cycle 2). The selective routing of GLUT4 into this slowly recycling 
pathway results in the effective sequestration of GLUT4 away from the cell surface, in a 
population of vesicles available for rapid mobilisation upon insulin binding (Bryant et al 
2002). 
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Figure  1-6: A model that depicts the transport of GLUT4 in insulin-responsive cells (adapted 
Bryant et al 2002) 
 
1.2.2.3 Other actions of insulin 
Insulin stimulates glycogen synthesis in muscle by inhibiting glycogen synthase kinase-3 
(GSK-3), and increasing the activity of glycogen synthase (GS) (Cross et al 1995, 
Borthwick et al 1995). Gluconeogenesis in the liver is inhibited by insulin via suppression 
of the genes for the key gluconeogenic enzymes phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (G6Pase) (Agati et al 1998, Dickens et al 1998). As 
previously described, insulin also inhibits lipolysis by reducing cyclic AMP levels via PKB 
mediated activation of PDE3B (Shaker et al 2001).  
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1.2.3 Lipotoxicity 
Lipotoxicity is characterised by the build up of fatty acids in tissues other than adipose. 
Circulating NEFA concentrations are higher in obese individuals than in lean people 
(Campbell et al 1994) and are proposed to cause insulin resistance through inhibition of the 
insulin signalling transduction system (Shulman 2000).  
For example, it has been shown that the decrease in insulin-induced IRS-1 tyrosine 
phosphorylation mediated by NEFAs is linked to an increase in the activity of protein 
kinase C (PKC) theta in rat skeletal muscle (Griffin et al 1999). Active PKC results in 
phosphorylation of IRS-1 at Ser 307 which inhibits the interaction of IRS-1 with the 
insulin receptor (Aguirre et al 2000, Aguirre et al 2002). In addition, it has also been 
shown that elevated concentrations of NEFAs inhibit insulin stimulation of PKB in muscle 
cells (Chavez et al 2003). It has been proposed that ceramides produced from the 
metabolism of NEFAs could activate protein phosphatase 2A, which dephosphorylates and 
inactivates PKB, thus inducing insulin resistance in target tissues (Chavez et al 2003). 
Thus impaired insulin action, induced by elevated NEFAs, results in an increase in hepatic 
gluconeogenesis, an increase in lipolysis and reduction of glucose uptake in adipose tissue, 
and a reduction in glucose uptake and glycogen synthesis in muscle. 
Elevated plasma NEFAs after a meal are transported into the β-cell via fatty acid binding 
protein 2. In the cytosol the NEFAs are converted to their acyl-CoA derivatives which 
have been shown to stimulate insulin secretion (Newgard and McGarry 1995, Prentki and 
Corkey 1996). Carnitine palmitoyl transferase 1 (CPT1) is associated with the 
mitochondria outer membrane and mediates the transport of long chain fatty acids across 
the membrane where they are subsequently oxidized. An increase in glucose levels after 
feeding leads to an increase in malonyl-CoA concentration within the β-cell. Malonyl-CoA 
inhibits CPT1, thus increasing cystolic fatty acyl-CoAs (Prentki and Corkey 1996). Thus it 
has been proposed (Prentki and Corkey 1996) that NEFAs work in tandem with glucose to 
stimulate insulin secretion. However, long term elevated NEFA levels have a detrimental 
effect on insulin secretion by the pancreatic β-cells. Chronic exposure to elevated NEFAs 
in human β-cells in vitro (Zhou and Grill 1995) and in vivo (Kashyap et al 2002) resulted 
in β-cell dysfunction characterized by enhanced insulin secretion at low glucose 
concentration, depletion of insulin stores and an impaired response of the β-cell to 
stimulatory concentrations of glucose. It has been demonstrated that apoptosis is increased 
in islets of obese Zucker diabetic fatty rats that are progressing through the pre-diabetic 
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and diabetic stages of their disease. The β-cell apoptosis is thought to be induced by 
NEFAs via de novo ceramide formation and increased nitric oxide (NO) production 
(Shimabukuro et al 1998). In addition, incubation of human β-cells with elevated levels of 
NEFAs also resulted in β-cell apoptosis (Lupi et al 2002), thought to be the result of 
caspase activation, partially dependent on the ceramide pathway and possibly Bcl-2 
regulation.  
1.2.4 Lipodystrophies 
Lipodystrophies are characterized by selective loss of body fat. They are classified 
according to their origin, either genetic or acquired, and on the extent of fat loss, either 
generalized or partial (Table 1.1). Interestingly, lipodystrophies pre-dispose to similar 
metabolic complications associated with obese patients including insulin resistance, type 2 
diabetes, hepatic steatosis (fatty liver) and dyslipidemia. 
 
Table  1-1: Classification of lipodystrophy syndromes (Garg et al 2006). 
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1.3 Adipocytokines 
1.3.1 The adipocyte and adipocytokines 
Historically the adipocyte was considered a passive tissue for the storage of excess energy 
in the form of fat. However, it has become apparent that adipocytes secrete a number of 
bioactive proteins called adipocytokines thus establishing adipose tissue as an endocrine 
organ (Table 1.2). 
Protein Reference 
Leptin [Campfield et al 1995] 
Adiponectin [Scherer et al 1995; Hu et al 1996; Maeda et al 1996] 
IL-6 [Mohaamed-Ali et al 1997] 
TNF-α [Kern et al 1995] 
resistin [Steppan et al 2001] 
Plasminogen activator-inhibitor [Wiman et al 1984] 
Adipsin [Cook et al 1985] 
Acylation-stimulating protein [Maslowska et al 1997] 
IL-8 [Bruun et al 2001] 
Agouti protein [Manne et al 1995] 
Transforming growth factor-β [Samad et al 1996, Jones et al 1997] 
Adipophilin [Heid et al 1998] 
Apelin [Castan-Laurell et al 2005] 
Omentin [Schaffler et al 2005] 
Visfatin   [Fukuhara et al 2005] 
Chemerin [Bozaogula et al 2007] 
Table  1-2: Bioactive proteins secreted by adipose.  
 
Leptin, tumour necrosis factor alpha (TNFα), interleukin (IL)-6 and adiponectin are some 
of the best characterized adipocytokines and are discussed below. They appear to play an 
important role in insulin resistance. In obesity the secretion levels of these adipocytokines 
are altered. Thus, there is intense interest in the role of adipocytokines in the pathogenesis 
of obesity related disorders such as type 2 diabetes. 
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1.3.2 Leptin 
Leptin is predominantly expressed in adipose tissue (Green et al 1995). It is the protein 
product of the ob (obese) gene and was discovered in 1994 after positional cloning of the 
monogenic mutant responsible for the morbidly obese phenotype observed in the obese 
(ob/ob) mouse (Zhang et al 1994).   
Leptin serves to inform the hypothalamus of the quantity of stored fat. In adults leptin 
crosses the blood brain barrier via a saturable transport system. In the arcuate nucleus 
(ARH) leptin stimulates the proconvertase 1-dependent cleavage of proopiomrlanocortin 
(POMC) neurons, to produce the anorexigenic peptide α-melanocyte-stimulating hormone 
(α-MSH) (Rouille et al 1995) which is an agonist of the melanocortin 4 receptor (MC4R). 
Also, in the ARH, leptin inhibits neurons which co-express the orexigenic peptides, 
neuropeptide Y (NPY) and agouti related peptide (AgRP), which is an antagonist of MC4R 
(Zigman and Elmquist 2003). This consequently results in the activation of the MC4R in 
the paraventricular nucleus (PVN) consequently resulting in a decrease in feeding and an 
increase in energy expenditure (Fig. 1.7). Thus, conversely a decrease in leptin levels 
results in a decrease in energy expenditure and an increase in food intake (Adan et al 1994) 
(Hwa et al 2001).  
 
Figure  1-7: Leptin stimulates decreased feeding and increased energy expenditure.  
POMC = proopiomrlanocortin, α-MSH = α-melanocyte-stimulating hormone, MC4R = melanocortin 
4 receptor, NPYR = neuropeptide Y receptor, AgRP = agouti related peptide, MC4R = melanocortin 
4 receptor, PVN = paraventricular. 
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Spontaneous mutations in leptin or in the leptin receptor result in obesity in mice and in 
humans (Chen et al 1996, Zhang et al 1994, Montague et al 1997, Clement et al 1998). 
Leptin deficient mice and humans were shown to be successfully treated with leptin (La 
Campfield et al 1995, Farooqi et al 1999). This finding fuelled excitement that leptin could 
be used to treat obese patients. Unfortunately the level of leptin secreted from adipocytes is 
proportional to body fat stores (Maffei et al 1995), with greater secretion occurring from 
subcutaneous adipose tissue compared with visceral adipose tissue (Fain et al 2004, 
Wajchenberg 2000). Thus, obese individuals have high levels of circulating leptin in their 
blood stream due to increased amounts of leptin-secreting adipose tissue (Considine et al 
1996). In fact most obese patients appear to be leptin resistant as treatment with exogenous 
leptin does not ameliorate their obesity (Bjorbaek and Kahn 2004, Flier 2004). Leptin 
resistance is thought to be due to saturable transport across the blood-brain barriers or due 
to abnormalities of the leptin receptor activation and / or signal transduction (El-Haschimi 
et al 2000). 
In addition to regulating appetite and bodyweight leptin has also been shown to be 
involved in other processes. Leptin appears to play a role in immune responsiveness by 
modulating the T-cell immune response (Gainsford et al 1996, Lord et al 1998), inhibit 
bone formation (Ducy et al 2000) and correct sterility in leptin deficient mice (Chehab et 
al 1996, Chehab et al 1997, Ahima et al 1997). 
1.3.3 TNFα 
TNFα is an inflammatory cytokine which can stimulate the production of other cytokines 
e.g IL-1 and IL-6 (Warne et al 2003, Wajant et al 2003). TNFα is produced by many 
different tissues including adipose (Kern et al 1995, Wajant et al 2003).  
Adipose tissue TNFα expression is increased in obese rodents and humans and positively 
correlates with adiposity and insulin resistance (Ruan and Lodish 2003, Hotamisligil 2003, 
Fernandez-Real and Ricart 2003). Targeted knock out of the TNFα gene in obese mice 
resulted in improved insulin sensitivity (Uysal et al 1997). In addition, in rat models of 
obesity and insulin resistance, neutralizing TNFα with injections of a soluble TNF-
receptor-immunoglobulin gamma (IgG) fusion protein, resulted in increased insulin 
sensitivity (Hotamisligil et al 1993). However the effects of neutralizing TNFα using an 
engineered human anti-TNFα antibody appeared to have no significant effects on insulin 
sensitivity in patients with type 2 diabetes (Ofei et al 1996).  
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1.3.4 IL-6 
IL-6 is another cytokine which positively correlates with body mass index (Vgontzas et al 
1997). As much as a third of total circulating concentrations of IL-6 is thought to originate 
from adipose tissue (Mohamed-Ali et al 1997, Xing et al 1997).  
Elevated levels of IL-6 are associated with obesity and insulin resistance (Fernandez-Real 
and Ricart 2003). TNFα whose expression is elevated in obesity has been shown to 
increase IL-6 production in 3T3-L1 adipocytes (Grunfeld and Feingold 1991). Peripheral 
administration of IL-6 was shown to induce hyperlipidemia, hyperglycemia and insulin 
resistance in rodents and humans (Fernandez-Real and Ricart 2003). In rats peripheral 
administration of IL-6 induced hypertriglyceridemia by stimulating hepatic triglyceride 
secretion (Nonogaki et al 1995), and in humans an IL-6 infusion resulted in an increase in 
NEFA concentration (Stouthard et al 1995). In addition IL-6 has been shown to inhibit 
insulin signalling by inducing suppressor of cytokine signalling-3 (SOCS-3), a negative 
regulator of insulin signalling (Senn et al 2003).  
1.3.5 Adiponectin 
Adiponectin is expressed exclusively in adipocytes (Weyer et al 2001). Adiponectin exists 
in plasma as trimeric, hexameric and higher order polymeric structures (Pajvani et al 
2003). Adiponectin is the only adipocytokine whose secretion is decreased in the obese 
state. Further more, adiponectin has been shown to be able to inhibit the secretion of 
inflammatory cytokines including IL-6 and IL-8 by human adipocytes (Sell et al 2006). 
Reduced adiponectin levels are documented in obese, insulin resistant and type 2 diabetes 
patients (Hotta et al 2000). Analysis of a Pima Indian population showed that the 
development of type 2 diabetes was associated with lower plasma adiponectin levels prior 
to diagnosis of type 2 diabetes (Lindsay et al 2002). Overexpression of adiponectin in mice 
resulted in improved insulin sensitivity, glucose tolerance and serum NEFAs (Combs et al 
2004). Conversely adiponectin deficient mice exhibit insulin resistance, glucose 
intolerance and increased serum NEFAs (Kubota et al 2002, Maeda et al 2002).  
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1.4 AMPK 
1.4.1 Reversible phosphorylation 
In 1992 Krebs and Fischer were awarded a Nobel Prize for ‘their discoveries concerning 
reversible protein phosphorylation as a biological regulatory mechanism’ (Kresge et al 
2005). Reversible protein phosphorylation regulates many cellular signal transduction 
pathways, which underlie many biological processes, including metabolism, growth, 
differentiation, membrane trafficking, muscle contraction, immunity, and memory 
(Manning et al 2002). Reversible phosphorylation involves the phosphorylation of a target 
protein by a protein kinase and subsequent dephosphorylation of that protein by a protein 
phosphatase. 
Protein kinases are one of the largest families of genes in eukaryotes. The human genome 
contains about 500 protein kinase genes, which accounts for approximately 2% of all 
human genes (Manning et al 2002). 
Approximately 30% of human proteins can be modified by kinases (Hubbard and Cohen, 
1993). Protein kinases phosphorylate target substrate proteins by catalyzing the transfer of 
the γ phosphate from ATP to a target amino acid residue. In eukaryotes, phosphorylation 
usually occurs on serine (Ser), threonine (Thr) and tyrosine (Tyr) residues. 
Phosphorylation of these residues is mediated by Ser/Thr-specific kinases such as PKA, 
PKB and PKC (Filippa et al 1999, Newton et al 1995), Tyr-specific kinases such as 
epidermal growth factor receptor (EGFR) and IR (Carpenter et al 2000) and dual 
specificity kinases such as mitogen activated protein (MAP) kinase kinases (MAPKK) 
(Dhanasekaran and Reddy 1998) which phosphorylate Ser/Thr and Tyr. Interestingly, of 
the ~500 protein kinases encoded by the human genome, the majority, ~400, encode 
Ser/Thr kinases, while only ~90 encode Tyr kinases and ~40 encode dual-specificity 
protein kinases (Manning et al 2002). 
Phosphorylation on other amino acid residues such as histidine, arginine and lysine occurs 
mostly in prokaryotic proteins (Cozzon 1988, Stock et al 1989). 
Eukaryotic protein kinases are structurally similar (Hanks et al 1988). The catalytic 
domain contains an N-terminal lobe of β-sheets and a larger C-terminal lobe of α-helices 
(Knighton et al 1991, Lowe et al 1997). This lobe structure forms an ATP-binding cleft 
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that constitutes the active site. ATP binds in a clef between the two lobes. It is orientated 
with adenosine sitting in a hydrophobic pocket and the hydrophilic phosphate chain 
pointing outwards away from the hydrophobic pocket. The substrate binds along the cleft 
and conserved residues within the kinase catalytic domain catalyse the removal of the γ 
phosphate from ATP and the covalent attachment of it to a free hydroxyl group on either 
Ser/Thr or Tyr residues. Despite the fact that kinases share a common fold, they can still 
selectively phosphorylate their target substrates. Specificity can be determined by the 
structure of the catalytic cleft of the kinase, local interactions between the cleft and the 
substrate phosphorylation site, and distal binding between the kinase and the substrate 
(Ubersax and Ferrell 2007).  
Phosphorylation of a protein can alter the protein activity, subcellular location, half-life 
and the association of that particular protein with other proteins. Thus, multisite 
phosphorylation of a protein can allow several of these effects to operate in the same 
protein (Cohen 2000). 
It is well established that protein kinases are themselves phosphorylated. Thus giving rise 
to protein kinase cascades, such as the AMPK signalling cascade (Hardie 2004a) and the 
MAPK signalling cascades (Seger and Krebs 1995), which are formed when two or more 
proteins act in series.  
Interestingly, the human genome encodes ~200 protein phosphatases, comprising of ~40 
Ser/Thr, ~100 Tyr and ~50 dual specificity (Alonso et al 2004, Arena et al 2005, 
Moorhead et al 2007). Thus is comparison to the number of protein kinases (~500) there 
are substantially less protein phosphatases. 
It has become apparent that each Ser/Thr phosphatase must regulate many more substrates 
than each Ser/Thr kinase since there are only ~40 Ser/Thr kinases compared to ~400 
Ser/Thr kinases. Specificity of Ser/Thr phosphatases is thought to occur through the 
association of phosphates catalytic domains with particular regulatory subunits, which 
target the catalytic core to different cellular locations and target substrates (Cohen 2002). 
In comparison, there are similar numbers of Tyr phosphatases and Tyr kinases. Thus, 
unlike Ser/Thr phosphatases, Tyr phosphatases do not require different regulatory subunits. 
They exist mostly as modular proteins with separate catalytic and targeting domains 
(Alonso et al 2004). 
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1.4.2 Discovery of AMPK 
AMP-activated protein kinase (AMPK) was initially discovered three decades ago. Two 
separate groups showed that preparations of two enzymes involved in liver fat metabolism; 
ACC (Carlson and Kim 1973) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) 
(Beg et al 1978) became inactivated in the presence of ATP. This effect was concluded by 
both groups to be due to the contamination of the enzyme preparation with a protein 
kinase. It was later shown that the kinases responsible for the inhibitory effects on ACC 
and HMGR were stimulated by 5’-adenosine monophosphate (AMP) (Yeh et al 1980) 
(Ferrer et al 1985). Subsequently, it was discovered that the inactivation of both ACC and 
HMGR was catalysed by the same single protein kinase (Carling et al 1987). It soon 
became apparent that the protein kinase initially termed HMGR kinase was in fact a 
multisubstrate kinase, thus it was renamed AMP-activated protein kinase after its allosteric 
activator 5’-AMP (Munday et al 1988). 
1.4.3 AMPK overview 
AMPK is a conserved sensor of cellular energy status and is present in all eukaryotes. 
AMPK is activated when there is a decrease in cellular energy level i.e an increase in the 
cellular AMP/ATP ratio. Metabolic stresses which activate AMPK include muscle 
contraction (Hutber et al 1997) which increases ATP consumption, and deprivation of 
oxygen (Kudo et al 1995, Marsin et al 2000) or glucose (Salt et al 1998b) which depletes 
ATP levels. AMPK exists as a heterotrimeric complex consisting of a catalytic α subunit 
and regulatory β and γ subunits. The β subunit contains a glycogen binding domain and the 
γ subunit contains cystathionine β-synthase (CBS) motifs which bind the two nucleotides; 
AMP and ATP (Towler and Hardie, 2007). AMPK is regulated by phosphorylation by 
upstream kinases. The tumour suppressor LKB1 (Hawley et al 2003; Woods et al 2003) 
and Ca2+/Calmodulin dependent protein kinase kinase (CaMKK) (Hawley et al 2005) are 
two well characterized AMPK kinases. Active AMPK stimulates ATP-producing pathways 
such as glycolysis and fatty acid oxidation, while inhibiting ATP consuming pathways 
such as gluconeogenesis, fatty acid synthesis and cholesterol synthesis (Hardie 2004a). 
AMPK mediates these effects via phosphorylation of downstream metabolic enzymes 
(Hardie 2004a) and by effects on gene (Foretz et al 1998) and protein expression (Winder 
et al 2000). In addition to regulating energy balance at the cellular level it has become 
apparent that AMPK also regulates food intake and energy expenditure at the whole body 
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level, in particular by mediating the effects of hormones and cytokines such as leptin 
(Minokoshi et al 2002, Minokoshi et al 2004) and adiponectin (Yamauchi et al 2002).  
1.4.4 AMPK Structure 
AMPK exists as a heterotrimer comprising of a catalytic α subunit and a regulatory β and γ 
subunit (Hardie et al 2003). In mammals there are two genes encoding isoforms of both the 
α and β subunits; α1, α2, β1 and β2, and three genes encoding isoforms of the γ subunit; 
γ1, γ2, and γ3 (Hardie et al 1998, Stapleton et al 1996, Stapleton et al 1997, Woods et al 
1996a/b). Along with splice variants and different combinations of isoforms there exists a 
diverse array of different complexes. Expression levels of the subunit isoforms vary 
between different tissues and cellular localization (Salt et al 1998a, Thornton et al 1998, 
Stapleton et al 1996, Mahlapuu et al 2004). 
AMPK appears to be a fundamental feature of all eukaryotic cells, as genes encoding 
orthologues of the α, β and γ subunits are present in all eukaryotic species whose genome 
sequence has been determined. Indeed orthologues of AMPK have been found in the yeast 
Saccharomyces cerevisiae and the parasite Giardia lamblai (Carling 2004, Hardie et al 
2003). 
The α1 and α2 mammalian subunits share 90% identity at their N-terminal catalytic 
domains, but only 60% identity at their C-terminal domains (Stapleton et al 1996). The C-
terminal domain has been shown to be required to form a complex with the non-catalytic 
subunits β and γ (Fig. 1.8) (Crute et al 1998). 
The β subunits contain two conserved regions (Fig. 1.8). These regions were originally 
termed kinase-interacting sequence (KIS) and association with Snf-1 complex (ASC) 
domains. Based on two hybrid analysis in yeast it was originally thought that the KIS 
domain was required for interacting with the α subunit, while the ASC domain was 
required for interaction with the γ subunit (Jiang and Carlson 1997). However, it has since 
been discovered that only the ASC domain is required for complex formation. The KIS 
domain is actually a glycogen binding domain (GBD) (Hudson et al 2003). This domain is 
present in enzymes which metabolize the α1→ 6 branch points in α1→ 4 linked glucans 
such as starch and glycogen (Hudson et al 2003, Polekhina et al 2003). GBD has been 
shown to cause association of AMPK with glycogen particles, where one of its substrates 
GS is located (Hudson et al 2003). Interestingly, prior glycogen loading of skeletal muscle 
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suppresses activation of AMPK by exercise in humans (Wojtaszewshi et al 2003). In 
addition, glycogen has also been shown to inhibit AMPK in cell-free assays, an effect that 
is dependent on binding to the GBD and varies according to the branching content of the 
glycogen i.e glycogen branch points inhibit AMPK activity (McBride et al 2009). Thus it 
has been proposed by McBride and co-workers that in muscle containing a high glycogen 
content, AMPK may be bound to the non-reducing ends at the surface of glycogen, 
sequestering AMPK away from other downstream targets. This is thought to account for 
the reduced apparent activation of AMPK in response to exercise (Wojtaszewshi et al 
2003) when muscle is in a glycogen-loaded state. Since the outer chains prevent access of 
AMPK to the internal glycogen branch points, AMPK would not be inhibited and thus 
would phosphorylate and inhibit GS. In contrast, exposure of the glycogen branch points 
by phosphorylase after contraction would inhibit AMPK. Thus, GS would no longer be 
phosphorylated and inhibited by AMPK, which would allow glycogen re-synthesis. Thus 
essentially the GBD may function as a regulatory domain which allows AMPK to act as a 
glycogen sensor in vivo. 
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Figure  1-8: Domain structure of AMPK subunit isoforms and splice variants  
Regions shown in the same colour are related, and their functions, where known, are indicated 
(amended from Towler and Hardie 2007). 
There exist three γ isoforms, with splice variants creating both long and short forms of γ2 
and γ3. The γ subunits differ from each other in the length of their N-terminal sequence, 
but they all contain conserved CBS motifs (Fig. 1.8). Bateman discovered the CBS motifs, 
which are named after the enzyme cystathionine β-synthase which contains a pair of such 
motifs at the C-terminus (Bateman 1997). These motifs occur as tandem pairs, therefore 
the term ‘Bateman domain’ was derived to describe the structure formed by two tandem 
CBS motifs (Kemp 2004). The recent determination of the crystal structure of the 
regulatory core of mammalian AMPK revealed that there was a nucleotide binding site on 
three of the four CBS motifs in the γ subunit. Two of these sites can bind AMP or ATP 
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with approximately equal affinity, and the third site contains a tightly-bound AMP that 
appears to be non-exchangeable (Xiao et al 2007). 
1.4.5 Naturally Occurring AMPK mutations 
Currently, a total of five missense mutations and an insert mutation in the γ2 subunit of 
AMPK have been detected in different families with the hereditary heart disease in humans 
called Wolff-Parkinson-White syndrome. Four of these mutations affect the N-terminal 
Bateman domain, while the other two affect the C-terminal Bateman domain (Fig. 1.9) 
(Gollob et al 2001, Arad et al 2002, Gollob et al 2002, Blair et al 2001). These mutations 
cause both defective activation of the intact AMPK complex by AMP (Daniel and Carling 
2002) and defective binding of AMP to the isolated Bateman domains (Scott et al 2004). 
Interestingly, the mutations also decrease the binding of the inhibitor ATP (Scott et al 
2004). Therefore, although the mutations prevent activation by AMP, they also appear to 
increase the basal activity (Burwinkel et al 2005). In addition, these studies provide strong 
evidence that the Bateman domains are indeed the regulatory AMP and ATP binding sites.  
 
Figure  1-9: The positions of known mutations that cause cardiac disease are marked on the 
γ2 subunit (adapted from Kemp et al 2003).  
 
A feature of Wolff-Parkinson-White syndrome is elevated storage of glycogen in cardiac 
myocytes (Burwinkel et al 2005). Thus the dominant effect of the mutations to increase 
basal AMPK phosphorylation has led to the proposal that elevated AMPK activity leads to 
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a higher basal glucose uptake into the myocytes. This would result in excessive glycogen 
storage, thought to underlie the cardiomyopathy (Arad et al 2007). 
1.4.6 Regulation of AMPK by AMP and phosphorylation 
AMPK is stimulated by an elevated AMP/ATP ratio. As eukaryotic cells have significant 
levels of adenylate kinase to maintain the reaction: 2 ADP ↔ ATP + AMP close to 
equilibrium, the AMP/ATP ratio varies approximately with the square of the ADP/ATP 
ratio (Hardie and Hawley 2001) making the AMP/ATP ratio extremely sensitive to cellular 
energy levels. 
It is thought that under physiological conditions, AMPK exists in its inactive form in 
complex with the much more abundant ATP, with only a small proportion binding AMP 
(Xiao et al 2007). Xiao and co-workers have proposed that a 2-3 fold increase in the AMP 
concentration (low µМ range) results in a similar fold increase in the proportion of AMP 
bound enzyme in the presence of a much higher (mМ range) concentration of ATP (Xiao 
et al 2007). 
AMPK is regulated by AMP by two distinct mechanisms. Firstly, AMP causes allosteric 
activation of AMPK (Hardie et al 1999). Secondly, the binding of AMP to AMPK makes it 
a worse substrate for protein phosphatases, especially protein phosphatase-2C (Davies et al 
1995). These effects by AMP are antagonised by high concentrations of ATP, 
demonstrating that the system responds to the AMP/ATP rather than to just AMP levels 
(Corton et al 1995, Hawley et al 1996, Davies et al 1995).  
AMPK is activated by an upstream kinase, AMPK kinase (AMPKK). Phosphorylation 
occurs in the α subunit at Thr172 which lies in the activation loop (Hawley et al 1996). 
The major breakthrough in identifying upstream kinases came from the study of the 
regulation of the AMPK orthologue, Snf-1 in Saccharomyces cerevisiae. Snf-1 was shown 
to be phosphorylated and activated by three closely related kinases, Elm 1, Pak 1 and Tos 3 
(Hong et al 2003). Database searches with these yeast sequences revealed that LKB1 and 
CaMKK α and β were closely related mammalian kinases.  
LKB1 is encoded by the Peutz-Jegher syndrome tumour suppressor gene (Jenne et al 
1998). Peutz-Jegher syndrome is an autosomal dominant disorder, characterised by a 
predisposition to gastrointestinal neoplasms marked by a high risk of benign and malignant 
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pancreatic tumours (Hemminki 1999). AMPK kinase purified from rat liver was found to 
correspond to LKB1 (Hawley et al 2003, Woods et al 2003). In addition, cells which 
lacked LKB1 were shown to have a reduced AMPK activity compared to cells expressing 
LKB1, and AMPK was not found to be activated by stimuli which normally activate it 
(Shaw et al 2004, Hawley et al 2003, Woods et al 2003). These findings provided evidence 
that LKB1 is an AMPKK. The discovery that LKB1 is not regulated by stimuli which 
activate AMPK in cells (Lizcano et al 2004, Woods et al 2003) or in skeletal muscle 
(Sakamoto et al 2004), and that it is not directly activated by AMP (Hawley et al 2003, 
Woods et al 2003) suggested that LKB1 is ‘constitutively active’ and that the regulation of 
AMPK phosphorylation is regulated by effects on AMPK itself. 
Initially it was thought that AMP also made AMPK a better substrate for the upstream 
kinase LKB1 (Hawley et al 1995). However, subsequent work has shown that this is not 
the case (Sanders et al 2007b). Earlier results indicating that AMP stimulates 
phosphorylation of AMPK by LKB1 can be plausibly explained by the presence of 
endogenous protein phosphatase 2C in the preparations of the rat liver kinases used in the 
study i.e AMP inhibited dephosphorylation of AMPK by the phosphatase, rather than 
increasing phosphorylation of AMPK by LKB1. 
The current AMP-dependent AMPK activation model proposed by Sanders and co-workers 
(Sanders et al 2007b) suggests that in addition to the allosteric effect of AMP on AMPK, 
when there is an increases in the AMP/ATP ratio, dephosphorylation of AMPK is 
inhibited. Since LKB1 functions as a constitutively active kinase, inhibition of the 
dephosphorylation reaction leads to an increase in AMPK Thr172 phosphorylation and 
activation of AMPK. Thus, AMPK phosphorylation by LKB1 occurs in response to 
decreased dephosphorylation following a rise in the AMP/ATP ratio.  
CaMKKα/β are also important intracellular AMPKKs which phosphorylate and activate 
AMPK in the presence of an increased calcium concentration, independently of an increase 
in AMP concentration. Hawley and co-workers showed that there is significant basal 
activity and phosphorylation of AMPK in LKB1-deficient cells that can be stimulated by 
Ca2+ ionophores, and studies using the CaMKK inhibitor STO-609 and CaMKK isoform-
specific siRNAs show that CaMKKβ is required for this effect (Hawley et al 2005). K+-
induced depolarization in rat cerebrocortical slices, which increases intracellular Ca2+ 
without disturbing cellular adenine nucleotide levels, was also shown to activate AMPK, 
and to be blocked by STO-609 (Hawley et al 2005).  It was also shown that CaMKKβ 
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appears to activate AMPK much more rapidly than CaMKKα in cell-free assays (Hawley 
et al 2005). However, 2-deoxyglucose- and ionomycin-stimulated AMPK activity and 
phosphorylation, was reported to be reduced in HeLa cells transfected with small 
interfering RNAs specific for both CaMKKα and CaMKKβ (Hurley et al 2005). 
Recently transforming growth factor-β activated kinase (TAK1) was identified as a 
possible candidate for a novel AMPK kinase in mammalian cells (Momcilovic et al 2006). 
TAK1 was shown to activate the Snf1 protein kinase in vivo and in vitro and co-expression 
of TAK1 and its binding partner TAB1 in HeLa cells stimulated AMPK Thr172 
phosphorylation.  
1.4.7 AMPK Function 
Active AMPK can inhibit ATP consuming pathways and stimulate ATP producing 
pathways. Historically AMPK was thought to act as a regulator of energy balance 
primarily at the cellular level (Fig. 1.10). However, it has since been shown to have a  
 
Figure  1-10: Role of AMPK in regulating energy balance at the cellular level.  
 
fundamental role in regulating energy balance at the level of the whole organism (Fig. 
1.11). Active AMPK results in many changes including glucose uptake and metabolism by 
muscle and other tissues, reduced glucose production in the liver and reduced synthesis and 
increased oxidation of fatty acids. All of these effects are beneficial to people with type 2 
diabetes and the metabolic syndrome, thus making AMPK an attractive therapeutic target. 
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Figure  1-11: Role of AMPK in regulating energy balance at the whole-body level (adapted 
from Hardie 2004b).  
 
 
1.4.8 Activators of AMPK 
Metabolic poisons such as arsenite, an inhibitor of the tricarboxylic acid cycle (Corton et al 
1994), antimycin A and azide, inhibitors of the respiratory chain (Witters et al 1991), 
oligomycin, an inhibitor of mitochondrial ATP synthase (Marsin et al 2000) and 
dinitrophenol, an uncoupler of oxidative phosphorylation (Witters et al 1991) all activate 
AMPK by depleting cellular ATP levels. 
Pathological stresses can activate AMPK by increasing the AMP/ATP ratio. These include 
glucose deprivation (Salt et al 1998b), ischemia (Kudo et al 1995, Marsin et al 2000) and 
oxidative stress (Choi et al 2001). Interestingly, hyperosmotic stress, induced by sorbitol, 
in muscle cells was shown to activate AMPK without altering the cellular AMP/ATP ratio 
(Fryer et al 2002b). 
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Exercise (Winder and Hardie 1996) or contraction in skeletal muscle (Hutber et al 1997) 
activates AMPK by increasing ATP consumption. In muscle the level of activation of 
AMPK depends on both the intensity and duration of the work. 
Leptin activates AMPK in muscle by direct effects via the leptin receptor and indirectly via 
the hypothalamic-sympathetic nervous system (SNS) axis through α-adrenergic receptors 
(Fig. 1.12). A decrease in cellular energy levels (AMP/ATP) is thought to occur during 
direct AMPK activation by leptin, but not during the indirect activation in muscle 
(Minokoshi et al 2002). 
 
Figure  1-12: Model for the stimulatory effect of AMPK on fatty acid oxidation in muscle. 
ACC = acetyl CoA carboxylase, CPT1 = carnitine palmitoyl transferase 1. 
 
In skeletal muscle, phosphorylation and activation of AMPK by leptin (Minokoshi et al 
2002), results in fatty-acid oxidation via phosphorylation and inhibition of ACC (discussed 
further in the text 1.4.11). Briefly, inhibition of ACC leads to a decrease in malonyl-CoA 
levels, which prevents inhibition of CPT1, subsequently allowing the uptake of fatty acids 
into the mitochondria where they are oxidized (Fig. 1.12).  
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As previously mentioned leptin has an anorexigenic action in the hypothalamus. This 
effect is mediated by inhibition of AMPK activity in the ART and PVN (Minokoshi et al 
2004). Decreased AMPK activity in the ART results in the inhibition of the orexigenic 
peptides NPY/AgRP. It would appear that that MC4Rs are required for the physiological 
and hormonal regulation of AMPK in the paraventricular hypothalamus as an agonist for 
this receptor which inhibits food intake also inhibits AMPK activity in the paraventricular 
nucleus, and mice lacking the MC4R are hyperphagic and obese and are unable to inhibit 
AMPK activity in response to feeding or leptin (Minokoshi et al 2004).  
In muscle and liver, in vivo and in vitro, adiponectin has been demonstrated to stimulate 
AMPK phosphorylation and activation (Yamauchi et al 2002). The activation of AMPK in 
muscle that occurs five minutes after adiponectin treatment may result from an increase in 
the concentration of cellular AMP (Yamauchi et al 2002). In parallel with its activation of 
AMPK, adiponectin stimulates phosphorylation of ACC, fatty-acid oxidation, glucose 
uptake and lactate production in myocytes, phosphorylation of ACC and reduction of 
molecules involved in gluconeogenesis in the liver, and reduction of glucose levels in vivo. 
Blocking AMPK activation by a dominant-negative mutant inhibits each of these effects 
demonstrating that the stimulation of glucose utilization and fatty acid oxidation by 
adiponectin occurs through activation of AMPK (Yamauchi et al 2002). In addition AMPK 
can also be activated in adipocytes by adiponectin, however the biological effect has yet to 
be determined (Wu et al 2003). 
The thiazolidinediones (TZDs) are a class of drugs used to treat type 2 diabetes. They 
stimulate PPARγ mediated adipocyte differentiation and increase the number of small 
adipocytes (Okuno et al 1998). This is associated with reduced serum NEFAs and reduced 
TNFα expression, which increases insulin sensitivity in the liver and skeletal muscle 
(Quinn et al 2008). In addition, TZDs can also elevate levels of adiponectin. This is 
achieved in part via the generation of the small adipocytes which abundantly express and 
secrete adiponectin (Yamauchi et al 2001) and by the up-regulation of adiponectin via 
direct effects of TZDs on adiponectin gene transcription (Iwaki et al 2003). As discussed, 
above, activation of AMPK by adiponectin results in reduced gluconeogenesis in the liver 
and increased fatty acid oxidation and glucose uptake in muscle. Therefore, TZDs are able 
to activate AMPK indirectly via adiponectin. In addition, the TZD, rosiglitazone (Fryer et 
al 2002b) has been shown to increase the activity of AMPK after 30min in H-2Kb muscle 
cells, suggesting that TZDs can also directly activate AMPK. 
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The biguanides are another class of drugs used for the treatment of type 2 diabetes. This 
class of drug primarily acts to inhibit hepatic gluconeogenesis. Metformin has been shown 
to stimulate AMPK activity in cultured primary rat and human hepatocytes (Zhou et al 
2001) and 3T3-L1 adipocytes (Huypens et al 2005). In addition another biguanide, 
phenformin, has been shown to activate AMPK in isolated rat adipocytes (Daval et al 
2005). 
The TZDs (Brunmair et al 2004) and metformin (El-Mir et al 2000) have also been 
reported to inhibit Complex 1 in the mitochondrial electron transport chain. In addition 
TZDs (Fryer et al 2002b, Saha et al 2004) have been reported to increase the intracellular 
AMP/ATP ratio, however this has not yet been demonstrated with metformin (Fryer et al 
2002b, Hawley et al 2002).  
Many studies of AMPK have utilised 5-aminoimidazole-4-carboxamide riboside (AICAR), 
which is a cell permeable molecule that is taken up readily by cells and phosphorylated by 
adenosine kinase (Bontemps et al 1986) to 5-aminoimidazole-4-carboxamide riboside 
monophosphate (ZMP), which functions as a cellular mimetic of AMP. Unfortunately 
ZMP is not a specific activator of AMPK in that it also mimics the effects of AMP on other 
molecules or processes. For example AICAR has been shown to suppress gluconeogenesis 
by inhibiting fructose-1, 6-bis phosphatase in isolated rat hepatocytes (Vincent et al 1991) 
and in vivo (Vincent et al 1996), and increase glycogenolysis by increasing glycogen 
phosphorylase activity in rat muscle preparations in vitro (Young et al 1996). 
Recently, a novel AMPK activator, A769662, was discovered (Cool et al 2006). This new 
AMPK activator, directly activates native rat AMPK by mimicking both effects of AMP, 
i.e. allosteric activation and inhibition of dephosphorylation (Göransson et al 2007). In 
addition, A769662 has been shown to have no direct effect on the ability of the LKB1 or 
CaMKK to phosphorylate AMPK (Sanders et al 2007a). However, the mechanism of 
AMPK activation by A769662 is thought to be distinct from that of AMP. AMP is unable 
to activate AMPK containing a mutation in the γ subunit, whereas A769662 can (Sanders 
et al 2007a). Also, A769662 stimulated AMPK activity was shown to be inhibited by a 
mutation in the β1 AMPK subunit (Ser108 to Ala), an autophosphorylation site within the 
GBD, however the same mutation only partially reduces AMPK activation by AMP 
(Sanders et al 2007a). Sanders and co-workers have proposed a model of AMPK activation 
by A769662 (Fig 1.13). They suggest that binding of A769662 to AMPK stabilizes a 
conformation that is resistant to dephosphorylation of Thr172. This conformation requires 
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phosphorylation of Ser108 within β1, and phospho-Ser108 is thought to then interact with 
another region of the AMPK heterotrimer (Sanders et al 2007a). Scott and co-workers 
showed that A769662 appears to exclusively activate AMPK containing the β1 subunit 
isoform (Scott et al 2008). Furthermore the activation of AMPK by A769662 appears to 
involve the interaction of the β1 subunit GBD and residues from the γ subunit that are not 
involved in AMP binding (Scott et al 2008). Currently, the mechanism of AMPK 
activation by A769662 is not completely understood, although the mechanism does not 
appear to involve the binding of A769662 to the GBD or the nucleotide binding sites on 
the γ subunit (Scott et al 2008). 
 
Figure  1-13: Model for activation of AMPK by A-769662 or AMP. 
In the inactive conformation, ATP is bound to the γ subunit, and Thr172 within the catalytic subunit 
(α) is freely accessible to protein phosphatases (PPase). In this conformation, Thr172 is maintained 
predominantly in the unphosphorylated form. Binding of A-769662 (denoted by the small white 
circle) stabilises a conformation of AMPK that inhibits dephosphorylation of Thr172, depicted here 
as steric hindrance by the β subunit. This conformation requires phosphorylation of Ser108 in the 
GBD of the β subunit. The active conformation is also promoted when AMP displaces ATP from the 
γ subunit. In this case, however, phosphorylation of Ser108 alone is not sufficient to maintain the 
conformation, and additional phosphorylation sites (within either α or β) may be required to 
maintain the active form (shown here by ?-PO4). 
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1.4.9 AMPK Targets 
AMPK targets many different proteins and pathways in different tissues. The well-
established downstream protein targets are summarized below (Fig. 1.14). 
 
Figure  1-14: Targets for AMPK (adapted from Hardie 2004a).  
Target proteins and processes activated by AMPK activation are shown in green, and those 
inhibited by AMPK activation are shown in red. Where the effect is caused by a change in gene 
expression, an upward-pointing green arrow next to the protein indicates an increase, whereas a 
downward-pointing red arrow indicates a decrease in expression. Abbreviations: ACC1/ACC2, 1 (α) 
and 2 (β) isoforms of acetyl-CoA carboxylase; CD36/FAT, CD36/fatty acid translocase; CFTR, 
cystic fibrosis transmembrane regulator; EF2, elongation factor-2; eNOS/nNOS. 
endothelial/neuronal isoforms of nitric oxide synthase; FAS, fatty acid synthase; G6Pase, glucose-
6-phosphatase; GLUT1/4, glucose transporters; GS, glycogen synthase; HMGR, 3-hydroxy-3-
methyl-CoA reductase; HSL, hormone-sensitive lipase; MEF2, myocyte-specific enhancer factor-2; 
NRF1, nuclear respiratory factor-1; PEPCK, phosphoenolpyruvate carboxykinase; PGC1 , 
peroxisome proliferator-activated receptor-  co-activator-1 ; TOR, mammalian target of 
rapamycin. 
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1.4.10 Role of AMPK in glucose homeostasis 
AMPK plays an important role in the regulation of glycogen synthesis, glycolysis, 
gluconeogenesis and glucose transport.  
It has been shown that AMPK can phosphorylate and inactivate the muscle isoform of GS 
(Carling and Hardie 1989) which is the key regulatory enzyme in glycogen synthesis.  
Phospho-fructose-kinase-2 (PFK-2) stimulates the production of fructose-2, 6-bisphosphate 
which is a physiological activator of a key enzyme in glycolysis, 6-phosphofructo-1-
kinase, also known as phospho-fructose-kinase-1 (PFK-1). In ischemic cardiac muscle, 
AMPK has been shown to stimulate glycolysis by phosphorylating and activating PFK-2 
(Marsin et al 2000).  
The AMPK activator AICAR has been shown to reduce the expression of the genes for the 
gluconeogenic enzymes PEPCK and G6Pase in hepatoma cells (Lochhead et al 2000). 
As discussed, the IRS-1 is phosphorylated by the active insulin receptor and then acts as a 
binding site for PI3K leading to the uptake of glucose by cells. Interestingly AMPK has 
been shown to phosphorylate the IRS-1 protein in the muscle cell line C2C12 in response 
to the AMPK activator AICAR (Jakobsen et al 2001). Thus potentially in muscle AMPK 
may play a role in increasing insulin sensitivity, thus consequently lowering blood glucose 
levels. 
In muscle AICAR, was shown to increase glucose uptake by promoting GLUT4 
translocation to the cell surface (Kurth-Kraczek et al 1999, Russell et al 1999, Ojuka et al 
2000) and GLUT4 gene transcription (Zheng et al 2001). In addition GLUT1 and GLUT4 
transport to the plasma membrane was also shown to be increased in the presence of a 
constitutively active AMPK mutant in a skeletal muscle cell line (Fryer et al 2002a). 
Furthermore, AICAR has been shown to potentiate insulin-stimulated glucose transport in 
isolated rat muscle (Bergeron et al 1999, Hayashi et al 1998). In 3T3-L1 adipocytes 
AICAR was found to stimulate basal glucose transport (Salt et al 2000, Yamaguchi et al 
2005) and inhibit insulin-stimulated glucose uptake and GLUT4 translocation to the plasma 
membrane (Salt et al 2000) which is in contrast to the effect of AICAR in muscle.  
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In contrast, another study reported that overexpression of a dominant negative mutant of 
AMPK in 3T3-L1 adipocytes treated with AICAR abolishes AMPK activation without 
affecting the increase in glucose uptake, suggesting that AICAR-induced glucose uptake 
by 3T3-L1 adipocytes is independent of AMPK activation (Sakoda et al 2002).  
1.4.11 Role of AMPK in lipid metabolism 
AMPK has been shown to phosphorylate and inhibit ACC activity (Park et al 2002, Kim et 
al 1989, Davies et al 1990). ACC is the rate-controlling step in the conversion of acetyl-
CoA to malonyl CoA (Tong 2005). The product of ACC, malonyl-CoA, is both a precursor 
for the biosynthesis of fatty acids (Wakil et al 1983) and a potent inhibitor of fatty acid 
oxidation because it inhibits CPT1 (McGarry 1995) and, thereby, the transport of long-
chain fatty acids into the mitochondrial matrix. In mammals there are two isoforms of 
ACC. ACC1 (265kDa) is expressed predominantly in lipogenic tissues such as liver, 
adipose and lactating mammary gland (Ha et al 1996, Abu-Elheiga et al 2005), and is 
reported to primarily regulate the biosynthesis of long-chain fatty acids (Ruderman et al 
2003). In contrast ACC2 (280kDa) is predominantly expressed in cardiac and skeletal 
muscle (Ha et al 1996, Abu-Elheiga et al 2005), and is reported primarily to regulate fatty 
acid oxidation (Merrill et al 1997).  
In adipocytes, ACC has been shown to be phosphorylated and inhibited by AICAR and 
overexpression of a constitutively active AMPK mutant (Sullivan et al 1994, Daval et al 
2005). Sullivan and co-workers also showed that this inhibition of ACC was concomitant 
with a decrease in the lipogenic rate (Sullivan et al 1994). In addition, Gaidhu and co-
workers also showed that AICAR stimulated AMPK activation inhibited lipogenesis in 
isolated rat adipocytes, (Gaidhu et al 2006). It has been proposed that inhibition of 
lipogenesis would conserve ATP under conditions of cellular stress (Gaidhu et al 2006). 
In skeletal muscle and liver it has been established that activation of AMPK results in 
increased mitochondrial import and oxidation of fatty acids to provide ATP as a fuel 
(Ruderman et al 1999, Chien et al 2000). Some studies suggest that AMPK activation in 
adipose tissue may also drive fatty acid oxidation. Overexpression of un-coupling protein 1 
(UCP-1) in white fat was reported to be associated with an increase in the AMP/ATP ratio, 
activation of AMPK and increased lipid oxidation (Matejkova et al 2004). In addition, in 
hyper-leptinized rats there is an increase in UCP-1 and UCP-2 expression, AMPK activity 
and inactivation of ACC (Orci et al 2004) in rat epididymal fat pads. However, in contrast 
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AICAR stimulated AMPK activation and subsequent inhibition of ACC in isolated rat 
adipocytes was shown to inhibit fatty acid oxidation (Gaidhu, et al 2006). Gaidhu and co-
workers proposed that suppression of fatty acid oxidation would spare fatty acids for 
exportation to other tissues where oxidation is crucial for energy production (Gaidhu, et al 
2006). Interestingly, a recent study by Gaidhu and co-workers showed that prolonged 
AICAR-induced AMPK activation promotes energy dissipation by activating fatty acid 
oxidation (Gaidhu et al 2008).  
As discussed, the β-adrenergic signalling pathway regulates triglyceride breakdown, acting 
via the accumulation of cAMP and subsequent PKA-dependent phosphorylation of HSL. 
The AMPK activator AICAR and was shown to antagonise isoproterenol induced lipolysis 
by phosphorylating HSL, which inhibits phosphorylation and activation of HSL by PKA in 
isolated adipocytes (Corton et al 1995, Sullivan et al 2004, Daval et al 2005, Dagon et al 
2006). In addition, overexpression of a constitutively active AMPK in rat adipocytes was 
also shown to inhibit isoproterenol-induced lipolysis, whereas overexpression of a 
dominant negative form of AMPK had a converse effect (Daval et al 2005). Gauthier and 
co-workers also showed that AMPK is activated as a consequence of lipolysis in 
adipocytes (Gauthier et al 2008). When the rate at which fatty acids are being produced by 
lipolysis exceeds the rate at which they are being exported from the cell, they are re-
esterified back into TG in an energy dependent manner. Thus, it has been proposed that 
AMPK activation and subsequent inhibition of lipolysis by AMPK would prevent futile 
cycling and depletion of ATP (Hardie et al 2007, Gauthier et al 2008). 
Contrary to the above findings, Yin and co-workers have shown that adrenergic 
stimulation results in AMPK phosphorylation and activation which results in the 
stimulation of lipolysis in 3T3-L1 adipocytes (Yin et al 2003). It has been proposed that 
upon β-adrenergic stimulation, AMPK is phosphorylated and activated via an intermediary 
rise in cAMP, and this activation contributes to lipolysis, possibly by phosphorylating HSL 
at Ser565 and promoting HSL translocation to the lipid droplet (Yin et al 2003). Yin and 
co-workers also showed that overexpression of a dominant negative form of AMPK 
inhibits isoproterenol-induced lipolysis suggesting, rather, a lipolytic action of AMPK 
activation (Yin et al 2003). However, AMPK activity was not measured in these conditions 
and thus final conclusions from these experiments are difficult to draw.  
It has been reported that the duration of AMPK stimulation may be important with respect 
to lipolysis, as Gaidhu and co-workers found that lipolysis was first suppressed in 
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adipocytes, but then increased both in vitro and in vivo with prolonged AICAR treatment 
(Gaidhu et al 2008). 
Other potential targets of AMPK include fatty acid translocase (FAT), which plays an 
important role in long-chain fatty acid uptake in adipocytes. FAT knock out mice showed 
increased serum fasting levels of NEFAs and showed reduced uptake of oleate in isolated 
adipocytes (Febbraio et al 1999). Interestingly, signalling through AMPK has been 
proposed to mediate FAT translocation to the membrane in rat cardiac myocytes (Luiken et 
al 2003).  Finally, cholesterol and isoprenoid biosynthesis, for which HMG-CoA reductase 
(HMGR) catalyses the rate limiting step is also influenced by AMPK activity. Active 
AMPK can phosphorylate and inactivate HMGR resulting in reduced cholesterol and 
isoprenoid synthesis (Beg et al 1978).  
1.4.12 Role of AMPK and adipocyte differentiation 
There is some evidence to suggest that AMPK activation can inhibit preadipocyte 
differentiation. Studies investigating the role of AMPK in adipogenesis have reported that 
AMPK activation by AICAR inhibits differentiation of 3T3-L1 preadipocytes into 
adipocytes and blocks the expression of the early adipogenic transcription factors PPARγ, 
CAAT/enhancer-binding protein alpha (C/EBPα), CAAT/enhancer-binding protein beta 
(C/EBPβ) and the late adipogenic markers such as FAS and ACC (Habinowski and Witters 
2001, Giri et al 2006, Tong et al 2008). Thus it has been suggested by these studies that 
AMPK activation inhibits differentiation of preadipocytes by turning off anabolic adipose-
specific gene expression. However, intra-peritoneal administration of AICAR to a mouse 
diet induced obesity model, blocked body weight gain and reduced total epididymal fat in 
these mice. The reduction in adipose tissue content was due to reduced lipid accumulation 
in the pre-existing adipocytes and by activating expression of peroxisome-proliferator-
activated receptor (PPAR)γ co-activator 1a (PGC1a) without reducing adipocyte-specific 
transcription factors such as C/EBPα and PPARγ in the diet induced obesity model mice 
(Giri et al 2006). 
Furthermore, other studies concluded that AMPKα2 does not regulate adipocyte 
differentiation in vivo. AMPKα2 knockout mice were subjected to a high-fat diet to 
examine the effect of AMPK on adipose tissue formation. These mice were found to 
exhibit higher body weight, with a specific increase in adipose tissue compared to wild 
type mice. However the expression of genes that control adipogenesis, including C/EBPα 
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and PPARγ were found not to be changed in the AMPKα2 knockout mice suggesting that 
the increased adipose tissue mass is not due to an enhancement of preadipocyte 
differentiation into adipocytes and therefore that AMPKα2 does not regulate adipocyte 
differentiation in vivo. The augmentation in adipose tissue mass in AMPKα2 knockout 
mice is thought to be due to the enlargement of pre-existing adipocytes, with an increase in 
triglyceride accumulation (Villena et al 2004).  
Thus it is currently not clear whether AMPK has a physiological regulatory function in 
adipocyte differentiation. 
1.4.13 Role of AMPK and adipokine secretion 
The biguanide metformin is used to treat type 2 diabetic patients. In these patients 
metformin lowers blood glucose levels by reducing hepatic glucose production and 
facilitating glucose utilization in skeletal muscle (Bailey et al 1996, Galuska et al 1991, 
Hundal et al 1992, Hundal et al 2000). These effects appear to be mediated through 
inhibition of complex I in the mitochondrial respiratory chain (Owen et al 2000, El-Mir et 
al 2000) and / or stimulation of AMPK (Zhou et al 2001). In 3T3-L1 adipocytes, 
metformin was shown to activate AMPK and suppress adiponectin expression and 
secretion (Huypens et al 2005). Since treatment of 3T3-L1 adipocytes with AICAR 
(Huypens et al 2005) also caused a decrease in adiponectin expression and secretion it has 
been proposed that metformin induced suppression involves AMPK activation. However, 
as metformin is a metabolic poison and not a specific AMPK activator, the role of AMPK 
is uncertain. In addition, there has been no observed change in adiponectin serum 
concentration or adiponectin mRNA concentration in adipose tissue of type 2 diabetic 
patients treated with metformin (Phillips et al 2003, Tiikkainen et al 2004). Conversely, 
AICAR has been shown to increase the expression of adiponectin in human adipose tissue 
(Sell et al 2006, Lihn et al 2004). AICAR has also been shown to inhibit the expression 
and secretion of the pro-inflammatory cytokines TNFα and IL-6 in human adipose tissue 
(Lihn et al 2004, Sell et al 2006). Given that adiponectin has also been shown to decrease 
the secretion of pro-inflammatory cytokines (Sell et al 2006), it has been proposed that 
AICAR may mediate its effects on the pro-inflammatory cytokines via adiponectin. Thus, 
the inhibition of secretion of these pro-inflammatory cytokines by AMPK could be 
beneficial, as inflammation contributes to disorders such as cardiovascular disease and 
insulin resistance, which are associated with obesity.  
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1.4.14 Role of AMPK in mitochondrial biogenesis 
Studies have shown that in rodent muscle AMPK activation correlates with increased DNA 
binding by the transcription factors nuclear respiratory factor-1 (NRF-1) (Bergeron et al 
2001) and myocyte enhancer factor-2 (MEF-2) (Zheng et al 2001) which results in 
increased mitochondrial biogenesis. In addition AMPK activation was also shown to 
correlate with the up-regulation of the expression of the co-activator PGC1α (Terada et al 
2002) which may also be involved in the increased expression of mitochondrial genes in 
muscle (Zong et al 2002). 
1.4.15 Role of AMPK in protein synthesis 
AMPK has been shown to inhibit protein synthesis and cell growth in cultured cells. 
Translational elongation is blocked through the activation of eukaryotic elongation factor-2 
(eEF-2) kinase, which phosphorylates and inhibits eEF2, allowing protein translocation to 
pause until ATP levels are restored. Hypoxia inhibits protein synthesis in hepatocytes and 
is mediated by AMPK-dependent activation of eEF2 kinase and subsequent 
phosphorylation of eEF2 (Horman et al 2002). 
The target of rapamycin (TOR) pathway is activated by growth factors and amino acids 
and is a major positive stimulus for protein synthesis, cell growth and cell size (Fig. 1.15) 
(Schmelzle and Hall 2000). Tuberous sclerosis complex 1/2 (TSC1/TSC2) form a stable 
complex in the cells, with mutations in either leading to the human disease tuberous 
sclerosis (Young and Povey 1998). Recent genetic studies in Drosophilia demonstrated 
that TSC1/TSC2 complex acts to negatively regulate cell growth and cell size and have 
shown that it acts downstream of PKB/Akt in the insulin-signalling pathway  
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Figure  1-15: Regulation of protein synthesis and cell growth by AMPK and PKB/Akt by the 
mTOR pathway.  
AMPK = AMP-activated protein kinase, PKB = protein kinase B, TSC1/2 = Tuberous sclerosis 
complex 1/2, TOR = target of rapamycin, S6K1 = ribosomal protein S6 kinase, 4E-BP1 = 
elongation factor-4E binding protein 1. 
 
and upstream of mammalian TOR (Gao and Pan 2001, Gao et al 2002, Tapon et al 2001). 
AMPK phosphorylates TSC2 at two sites, Thr1227 and Ser1345. Activation of TSC2 by 
AMPK-dependent phosphorylation results in activation of the TSC1/TSC2 complex and 
subsequent inhibition of the TOR pathway, thus inhibiting protein synthesis and cell 
growth through ribosomal protein S6 kinase (S6K1) and elongation factor-4E binding 
protein 1 (4E-BP1) (Inoki et al 2003). 
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1.5 Aims 
The overall aim of this study was to characterise the role of AMPK in adipocytes. 
Although AMPK activation has been previously reported in adipose tissue and cultured 
adipocytes, a thorough investigation of the expression of components of the AMPK 
cascade, kinetics/mechanism of AMPK stimulation and role of AMPK in adipocyte insulin 
action has yet to be undertaken.  
The initial aim of this study was to investigate the expression of the upstream AMPK 
kinases; LKB1 and CaMKKα/β, and the downstream AMPK substrates ACC1/2 in 3T3-L1 
adipocytes. Since AMPK has been shown to play a role in the regulation of adipogenesis 
and 3T3-L1 cells are widely used as a model system to study the differentiation of 
preadipocytes to adipocytes, the expression of AMPK subunit isoforms and the relative 
contribution of the catalytic AMPKα subunits to total AMPK activity throughout 
development from fibroblasts to adipocytes in 3T3-L1 cells was also investigated.  
The parameters of AMPK activation in 3T3-L1 in response to various stimuli; AICAR, 
arsenite, azide, metformin, rosiglitazone, leptin, sorbitol, hydrogen peroxide, A23187, 
isoproterenol and A769662 were then determined. In addition, the mechanism by which 
each activator stimulates AMPK activity in 3T3-L1 adipocyte was investigated using the 
CaMKK inhibitor STO-609 and high performance liquid chromatography (HPLC) to 
detect changes in cellular energy levels.  
Acute AICAR treatment has previously been shown in our laboratory to modestly 
stimulate basal glucose transport and inhibit insulin stimulated glucose transport in 3T3-L1 
adipocytes (Salt et al 2000), which is in contrast to the effect of AICAR in muscle 
Bergeron et al 1999) . In order to further characterise the role of AMPK in the inhibition of 
insulin-stimulated glucose transport the acute effect of various other AMPK activators on 
basal and insulin stimulated glucose uptake was assessed using 2-[3H] deoxy-D-glucose. 
The effect of AMPK inhibition and knockdown, using Compound C and Ad.α1DN 
respectively, on AICAR stimulated basal glucose transport and inhibition of insulin-
stimulated glucose transport was also assessed to determine whether the effects of AICAR 
on glucose transport are dependent on AMPK activation. 
Previous work in our laboratory also showed that AICAR did not alter IRS-1 
phosphorylation, PI3K association with IRS-1 or PKB activity in 3T3-L1 adipocytes (Salt 
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et al 2000). During the course of this project AS160 and TBC1D1 have emerged as Rab 
GAPs (Thong et al 2007, Roach et al 2007) involved in the regulation of glucose transport. 
Therefore another aim of this study was to investigate the mechanism by which AICAR 
inhibits insulin-stimulated glucose transport in adipocytes, with particular attention being 
paid to the effect of AICAR on basal and insulin-stimulated AS160/TBC1D1 
phosphorylation at phospho-Akt/PKB (PAS) sites. 
Finally the effect of sustained AMPK activation on glucose transport and insulin signaling 
in 3T3-L1 adipocytes was also to be determined. In addition, the effects of sustained 
AMPK activation on insulin signaling in human adipose tissue was investigated.
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Chapter 2 – Materials and methods 
2.1 Materials 
2.1.1 List of materials and suppliers 
American Type Culture Collection, Manassas, Virginia, USA 
3T3-L1 preadipocytes 
 
AXXORA (UK) Ltd, Bingham, Nottingham, UK 
Rosiglitazone  
Gliclazide  
 
BDH Laboratory Supplies, Poole, UK 
Calcium chloride (CaCl2) 
Coomassie Brilliant Blue G-250  
Dipotassium hydrogen phosphate (K2HPO4)  
Hydrogen peroxide (H2O2) 
Magnesium chloride (MgCl2) 
Magnesium sulphate (MgSO4)   
Potassium chloride (KCl)  
Sodium chloride (NaCl)   
Tetrasodium pyrophosphate (Na4P2O7)  
 
Cambridge Bioscience Ltd, Cambridge, UK 
Quick TiterTM Adenovirus Titer Immunoassay kit  
 
Dundee University, Dundee, UK 
A-769662 (AMPK activator), was a generous gift from Prof. D.G. Hardie. 
 
Eastman Kodak Company, Rochester, New York, USA 
Kodak Medical X-ray film 
 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
Corning tissue culture T75/ T150 flasks 
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D-Glucose  
Ethanol   
Glycine  
HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethane sulphonic acid)   
Potassium dihyrogen phosphate (KH2PO4)  
Tris base (tris(hydroxymethyl)aminoethane) 
 
GE Healthcare, Little Chalfont, Buckinghamshire, UK 
Protein A-sepharose beads   
Protein G-sepharose beads   
 
Hopkin and Williams, Chadwell Health, Essex, UK 
Sodium azide (NaN3) 
 
Inverclyde Biologicals, Bellshill, Lanarkshire, UK 
Nitrocellulose transfer membrane, 0.45 µm pore size 
 
Invitrogen (GIBCO Life Technologies Ltd), Paisley, UK 
Dulbecco’s modified Eagles media (DMEM) 
Foetal calf serum (FCS) (USA origin)  
Newborn calf serum (NCS) (EU origin) 
Penicillin/streptomycin  
L-glutamine  
Trypsin  
 
Premier International Foods, Cheshire, UK 
Dried skimmed milk 
 
Melford Laboratoried Ltd, Chelsworth, Ipswich, Suffolk, UK 
Dithiothreitol (DTT) 
 
Merck Chemicals Ltd, Nottingham, UK 
Compound C 
A23187  
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National Diagnostics (UK) Ltd, Hessle, East Riding of Yorkshire, UK 
Ecosint A   
 
New England Biolabs, Hertfordshire, UK 
Prestained protein markers (broad range 6-175kDa) 
 
Novo-Nordisk, Bagsvaerd, Denmark 
Porcine insulin 
 
Pepceuticals, Leicester, UK 
SAMS peptide (HMRSAMSGLHLVKRR) 
 
PeproTech, London, UK 
Leptin  
 
Perkin Elmer, Beaconsfield, Buckinghamshire, UK 
2-[3H]-deoxy-D-glucose  
[γ-32P] ATP  
 
Pierce, Perbio Science, UK Ltd, Tattenhall, Cheshire, UK 
10,000 MWCO slide-a-lyzer  
 
Severn Biotech Ltd, Kidderminster, Hereford, Worcester, UK 
Acrylamide:Bisacrylamide (37.5:1; 30% (w/v) Acrylamide)  
 
Sigma-Aldrich (Steinheim, Germany; Seelze, Germany; St Louis, MO, USA) 
5-Amino-2,3-dihydro-1,4-phthalazinedione (luminol) 
Adenosine 5’-diphosphate (ADP) 
Adenosine 5’-monophosphate (AMP)  
Adenosine 5’-triphosphate (ATP) 
Ammonium peroxydisulphate (APS) 
Bovine serum albumin (BSA)  
Benzamidine 
p-Coumaric acid 
Cytochalasin B  
Dexamethasone 
Pamela Jane Logan, 2009   Chapter 2, 64 
Dimethyl sulphoxide (DMSO) 
Disodium hydrogen phosphate (Na2HPO4) 
D-mannitol 
Ethylenediamine tetraacetic acid (EDTA) 
Ethylene glycol-bis (β-amino-ethylether)-N,N,N’,N’-tetraacetic acid (EGTA) 
Glycerol 
Isobutylxanthine (IBMX)  
Metformin  
Methanol 
ProteoPrep Blue Albumin and IgG Depletion Kit  
Sodium flouride (NaF) 
Sodium hydrogen carbonate (NaHCO3) 
Sodium dihydrogen phosphate (NaH2PO4) 
Sodium orthovanadate (Na4VO3) 
Soybean trypsin inhibitor (SBTI) 
Sodium dodecyl sulphate (SDS) 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
Triethylamine (TEA) 
Triton X-100  
Tween-20  
 
Tocris Cookson Ltd, Fouth Way, Avonmouth, UK 
STO-609  
 
Toronto Research Chemicals Inc, Ontario, Canada 
AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) 
 
Varian, California, USA 
Chrom Spher C18 octadecylsilane (5 µm)  
 
VWR, Lutterworth, Leicestershire, UK 
Falcon tissue culture 10 cm dishes and 6/12 well plates 
Whatman P81 phosphocellulose paper   
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2.1.2 List of specialist equipment and suppliers 
Beckman CoulterTM High Wycombe, UK 
OptimaTM XL-80K ultracentrifuge 
SW40 rotor 
Multi-Purpose scintillation counter LS 6500 
 
Bio-Rad Laboratories, Hemel Hempstead, UK 
Protein gel casting and Western blotting equipment (Mini Protean III) 
 
Fisher Scientific, Loughborough, UK 
Polycarbonate freezing container 
 
Optika Microscopes, Ponteranica, Italy 
XDS-1B light microscope 
 
WPA, Cambridge, UK 
S2000 spectrophotometer 
 
Varian Limited, Oxford, UK 
Varian ProStar 410 high performance liquid chromatography (HPLC) AutoSampler   
Stainless-steel column (250 x 4.6 mm I.D) packed with Chrom Spher C18 octadecylsilane 
(ODS)  
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2.1.3 List of antibodies and conditions of use 
2.1.3.1 Primary antibodies for Western blotting 
Table  2-1: Primary antibodies used for western blotting 
n/a: not applicable. All antibodies were incubated overnight at 4°C. 
Epitope Clonality Host 
species 
Dilution Diluent 
(w/v in 
TBST) 
Source 
14-3-3  polyclonal rabbit 1:1000 5% milk Abcam, Cambridge, 
UK. (#9093) 
ACC1 N-
term (cDEP) 
polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK. 
CDEPSPLAKTLELN
Q (C + residues 2-15 of 
rat ACC coupled to 
KLH. 
ACC2 (146) polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK. 
CEDKKQAPIKRQLM
T (C + residues 146-
159 of rat ACC2 
coupled to KLH. 
ACC Ser79  polyclonal rabbit 1:1000 5% BSA New England Biolabs, 
Hertfordshire, UK. 
(#3661) 
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AMPKα1 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK (Woods et 
al 1996b). 
AMPKα2 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK (Woods et 
al 1996b). 
AMPK Pan 
α1/ α2 
polyclonal sheep 1:500 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK. 
CDPMKRAT(phospho
)IKDIRE (C + residues 
252-264 of rat alpha-1). 
AMPK 
T172  
polyclonal rabbit 1:1000 5% BSA New England Biolabs, 
Hertfordshire, UK. 
(#2531) 
AMPKβ1 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK (Woods et 
al 1996a). 
AMPKβ2 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
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Dundee, UK (Woods et 
al 1996a). 
AMPKγ1 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK (Cheung 
et al 2000). 
AMPKγ2 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK 
DLEGSGKHSSRKVD 
(residues 51-63 human 
gamma 2). 
AMPKγ3 polyclonal sheep 1:1000 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK 
LSPAGIDPSGPEKI 
(residues 479-492 
human gamma 3). 
AS160  polyclonal rabbit 1:1000 5% BSA New England Biolabs, 
Hertfordshire, UK. 
(#2447) 
CaMKKα  monoclonal 
clone: F-2 
mouse 1:200 5% milk Santa Cruz, 
Biotechnology, 
California. (#17827) 
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CaMKKβ  polyclonal goat 1:200 5% milk Santa Cruz, 
Biotechnology, 
California. (#9629) 
FAS  monoclonal
clone: 23 
mouse 1:250 5% milk BD transduction 
laboratories, Oxford 
science park, Oxford, 
UK. (#610962) 
GAPDH  monoclonal
clone: 6C5 
mouse 1:40000 5% milk Ambion, Ermine 
Business Park, 
Cambridgeshire, UK. 
(#4300) 
IRS1  polyclonal rabbit 1:1000 5% BSA New England Biolabs, 
Hertfordshire, UK. 
(#2382) 
LKB1  polyclonal sheep 1:500 5% milk A generous gift from 
Prof. D.G. Hardie, 
University of Dundee, 
Dundee, UK. 
LKB1 antibody was 
raised against the 
whole protein in sheep 
and was purified using 
protein G. 
myc  monoclonal
clone: 9E10 
mouse 1:1000 5% milk Sigma, St Louis, MO, 
USA. (#5546) 
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PAS  monoclonal
clone:110B 
rabbit 1:1000 5% BSA New England Biolabs, 
Hertfordshire, UK. 
(#9614) 
PKB  ployclonal rabbit 1:1000 5% milk New England Biolabs, 
Hertfordshire, UK. 
(#9272) 
PKB Ser473  polyclonal rabbit 1:1000 5% BSA New England Biolabs, 
Hertfordshire, UK. 
(#9271) 
TBC1D1 polyclonal sheep 1:1000 5% BSA A generous gift from 
Prof. C. Mackintosh 
University of Dundee, 
Dundee, UK, (Chen et 
al 2008). 
 
2.1.3.2 Secondary detection agents for Western blotting 
Table  2-2: Secondary detection agents for western blotting 
Linked 
molecule 
Epitope Host 
species 
Dilution Diluent       
(w/v in 
TBST) 
Source 
HRP mouse IgG  sheep 1:1000 5% milk or 
BSA 
GE Healthcare, 
Little Chalfont, 
Buckinghamshire, 
UK. (#NA931) 
 
HRP rabbit IgG  donkey 1:1000 5% milk or 
BSA 
GE Healthcare, 
Little Chalfont, 
Buckinghamshire, 
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UK. (#NA934) 
 
HRP streptococcus 
sp. Protein G  
n/a 1:1000 5% milk or 
BSA 
Sigma, St Louis, 
MO, USA. 
(#P8170) 
 
2.1.4 Standard solutions 
Unless stated otherwise, all buffers and reagents were made up with distilled water. 
Bradford’s reagent 
35.0 mg/L coomassie brilliant blue 
5.0% (v/v) ethanol 
5.1% (v/v) orthophosphoric acid 
Bradford’s reagent was filtered and stored in the dark. 
 
Coomassie stain 
0.05% (w/v) coomassie brilliant blue  
50% (v/v) methanol 
10% (v/v) acetic acid 
Coomassie stain was filtered. 
 
Coomassie de-stain 
10% (v/v) methanol 
10% (v/v) acetic acid 
 
Enhanced chemiluminescence (ECL) detection reagents 
Solution 1 
0.1 mM Tris-HCl, pH 8.5  
450 mg/L luminol in 2% (v/v) DMSO 
130 mg/L coumaric acid in 1% (v/v) DMSO 
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Solution 2 
0.1 mM Tris-HCl , pH 8.5 
0.02% (v/v) H2O2 
 
HEPES Brij-35 buffer 
50 mM HEPES, pH 7.4 at 4˚C 
1 mM DTT  
0.02% (v/v) Brij-35 
 
Immunoprecipitation (IP) buffer 
50 mM Tris-HCl, pH 7.4 at 4˚C 
150 mM NaCl 
50 mM NaF 
5 mM Na4P2O7 
1 mM EDTA  
1 mM EGTA 
1% (v/v) Triton X-100  
1% (v/v) glycerol 
1 mM DTT 
0.1 mM benzamidine                            added on day of use 
0.1 mM PMSF  
5 µg/ml SBT1  
1 mM Na3VO4 
 
Krebs-Ringer HEPES (KRH) buffer 
119.0 mM NaCl 
20.0 mM HEPES-NaOH, pH 7.4 
5.0 mM NaHCO3 
10.0 mM glucose  
4.8 mM KCl 
2.5 mM CaCl2 
1.2 mM MgSO4 
1.2 mM NaH2PO4  
0.1 mM L-Arginine 
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Krebs-Ringer phosphate (KRP) buffer 
130 mM NaCl 
4.8 mM KCl 
5 mM NaH2PO4, pH 7.4 
1.25 mM MgSO4 
1.25 mM CaCl2 
 
Lysis buffer 
50 mM Tris-HCl, pH 7.4 (at 4°C)     
50 mM NaF              
1 mM Na4P2O7          
1 mM EDTA              
1 mM EGTA              
1% (v/v) Triton X-100 
250 mM mannitol 
1 mM DTT 
1 mM Na3VO4                            added on day of use 
0.1 mM benzamidine  
0.1 mM PMSF 
5 µg/ml SBTI 
 
Phosphate-buffered saline (PBS) (pH 7.2) 
85 mM NaCl 
1.7 mM KCl 
5 mM Na2HPO4 
0.9 mM KH2PO4 
 
Ponceau S Stain 
0.2% (w/v) ponceau S 
1% (v/v) acetic acid 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) Running buffer 
190 mM glycine 
 62 mM Tris base 
 0.1% (w/v) SDS 
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4 X SDS-PAGE sample buffer 
200 mM Tris-HCl, pH 6.8 
8% (w/v) SDS 
40% (v/v) glycerol 
0.4% (w/v) bromophenol blue 
200 mM DTT 
 
Transfer buffer 
25 mM Tris base 
192 mM glycine 
20% (v/v) ethanol 
 
Tris buffered saline (TBS)  
20 mM Tris-HCl, pH 7.5  
137 mM NaCl 
 
Tris buffered saline + Tween 20 (TBST) 
20 mM Tris-HCl, pH 7.5  
137 mM NaCl 
0.1% (v/v) tween 20 
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2.2 Methods 
2.2.1 Cell Culture Procedures 
2.2.1.1 Cell culture plastic ware 
3T3-L1 cells were cultured in Corning T75 flasks and Falcon 10 cm dishes, 6 well plates 
and 12 well plates. 
Human embryonic kidney (HEK) 293 cells, a generous gift from Dr. S. Yarwood, 
University of Glasgow, were cultured in Corning T75 flasks, T150 flasks, and 24 well 
plates. 
2.2.1.2 Cell culture growth media for 3T3-L1 preadipocytes 
Preadipocytes were maintained as fibroblasts (passage 2-12) in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) newborn calf serum (NCS) and 
200 IU penicillin and 200 µg streptomycin/500ml. Cells were cultured at 37˚C in a 
humidified atmosphere of 10% (v/v) CO2 in media replaced every 48 hr. 
2.2.1.3 Cell culture growth media for HEK 293 cells 
HEK 293 cells were maintained in DMEM supplemented with 5% (v/v) foetal calf serum 
(FCS), 2 mM glutamine and 200 IU penicillin and 200 µg streptomycin/500ml. Cells were 
cultured at 37˚C in a humidified atmosphere of 5% (v/v) CO2 in media replaced every 48 
hr. 
2.2.1.4 Preparation of 3T3-L1 fibroblast differentiation medium 
Differentiation was initiated using DMEM medium containing 10% (v/v) FCS, 0.5 mM 
methyl isobutylxanthine (IBMX), 0.25 µM dexamethasone, and porcine insulin (1 µg/ml), 
prepared as outlined below. 
A 2.5 mM sterile solution of dexamethasone in ethanol was diluted 1:20 with 10% (v/v) 
FCS/DMEM medium immediately prior to use yielding a 500X stock solution. A 500X 
concentrated sterile solution of IBMX was also prepared by dissolving 110 mg IBMX in 2 
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ml of 1 M KOH. Insulin (1 mg/ml) was then prepared in 0.01 M HCl. Sterile solutions of 
dexamethazone, IBMX and insulin were achieved by passing through a 0.22 µm filter.  
3T3-L1 differentiation medium was prepared by diluting both the dexamethasone and 
IBMX solutions to a 1X concentration in 10% (v/v) FCS/DMEM and then adding insulin 
to a final concentration of 1 µg/ml. 
2.2.1.5 3T3-L1 fibroblast differentiation protocol 
To differentiate the 3T3-L1 fibroblast cells into adipocytes, the cells were grown to 
confluency in 10% (v/v) NCS/DMEM. At 48 hr post confluence, cell medium was 
aspirated and replaced with differentiation medium consisting of 10% (v/v) FCS/DMEM 
containing 0.25 µM dexamethasone, 0.5 mM IBMX and insulin (1 µg/ml). After a further 
two days this medium was aspirated and replaced with 10% (v/v) FCS/DMEM containing 
1 µg/ml insulin. The cells were incubated in this medium for two days, and then the 
medium was aspirated and replaced with 10% (v/v) FCS/DMEM.  At 8-12 days post-
induction of differentiation, cells were used for experimentation.   
2.2.1.6 Passaging of 3T3-L1 fibroblasts 
When cells in T75 flasks were 70-80% confluent, DMEM growth medium was aspirated 
and 5 ml of sterile trypsin (0.05% (v/v) in diaminoethanetetra-acetic acid, disodium salt 
(EDTA)) was added to each T75 flask.  Flasks were then incubated at 37˚C until the cells 
began to lift off. Trypsin was titurated over the surface of the flask until all of the cells 
were detached. An appropriate amount of DMEM growth medium was then added to the 5 
ml of trypsin and used to seed 10 cm cell culture plates, 12 well plates, 6 well plates and 
T75 flasks. 
2.2.1.7 Passaging of HEK 293cells 
When cells in T75 flasks were 70-80% confluent, DMEM growth medium was aspirated 
and 5 ml of sterile trypsin (0.05% (v/v) in EDTA) was added to each T75 flask.  Flasks 
were then incubated at 37˚C until the cells began to lift off. Trypsin was titurated over the 
surface of the flask until all of the cells were detached. 10-15 ml of DMEM was added to 
neutralize the trypsin. The trypsinised cells were then transferred to a 50 ml falcon tube. 
Cells were centrifuged at 2000 x g for 5 min. The media was then aspirated and the cells 
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re-suspended in the appropriate amount of media to seed T75, T150 flasks and 12 well 
plates. 
2.2.1.8 Resurrection of frozen 3T3-L1 cell stocks from liquid nitrogen 
Cell cryogenic vials were removed from liquid nitrogen and incubated in a water bath at 
37°C until the cells were thawed. Vials were then transferred to a cell culture sterile flow 
hood where the following procedure was performed. 
The cells were transferred to a T75 flask containing 15 ml of 10% (v/v) NCS/DMEM. 3T3-
L1 cells were then maintained in an incubator at 37°C in an atmosphere of 10% CO2. The 
following day the medium was aspirated to remove dead cell debris and was replaced with 
fresh medium. 
2.2.1.9 Resurrection of frozen HEK 293 cell stocks from liquid nitrogen 
Cell cryogenic vials were removed from liquid nitrogen and incubated in a water bath at 
37°C until the cells were thawed. Vials were then transferred to a cell culture sterile flow 
hood where the following procedure was performed. 
The cells were transferred to a T75 flask containing 15 ml of 5% (v/v) FCS/DMEM. HEK 
293 cells were then maintained in an incubator at 37°C in an atmosphere of 5% CO2. The 
following day the medium was aspirated to remove dead cell debris and was replaced with 
fresh medium. 
2.2.1.10 Preparation of 3T3-L1 murine fibroblast cells for freezing 
DMEM medium was aspirated from T75 flasks and 5 ml of trypsin (0.05% (v/v) in EDTA) 
was added to each flask. Flasks were then incubated at 37˚C for 3-5 min until the cells 
were just beginning to lift off the flask. The trypsin solution was gently titurated over the 
surface of the flask until all of the cells were detached. 5 ml of 10% (v/v) NCS/DMEM 
was added to each flask. The cell suspension was then transferred to a 15 ml universal 
tube. The trypsin/cell mix was then centrifuged at 2000 x g for 3 min and the trypsin 
supernatant aspirated. The cell pellet was then re-suspended in 1 ml of freeze medium; 
10% (v/v) NCS/DMEM containing 10% (v/v) dimethyl sulphoxide (DMSO). The re-
suspended cell pellet was then transferred into 1.8 ml polypropylene cryogenic tubes and 
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left for 10 min at room temperature. The cryogenic tubes were then placed into a 
polycarbonate container and stored overnight at -80˚C. The following morning the vials 
were transferred to liquid nitrogen and stored until required. 
2.2.1.11 Preparation of HEK 293 for freezing 
DMEM medium was aspirated from T75 flasks and 5ml of trypsin (0.05% (v/v) in EDTA) 
was added to each flask. Flasks were then incubated at 37˚C for 3-5 min until the cells 
were just beginning to lift off the flask. The trypsin solution was gently titurated over the 
surface of the flask until all of the cells were detached. 5 mls of 5% (v/v) FCS/DMEM was 
added to each flask containing HEK 293 cells. The cell suspension was then transferred to 
a 15 ml universal tube. The trypsin/cell mix was then centrifuged at 2000 x g for 3 min and 
the trypsin supernatant aspirated. The cell pellet was then re-suspended in 1 ml of freeze 
medium; 5% (v/v) FCS/DMEM containing 10% (v/v) DMSO. The re-suspended cell pellet 
was then transferred into 1.8 ml polypropylene cryogenic tubes and was left for 10 min at 
room temperature. The cryogenic tubes were placed into a polycarbonate container and 
stored overnight at -80˚C. The following morning the vials were transferred to liquid 
nitrogen and stored until required. 
2.2.2 Preparation of 3T3-L1 lysates 
3T3-L1 cells cultured on 10 cm diameter Falcon tissue culture dishes were incubated for 2 
hr at 37˚C in 5 ml Krebs-Ringer HEPES (KRH) per dish. After incubating the cells in fresh 
KRH, test substances were then added to the dishes for various durations at 37˚C. The 
medium was removed and 0.4 ml lysis buffer was added to the dishes on ice. The cell 
extract was scraped off using a cell lifter and transferred into pre-cooled 1.5 ml 
microcentrifuge tubes. The extracts were vortex-mixed and centrifuged (21,910 x g, 3 min, 
4˚C) on a bench top centrifuge. The supernatants were stored at -80˚C. 
2.2.3 Protein concentration determination 
Spectrophotometric analysis of 3T3-L1 lysates according to the Bradford method 
(Bradford 1976) was carried out at 595 nm in a spectrophotometer using disposable plastic 
cuvettes. Duplicates of 2 µg, 4 µg and 6 µg bovine serum albumin (BSA) were made up to 
100 µl with H2O and utilised as reference standards. Lysates, analysed in duplicate, were 
diluted (1:10) using distilled water. 5 µl of diluted lysate was then added to 95 µl of 
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distilled water in a cuvette. To all samples and reference standards, 1 ml Bradford’s 
reagent was added and spectrophotometric analysis performed in a WPA S2000 
spectrophotometer within 10 min of reagent addition. The mean absorbance for each 
sample duplicate was calculated and the protein concentration determined by comparison 
to the calculated mean A595 / µg BSA derived from the linear portion of the BSA reference 
standard curve.  
2.2.4 Immunoprecipitation 
2.2.4.1 Immunoprecipitation of AMPK α1, AMPK α2 and CaMKK β from 3T3-
L1 adipocytes 
10 µl (per sample) of protein G-sepharose beads were washed three times in screw cap 
microcentrifuge tubes using 1 ml of immunoprecipitation (IP) buffer (21,910 x g, 1 min at 
4˚C). AMPK α1 (2 ug/sample), AMPK α2 (2 ug/sample) or CaMKKβ (2 ug/sample) were 
then added to the beads. 250 µl of IP buffer was added to the mixture and mixed by 
rotation for 1 hr at 4˚C.
 
The beads were pelleted (21,910 x g, 1 min at 4˚C) and re-
suspended in IP buffer (25% v/v). In 1.5 ml microcentrifuge tubes, 3T3-L1 adipocyte 
lysate (200 µg) was added to 20 µl of the protein G-sepharose bead slurry pre-bound to 
sheep anti-AMPK α1, sheep anti-AMPK α2 antibody or goat anti-CaMKKβ antibody. The 
volume was made up to 300 µl with IP buffer and was mixed for 4 hr at 4˚C on a rotating 
mixer. The beads were then pelleted (21,910 x g, 1 min at 4˚C) and the supernatant 
aspirated. The pellet was washed twice (21,910 x g, 1 min at 4˚C) with 1 ml of high salt (1 
M NaCl) IP buffer and twice (21910 x g, 1 min at 4˚C) with 1 ml of IP buffer. For AMPK 
IPs the pellets were washed (21910 x g, 1 min at 4˚C) with 1 ml of HEPES Brij-35. The 
pellets were stored at -20˚C. 
2.2.4.2 Immunoprecipitation of AS160 and TBC1D1 from 3T3-L1 adipocytes 
Using 1.5 ml microcentrifuge tubes, 3T3-L1 adipocyte lysate (200 µg) was added to 6 µl 
of rabbit anti-AS160 antibody (1:12) or (1.5 µg/sample) of sheep anti-TBC1D1 antibody 
and mixed by rotation overnight at 4˚C in screw cap micocentrifuge tubes. The following 
morning 10 µl (per sample) of protein A-sepharose beads or protein G-sepharose beads 
were washed three times (21,910 x g, 1 min at 4˚C) with 1 ml of IP buffer. The beads were 
then re-suspended in IP buffer (25% v/v). 20 µl of the protein A-sepharose bead slurry was 
added to the lysate/anti-AS160 antibody mixture and 20 µl of the protein G-sepharose bead 
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slurry was added to the lysate/anti-TBC1D1 antibody mixture. The mixture was then 
mixed by rotation for 3 hr at 4˚C. The beads were then pelleted (21,910 x g, 1 min at 4˚C) 
and the supernatant aspirated. The pellet was washed twice with 1 ml of high salt (1 M 
NaCl) IP buffer (21,910 x g for 1 min at 4˚C), except when looking for 14-3-3 co-
immunoprecipitation, before washing three times with 1 ml of IP buffer (21,910 x g for 1 
min at 4˚C). The pellets were stored at -20˚C. 
2.2.5 AMPK Assay 
AMPK activity in immunocomplexes was determined by phosphorylation of the peptide 
HMRSAMSGLHLVKRR [SAMS]. The AMPK pellets were re-suspended in 20 µl of 
HEPES Brij-35 buffer. Reaction mixtures (20 µl) containing 5 µl of HEPES Brij-35 buffer, 
5 µl of 1 mM SAMS peptide in HEPES Brij-35 buffer, 5 µl of 1 mM AMP in HEPES Brij-
35 buffer and 5 µl of immunoprecipitate re-suspended in HEPES Brij-35 buffer, were 
prepared in 1.5 ml microcentrifuge tubes on ice and the reaction initiated by the addition of 
5 µl of MgATP solution (1 mM [γ-32P] ATP, 250 - 500 c.p.m./pmol; 25 mM MgCl2 in 
HEPES Brij-35 buffer). Reaction mixtures were then incubated on a vibrating platform in 
an air incubator at 30°C for 10 min. Assay mixtures (15 µl) were spotted onto P81 
phosphocellulose paper, and rinsed, with gentle stirring to remove free ATP, for 5 min in 
1% (v/v) phosphoric acid. A further 2 x 5 min water washes were performed on the 
phosphocellulose paper, before a final 5 min wash with 1% (v/v) phosphoric acid. A 
Beckman Multi-Purpose scintillation counter LS 6500 was used to measure [32P]-labelled 
substrate. 3 ml of scintillation fluid was used per sample. Results were corrected for 
radioactivity recovered in blank reactions lacking the SAMS peptide. One unit of AMPK 
activity is that required to incorporate 1 nmol of 32P into the SAMS substrate 
peptide/min/mg protein.  
2.2.6 SDS-Polyacrylamide Gel Electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using 1.5 mm thick vertical slab gels containing either 6% or 10% acrylamide. 
Slab gels were prepared using Bio-Rad mini-Protean III gel units, with a stacking gel of 
approximately 2 cm deep. The stacking gel consisted of 5% acrylamide/0.136% 
bisacrylamide in 125 mM Tris-HCl, pH 6.8, 0.1% SDS, polymerized with 0.1% (w/v) 
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ammonium peroxidisulphate (APS) and 0.05% (v/v) tetramethylethylenediamine 
(TEMED). 
Cell lysate samples were mixed 3:1 with 4 X SDS-containing sample buffer and heated to 
95°C in a heating block for 5 min prior to separation by SDS-PAGE on Tris buffered gels. 
Prestained broad range (6-175 kDa) protein markers, were used as a standard. 
Gels were electrophoresed using the Bio-Rad Protean III system at a constant voltage of 80 
V for stacking and 150 V through the separating gel. Gels were electrophoresed until the 
tracking dye had migrated to the bottom of the gel and good separation of the molecular 
weight markers had been obtained. 
2.2.7 Western Blotting of Proteins 
2.2.7.1 Electrophoretic transfer of proteins from gels onto nitrocellulose 
membranes 
Proteins were separated by SDS-PAGE as previously described (2.2.6). The gels were 
removed from the plates and placed on top of an equal-sized sheet of nitrocellulose (0.45 
µm pore size), pre-wet with transfer buffer and then placed between 2 layers of 3 MM filter 
paper also pre-wet with transfer buffer. The ‘sandwich’ was then inserted between the 
plates of the gel holder cassette and transfer was performed using a Bio-Rad mini Protean 
III trans-blot electrophoretic transfer cell at a constant current of 40 mA overnight or at 60 
V for 2 hr. The nitrocellulose membranes were then removed from the transfer cassette and 
the efficiency of transfer determined by the presence and intensity of pre-stained molecular 
weight standards. Membranes were also briefly stained with Ponceau to check for equal 
loading of the gels. 
2.2.7.2 Blocking of membranes and probing with antibodies 
Non-specific sites on the nitrocellulose membranes were blocked by incubation with 
shaking in tris buffered saline (TBS)/5% (w/v) milk for 30 min at room temperature. After 
washing (3 x 5 min) the membrane in tris buffered saline tween (TBST), the primary 
antibody was applied to the blot and incubated, with shaking, overnight at 4˚C in 
TBST/5% (w/v) milk or TBST/5% (w/v) BSA. After washing (3 x 5 min) in TBST the 
membranes were incubated, with shaking, for 1 hr at room temperature with the 
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appropriate horseradish peroxidase (HRP)-conjugated secondary antibody in TBST/5% 
(w/v) milk or TBST/5% (w/v) BSA. The membranes were then washed (5 x 5 min) in 
TBST. If required, membranes were further washed (3 x 5 min) in high salt (0.5 M NaCl) 
TBST and then washed (2 x 5 min) in TBST.  
2.2.7.3 Immunodetection of proteins using western blotting and the ECL 
detection system 
Enhanced chemiluminescence (ECL) is a light emitting non-radioactive method for the 
detection of immobilized specific antigens, conjugated directly or indirectly with HRP-
labeled antibodies. HRP is used to catalyze the oxidation of luminol in the presence of 
hydrogen peroxide. Immediately after the oxidation, the luminol is in an excited state 
which decays to ground state via a light emitting pathway. 
Equal volumes of ‘detection reagent 1’ and ‘detection reagent 2’ were mixed and the 
membranes, prepared as described in 2.2.7.2, were immersed in the mix with shaking for 
60 seconds. The detection reagents were then removed, membranes wrapped in cling-film 
and exposed to Kodak film. Finally the films were developed using the X-OMAT 
processor. 
2.2.7.4 Stripping of nitrocellulose membranes 
Nitrocellulose membranes were incubated in 50 mM glycine, pH 2.5 with shaking for 5 
min. Membranes were then washed in TBST for 5 mins. 
2.2.7.5 Densitometric quantification of protein bands 
The antibody-detected bands on the developed film were scanned on a Mercury 1200c 
scanner, using Adobe Photoshop software. The intensity of the immuno-detected protein 
bands on the film was measured using ImageJ software. 
2.2.8 2-deoxy-D-glucose uptake assay 
Glucose uptake was measured by the uptake of 2-[3H]-deoxy-D-glucose according to the 
method of Gibbs (Gibbs et al 1988). Cells were cultured on 12 well plates and incubated at 
37˚C in 1 ml of serum free DMEM for 2 hr prior to use. Cells were subsequently incubated 
at 37˚C in 475 µl/well of Krebs-Ringer phosphate (KRP) for 1 hr and test substances added 
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to the plates for various durations at 37˚C. The cells were then stimulated with 10 nΜ 
insulin for 15 min. Glucose transport was initiated by the addition of 2-[3H]-deoxy-D-
glucose (final concentration 50 µmol/l and 1 µCi/ml) to each well. The reaction was 
terminated after 3 min by inverting the plates rapidly to remove the incubation buffer, and 
then by immersing them sequentially in 2 x 2l and 1l of ice-cold phosphate buffered saline 
(PBS). After air drying the plates for 1 hr, 0.5 ml of 1% (v/v) Triton X-100/H2O was 
added to the cell monolayers. A Beckman Multi-Purpose scintillation counter LS 6500 was 
used to measure 2-[3H]-deoxy-D-glucose uptake. 5 ml of scintillation fluid was used per 
sample. Non-specific association of radioactivity was determined in parallel incubations in 
the presence of 10 µmol/l cytochalasin B. 
2.2.9 Nucleotide extraction and analysis 
2.2.9.1 Nucleotide extraction 
3T3-L1 cells cultured in 10 cm diameter dishes were incubated for 2 hr at 37˚C in 5 ml of  
KRH buffer. Test substances were added at 37˚C for various durations. The buffer was 
removed and 500 µl of 5% (w/v) ice cold perchloric acid added to the dishes on ice. The 
extract was scraped off with a cell scraper and transferred to a screw cap microcentrifuge 
tube. Precipitated protein was removed by centrifugation of the extract at 21,910 x g for 3 
min in a microcentrifuge at 4˚C. The supernatant was then extracted twice to remove 
perchloric acid with 10% excess (by volume) of a 1:1 mixture of tri-n-octylamine and 
1,1,2-trichlorotrifluoroethane. Nucleotides were separated by reversed-phase 
chromatography adapted from the method published by Uesugi (Uesugi et al 1997).  
2.2.9.2 Reversed-phase chromatography 
Neutralised perchloric acid extracts were prepared as described (see 2.2.9.1). All analyses 
were performed on a stainless-steel column (250 x 4.6 mm I.D) packed with Chrom Spher 
C18 octadecylsilane (ODS) (5 µm) attached to a Varian Prostar HPLC system. The column 
was equilibrated (30-60 min) with the eluent 0.1 M triethylamine (TEA) phosphate buffer 
pH 8 and methanol (96:4, v/v) at a flow rate of 1.0 ml/min for 25 min at ambient 
temperature (22-23˚C) prior to sample injection. Nucleotides were detected by their 
absorbance at 259 nm, and compared with the elution position of standards; AMP, ADP 
and ATP. Retention times were measured from the time between the injection point (50 µl 
sample) and the peak maximum on the chromatogram. 
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The concentration of each nucleotide was determined by quantifying the area under the 
peaks, after calibration using standards of a known concentration.  
2.2.9.3 Preparation of TEA phosphate buffer 
Stock solutions of 0.1 M TEA and a mixture of 0.1 M TEA and 0.1 M phosphoric acid 
were filtered through a 0.45 µM filter and kept at 4˚C. The pH of the TEA phosphate buffer 
was adjusted to pH 8 by admixing both of the stock solutions at 23˚C. 
2.2.10 Recombinant  adenoviruses  
2.2.10.1 AMPK adenoviruses 
Adenovirus encoding a dominant negative AMPK mutant (Ad.α1-DN) was constructed 
from cDNA encoding AMPKα1 containing a mutation that alters aspartic acid residue 157 
to alanine (D157A), and adenovirus encoding a constitutively active AMPK mutant 
(Ad.α1312) was constructed from cDNA encoding residues 1-312 of AMPKα1, containing a 
mutation that alters threonine 172 to an aspartic acid (T172D) as described previously 
(Woods et al 2000). These AMPK adenoviruses were a generous gift from Dr. F. Foufelle, 
Centre Biomédical des Cordeliers, Paris. 
2.2.10.2 Adenovirus propagation  
HEK 293 cells in T75 flasks were cultured in DMEM growth media (see 2.2.1.5) and 
passaged at 70-80 % confluency (see 2.2.1.7). Each T75 flask was split into 5 x T150 
flasks. Once 30 x T150 flasks were obtained, and grown to 70-80% confluency, 
recombinant adenoviruses were propagated in the HEK 293 cells. Detached cells were then 
pelleted in 50 ml falcon tubes (5 min at 2000 x g). 100 ml of the supernatant was retained 
to infect more HEK 293 cells, and the pellets pooled and re-suspended in 5 ml of sterile 
PBS.  
2.2.10.3 Adenovirus purification 
In order to lyse the HEK 293 cells containing the adenovirus particles, 5 ml of Arklone P 
(trichlorotrifluroethane) was added to the HEK 293 cell suspension (2.2.10.2) and mixed 
gently by inverting the tube for about 10 seconds. The mixture was left at room 
temperature for 3 min and then centrifuged at 2000 x g for 10 min. The upper layer 
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containing virus was separated from cell debris (interface) and the Arklone P layer (bottom 
layer). 2.5 ml sterile CsCl dissolved in Tris/EDTA (5 mM Tris-HCl, 1 mM EDTA pH 7.8) 
at a density of 1.33 g/ml was added to a sterile centrifuge tube. This was underlaid with 1.5 
ml of sterile 1.45 g/ml CsCl. The virus layer was loaded on the CsCl gradient and 
centrifuged at 100,000 x g in a SW40 rotor using an OptimaTM XL-80K ultracentrifuge at 
8˚C for 90 min. The tube was then punctured just below the virus band with a 21 guage 
needle, and withdrawn into a 2.5 ml syringe. The virus was transferred to a 10 micron 
Slide-A-Lyzer cassette and dialysed against cold Tris/EDTA buffer at 4˚C overnight, and 
against fresh buffer containing 10% (v/v) glycerol for a further 2 hr the following morning. 
The purified virus was removed and stored at -80˚C. 
2.2.10.4 Adenovirus titration 
The Quick TiterTM Adenovirus Titer Immunoassay kit was used to titre the virus. Briefly, 
HEK cells were plated onto a 24 well plate. After 1 hr 100 µl of 10-3, 10-4, 10-5 and 10-6 
diluted virus solutions were added to the wells. The cells were then incubated for 48 hr at 
37°C, 5% (v/v) CO2. To fix the cells the media was removed and replaced with 0.5 ml cold 
methanol and incubated for 20 min at 20˚C. Cells were washed three times in PBS prior to 
blocking with PBS containing 1% (w/v) BSA at room temperature for 1 hr. 250 µl of anti-
Hexon antibody was added to each well and incubated for 1 hr at room temperature. The 
cells were then washed three times in PBS prior to the addition of 250 µl of the HRP-
conjugated secondary antibody to each well and incubated for 1 hr at room temperature. 
The cells were then washed five times in PBS. 250 µl of diaminobenzidine (DAB) was 
added to each well and incubated for 10 min at room temperature. DAB was then aspirated 
and the wells were washed twice with PBS. 1 ml of PBS was added to each well. The 
positive stained cells were counted for at least five separate fields per well using a light 
microscope and 10X objective. Calculation of adenovirus titre was determined (Infectious 
Units/ml). 
2.2.10.5 3T3-L1 adipocyte adenovirus infection 
6 days post differentiation 500 µl of serum free DMEM was added to 3T3-L1 adipocytes 
cultured on 12 well plates. Adenovirus was added (600 ifu/cell) to the dishes and incubated 
for 6 hr at 37˚C in a humidified atmosphere of 10% (v/v) CO2. 500 µls of DMEM / 20% 
FCS was added to the cells for a further 24 hr. The media was replaced with 1 mls DMEM 
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/ 10% FCS and incubated for a further 24 hr before 3T3-L1 cell lysates were prepared (see 
2.2.2) or a glucose transport assay performed (2.2.8). 
2.2.11 Albumin and IgG depletion 
Albumin and immunoglobulin gamma (IgG), two abundant proteins in serum, were 
depleted from human adipose samples collected by Dr J Boyle, University of Glasgow, 
using the ProteoPrep Blue Albumin and IgG Depletion Kit. 
2.2.12 Statistical Analysis 
Results are expressed as mean +/- SEM. Statistically significant differences were 
determined using a one or two-tailed Student's t test (two-sample assuming unequal 
variance), or one-way ANOVA where appropriate, with p < 0.05 as significant.  
The statistics package, Minitab, was used for data analysis of results obtained from human 
adipose tissue samples (chapter 5). Each data set was tested separately for normality using 
the Ryan-Joiner test and subsequently (when required) transformed by logarithmic (log10) 
or square route (sqrt) transformation. The mean and 95% confidence intervals of the mean 
were calculated using transformed data; however, for presentation results were back 
transformed. Statistically significant differences were determined using a paired T-test, 
with p < 0.05 as significant. 
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Chapter 3  - Activation parameters and mechanism 
of AMPK activation by various stimuli in 3T3-L1 
cells 
3.1 Introduction 
3.1.1 Known activators of AMPK in adipocytes 
AMPK has been shown to be activated by some AMPK activators in adipocytes and 
adipose tissue. The adipocytokines leptin (Orci et al 2004) and adiponectin (Wu et al 
2003) have both been shown to activate AMPK in rat white fat tissue and isolated rat 
adipocytes respectively. AICAR has been shown to activate AMPK in isolated rat 
adipocytes and 3T3-L1 adipocytes (Corton et al 1995, Salt et al 2000). The biguanides 
metformin and phenformin have been reported to activate AMPK in 3T3-L1 adipocytes 
and isolated rat adipocytes respectively (Huypens et al 2005, Daval et al 2005). In addition 
the TZD, pioglitazone has also been shown to activate AMPK in vivo in rat adipose tissue 
(Saha et al 2004). Furthermore, the β adrenergic agonist, isoproterenol, has been shown to 
stimulate AMPK activity in isolated rat adipocytes (Moule and Denton 1998) and in 3T3-
L1 adipocytes (Yin et al 2003, Gauthier et al 2008). 
3.1.2 Role for LKB1 as an AMPK kinase in adipocytes 
Indirect arguments suggest that the upstream kinase LKB1 is involved in AMPK activation 
in adipocytes. Phenformin can induce AMPK activation in isolated rat adipocytes by 
decreasing the ATP concentration (Daval et al 2005) and AICAR, which is converted to 
ZMP, a cellular mimetic of AMP, activates AMPK in isolated rat adipocytes and 3T3-L1 
adipocytes (Corton et al 1995, Salt et al 2000). In addition, in transgenic mice expressing 
UCP1 in white adipose tissue, the AMP/ATP ratio is increased and AMPK is activated 
(Matejkova et al 2004). However, a potential role for CaMKK in AMPK activation has yet 
to be demonstrated in adipocytes.  
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3.1.3 AMPK subunit isoform expression  
AMPK is a heterotrimeric complex containing two α, two β, and three γ subunit isoforms 
of which the expression level of each varies between different tissues. The liver 
predominantly expresses the α1 subunit (Stapleton et al 1996) and β1 subunit (Thornton et 
al 1998), where as skeletal muscle predominantly expresses the α2 subunit (Stapleton et al 
1996) and β2 subunit (Thornton et al 1998). Expression profiling of the AMPK γ subunit 
expression across different tissues in human, rat and mouse found that the γ3 subunit 
appears to be predominantly expressed in skeletal muscle, while the γ1 and γ2 subunits 
showed broad tissue distributions (Cheung et al 2000, Mahlapuu et al 2004). In 3T3-L1 
adipocytes both the α1 and α2 catalytic subunits have been shown to be expressed (Salt et 
al 2000). 
In addition to tissue distribution, subunit isoforms can also exhibit preferential cellular 
localization. Salt and co-workers showed that the α2 subunit was clearly localized in the 
nucleus of both INS-1 cells and CCL13 cells, while both α subunit isoforms could be 
found in the cytoplasm (Salt et al 1998a). 
3.1.5 Aims 
Although AMPK activation has been previously reported in adipose tissue and cultured 
adipocytes, a thorough investigation of expression of components of the AMPK cascade 
and kinetics of AMPK stimulation has yet to be undertaken.  
AMPK has been shown to be involved in the regulation of adipogenesis (Habinowski and 
Witters 2001, Dagon et al 2006, Giri et al 2006, Tong et al 2008), however the AMPK 
subunit isoform expression throughout adipogenesis remains unknown. 
The 3T3-L1 cell line is derived from disaggregated Swiss mouse embryos. The cell line 
isolated and cloned by Green and Kehinde have a fibroblast like morphology, but, under 
appropriate conditions, the cells differentiate into cells resembling adipocytes which 
synthesise and store TG (Green and Hehinde 1974, Green and Hehinde 1975, Green and 
Hehinde 1976). 3T3-L1 fibroblasts, once confluent, convert to adipocytes in the presence 
of IBMX, dexamethasone, and insulin. Thus, 3T3-L1 cells are used widely as a model 
system to study the differentiation of preadipocytes to adipocytes.  
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In the current study the expression of the upstream AMPK kinases; LKB1 and CaMKKα/β, 
and the downstream AMPK substrates ACC1/2 in 3T3-L1 adipocytes, was investigated. In 
addition, the expression of AMPK subunit isoforms and the relative contribution of the 
catalytic AMPKα subunits to total AMPK activity throughout development from 
fibroblasts to adipocytes was determined using 3T3-L1 cells as a model system. Finally, 
the parameters and molecular mechanism of AMPK activation by various stimuli in 3T3-
L1 adipocytes was investigated.  
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3.2 Results 
3.2.1 Investigating the expression of LKB1, CaMKKα, CaMKKβ, 
ACC1 and ACC2 in 3T3-L1 adipocytes 
The expression of molecules both upstream and downstream of AMPK in the AMPK 
signalling cascade was investigated. The presence of the upstream AMPK kinases; LKB1, 
CaMKKα and CaMKKβ and the downstream substrates of AMPK; ACC1 and ACC2  
were determined by western blotting analysis of 3T3-L1 adipocyte lysates. 
The tumour suppressor LKB1, is expressed in 3T3-L1 adipocytes as demonstrated by the 
presence of two bands (splice variants of LKB1) situated between the 62kDa and 47.5kDa 
molecular weight markers (Fig. 3.1A). These two bands are not present in HeLa cells, 
which lack LKB1. CaMKKα is expressed in 3T3-L1 adipocytes as demonstrated by the 
presence of a band at approximately 63kDa in 3T3-L1 cell lysates (Fig. 3.1B) which 
corresponds to a band present in rat brain extract which is rich in CaMKKα. It appears that 
CaMKKβ is also expressed in 3T3-L1 adipocytes, as there appears to be a faint band at 
approximately 66kDa (Fig. 3.1C) in the 3T3-L1 cell lysate immunoprecipitated with anti-
CaMKKβ antibody corresponding to a band present in rat brain extract, which is abundant 
in CaMKKβ.  
Using anti-ACC antibodies, the presence of a band at approximately 260kDa (Fig. 3.2A) in  
the 3T3-L1 cell lysate, corresponds to a band present in rat liver extract which is rich in 
ACC1, indicating that 3T3-L1 adipocytes express ACC1.  
3T3-L1 cell lysate probed with anti-ACC2 antibody displays a doublet at approximately 
280kDa (Fig. 3.2B). Muscle is rich in ACC2, yet the band detected by the anti-ACC2 
antibody in the rat muscle extract, runs at a molecular weight in between the doublet in the 
3T3-L1 lysate. In addition, the single band in the rat muscle extract (assumed to be ACC2), 
corresponds to the lower molecular weight band, from the doublet, in the rat liver extract. 
Thus the higher molecular weight band, from the rat liver doublet, may be a non-specific 
band and the lower band may correspond to ACC2.  
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Figure  3-1: LKB1, CaMKKα, CaMKKβ and LKB1 expression in 3T3-L1 adipocytes.    
3T3-L1 lysate (25 µg) was resolved by 10% SDS-PAGE, transferred to nitrocellulose, and probed 
with (A) anti-LKB1 antibody or (B) anti-CaMKKα antibody. (C) 3T3-L1 lysate (200 µg) was 
immunoprecipitated using anti-CaMKKβ antibody, resolved by 6% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-CaMKKβ antibody. Negative control for LKB1 was HeLa cell 
lysate. Br = rat brain extract. IP+ = immunoprecipitation using anti-CaMKKβ antibody in the 
presence of 3T3-L1 lysate. IP- = immunoprecipitation using anti-CaMKKβ antibody in the absence 
of 3T3-L1 lysate. The positions of the molecular weight markers are shown to the left of the gels. 
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Figure  3-2: ACC1 and ACC2 expression in 3T3-L1 adipocytes. 
3T3-L1 lysate (60 µg) was resolved by 6% SDS-PAGE, transferred to nitrocellulose, and probed 
with (A) anti-ACC1 antibody or (B) anti-ACC2 antibody. Li = rat liver extract, Mu = rat muscle 
extract. The position of the molecular weight markers are shown to the left of the gel. 
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3.2.2 AMPK subunit isoform expression during adipogenesis 
To investigate AMPK subunit isoform expression during adipogenesis, lysates obtained 
from 3T3-L1 cells every 48 hr post differentiation were analysed by western blotting.  
As shown below (Fig. 3.3) the α1 subunit isoform expression level was not significantly 
altered throughout adipogenesis.  
Unfortunately, densitometric analysis for α2 expression could not be accurately performed 
on fibroblasts (day 0) due to smearing in most blots. The α2 subunit isoform expression 
level (Fig. 3.4) is undetectable at 2 days post differentiation. Modest expression levels of 
α2 were detected at 4 days post differentiation, however a significant (p < 0.05) increase, 
compared to 2 days post differentiation, in α2 expression was observed at 6, 8, 10 and 12 
days post differentiation. Interestingly, there is also an intense band recognised by the anti- 
AMPK α2 antibody resolving with a higher molecular mass than that of α2 which appears 
to decrease throughout adipogenesis. 
β1 is expressed in fibroblasts, however expression levels (Fig. 3.5) are significantly (p < 
0.05) decreased throughout differentiation. The maximum significant (p < 0.05) reduction 
in expression level, compared to fibroblasts at day 0, was 74 +/- 3.5 % which was observed 
after 8 days post differentiation.  
β2 (Fig. 3.6) is also expressed in fibroblasts, however there is a general increase in β2 
expression levels throughout adipogenesis. A maximum 1.66 +/- 0.2 fold increase in 
expression levels, of β2 was observed at 10 days post differentiation, compared to 
fibroblasts at day 0.  
γ1 (Fig. 3.7) is expressed in fibroblasts, and expression levels were found to increase 
during adipogenesis with significant (p < 0.05) increases, compared to fibroblasts, in 
expression levels at 10 and 12 days post differentiation. A maximum significant (p < 0.05), 
2.55 +/- 0.31 fold increase in expression levels of γ1 was observed at 12 days post 
differentiation, compared to fibroblasts at day 0. 
 γ2 (Fig. 3.8) and γ3 (Fig. 3.9) are both expressed in fibroblasts. It should be noted that the 
doublet (52/54 kDa) recognised by the anti-AMPK γ3 antibody corresponds to different 
splice variants of the γ3 isoform. Unfortunately, densitometric analysis could not be 
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accurately performed on fibroblasts (day 0) due to smearing.  In general, the expression 
levels of both γ2 and γ3 are decreased through out adipogenesis. Significant (p < 0.05) 
reductions in γ3 expression levels occurred at 8, 10 and 12 days post differentiation, with a 
maximum significant (p < 0.05) 51 +/- 13 % reduction in expression occurring at 12 days 
post differentiation, compared to 2 days post differentiation.  
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Figure  3-3: AMPK α1 subunit expression during adipogenesis 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK α1 and anti-GAPDH 
antibodies. K = purified rat liver AMPK (positive control). (A) Quantification of AMPK α1 expression 
was determined by comparison with total GAPDH by densitometric analysis. Data shown 
represents the mean % maximum +/- S.E.M of three independent experiments. (B) Representative 
blots from three independent experiments. The position of the molecular weight markers are shown 
to the left of the gel. 
Pamela Jane Logan, 2009   Chapter 3, 96 
 
Figure  3-4: AMPK α2 subunit expression during adipogensis. 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK α2 and anti-GAPDH 
antibodies. K = purified rat liver AMPK (positive control). (A) Quantification of AMPK α2 expression 
was determined by comparison with total GAPDH using densitometric analysis, *p < 0.05 (one-way 
ANOVA), compared to 2 days post differentiation. Data shown represents the mean % maximum 
+/- S.E.M of three independent experiments. (B) Representative blots from three independent 
experiments. The position of the molecular weight markers are shown to the left of the gel. 
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Figure  3-5: AMPK β1 subunit expression during adipogenesis 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK β1 and anti-GAPDH 
antibodies. K = purified rat liver AMPK (positive control). (A) Quantification of AMPK β1 expression 
was determined by comparison with total GAPDH using densitometric analysis, *p < 0.05 (one-way 
ANOVA), compared to 0 days post differentiation. Data shown represents the mean % maximum 
+/- S.E.M of three independent experiments. (B) Representative blots from three independent 
experiments. The position of the molecular weight markers are shown to the left of the gel. 
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Figure  3-6: AMPK β2 subunit expression during adipogenesis. 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK β2 and anti-GAPDH 
antibodies. H = rat heart extract, M = rat muscle extract (positive controls). (A) Quantification of 
AMPK β2 expression was determined by comparison with total GAPDH using densitometric 
analysis. Data shown represents the mean % maximum +/- S.E.M, of three independent 
experiments. (B) Representative blots from three independent experiments. The position of the 
molecular weight markers are shown to the left of the gel. 
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Figure  3-7: AMPK γ1 subunit expression during adipogenesis. 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK γ1 and anti-GAPDH 
antibodies. (A) Quantification of AMPK γ1 expression was determined by comparison with total 
GAPDH using densitometric analysis, *p < 0.05 (one-way ANOVA), compared to 0 days post 
differentiation. Data shown represents the mean % maximum +/- S.E.M of three independent 
experiments. (B) Representative blots from three independent experiments. The position of the 
molecular weight markers are shown to the left of the gel. 
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Figure  3-8: AMPK γ2 subunit expression during adipogenesis. 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK γ2 and anti-GAPDH 
antibodies. (A) Quantification of AMPK γ2 expression was determined by comparison with total 
GAPDH using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of 
three independent experiments. (B) Representative blots from three independent experiments. The 
position of the molecular weight markers are shown to the left of the gel. 
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Figure  3-9: AMPK γ3 subunit expression during adipogenesis. 
Lysates (15 µg) obtained from cells at various time points post differentiation were resolved by 10% 
SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK γ3 and anti-GAPDH 
antibodies. (A) Quantification of AMPK γ3 expression was determined by comparison with total 
GAPDH using densitometric analysis, *p < 0.05 (one-way ANOVA), compared to 2 days post 
differentiation. Data shown represents the mean % maximum +/- S.E.M of three independent 
experiments. (B) Representative blots from three independent experiments. The position of the 
molecular weight markers are shown to the left of the gel. 
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3.2.3 Investigating catalytic α-subunit isoform specific AMPK 
activity during adipogenesis 
AMPK was immunoprecipitated from fibroblasts and 3T3-L1 adipocytes in order to 
determine the contribution of the two catalytic AMPK subunits to total AMPK activity 
throughout adipogenesis. As shown below (Fig. 3.10A), the α1 subunit was found to 
contribute almost all of the total basal AMPK activity in both fibroblasts and adipocytes. In 
addition there was no significant change in total AMPK activity observed between 
fibroblasts and adipocytes throughout adipogenesis. To ensure that the α2 AMPK subunit 
was successfully immunoprecipitated from the 3T3-L1 lysates, α2 immunoprecipitates 
were subjected to western blotting. As shown in figure 3.10B the α2 AMPK subunit was 
successfully immunoprecipitated. Western blotting of the α2 AMPK subunit 
immunoprecipitates also clearly shows (Fig. 3.10B) that α2 AMPK subunit expression is 
increased throughout adipogenesis, which is in support of a previous observation (Fig. 3.4). 
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Figure  3-10: Contribution of the AMPK α1 and AMPK α2 subunits to total AMPK activity 
throughout adipogenesis.  
Fibroblast and 3T3-L1 adipocyte lysates were prepared at the indicated time points throughout 
adipogenesis. Anti-α1 and anti-α2 antibodies were used to immunoprecipitate α1 containing AMPK 
complexes, α2 containing AMPK complexes and total AMPK complexes (α1 and α2) from 3T3-L1 
lysates (100 µg). (A) Immunoprecipitates were then assayed for AMPK activity. Data shown 
represents the mean % basal +/- S.E.M of three independent experiments. The remaining 5 µl from 
the AMPK α2 immunoprecipitates were resolved on 10% SDS-PAGE, transferred to nitrocellulose 
and probed with anti-AMPK α2 antibody. (B) Representative blot from the three independent 
experiments. K=purified rat liver kinase, 3T3-L1 = adipocyte lysate (3 µg) from 12 days post 
differentiation. The position of the molecular weight markers are shown to the left of the gel. 
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3.2.4 Investigating AMPK activation parameters by various stimuli 
in 3T3-L1 adipocytes 
Using a mixture of anti-AMPKα1 and anti-AMPKα2 antibodies, AMPK was 
immunoprecipitated from 3T3-L1 lysates prepared from cells incubated for various 
durations with different stimuli and assayed for AMPK activity. In addition, 
phosphorylation of AMPK at Thr172 in these lysates was also assessed by western 
blotting.  
The AMPK activation parameters and the extent of Thr172 phosphorylation after 
incubation of 3T3-L1 adipocytes with 0.6 M sorbitol, 2 mΜ AICAR, 100 µΜ arsenite, 5 
µΜ A23187, 100 µΜ rosiglitazone, 1 mΜ metformin, 1 µΜ isopreterenol, 5 mΜ sodium 
azide, 1 mΜ H2O2  0.1 µΜ leptin and 300 µM A769662, are shown below (Figs. 3.11 – 
3.21).  
Sorbitol 
Incubation of 3T3-L1 adipocytes with sorbitol (Fig. 3.11) caused a significant (p < 0.05) 
increase, compared to the basal level, in AMPK activity after 5 min, 15 min, 30 min and 60 
min. A significant (p < 0.05) maximum 3.71 +/- 0.54 fold increase in AMPK activity 
occurred after 30 min and was sustained for a further 30 min. In parallel, AMPK Thr172 
phosphorylation was also increased, compared to the basal level. Statistically significant (p 
< 0.05) increases in Thr172 phosphorylation were observed after 5 min, 15 min, 30 min 
and 60 min, with a significant (p < 0.05) maximum 3.5 +/- 0.6 fold increase in Thr172 
phosphorylation, occurring after 30 min.  
AICAR 
AICAR (Fig. 3.12) displayed a tendency to increase AMPK activity. A maximum 2.05 +/- 
0.55 fold increase, compared to the basal level, in AMPK activity, occurred after 30 min, 
although this did not reach statistical significance (p < 0.05), and was sustained for a 
further 30 min. A maximum 1.38 +/- 0.24 fold increase, compared to the basal level, in 
AMPK Thr172 phosphorylation, was observed after 15 min.  
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Figure  3-11: Effect of 0.6 M sorbitol on AMPK activity and Thr172 phosphorylation. 
3T3-L1 cells were incubated in 0.6 M sorbitol for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % basal +/- S.E.M 
of three independent experiments performed in duplicate, *p < 0.05 (1-tail t-test). Basal AMPK 
activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) is 0.15 +/- 0.03 
(mean +/- S.E.M). Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to nitrocellulose, 
and probed with anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) Representative blots are 
shown, from three independent experiments in duplicate. (C) Quantification of AMPKα Thr172 
phosphorylation was determined by comparison with total AMPK using densitometric analysis. 
Data shown represents the mean % maximum +/- S.E.M of three independent experiments 
performed in duplicate, *p < 0.05 (one-way ANOVA). 
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Figure  3-12: Effect of 2 mM AICAR on AMPK activity and Thr172 phosphorylation. 
3T3-L1 cells were incubated in 2 mM AICAR for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti- AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % basal +/- S.E.M 
of three independent experiments performed in duplicate. Basal AMPK activity (nmol 32P 
incorporated into the SAMS substrate peptide/min/mg protein) is 0.28 +/- 0.06 (mean +/- S.E.M). 
Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to nitrocellulose, and probed with 
anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) Representative blots are shown, from 
three independent experiments in duplicate. (C) Quantification of AMPKα Thr172 phosphorylation 
was determined by comparison with total AMPK using densitometric analysis. Data shown 
represents the mean % maximum +/- S.E.M of three independent experiments performed in 
duplicate. 
 
 
Pamela Jane Logan, 2009   Chapter 3, 107 
Arsenite 
There was no significant (p < 0.05) increase, compared to the basal level, in AMPK 
activity in 3T3-L1 adipocytes incubated with arsenite for various durations. However, a 
modest maximum 1.76 +/- 0.8 fold increase, compared to the basal level, in AMPK 
activity, was obtained after incubation of 3T3-L1 adipocytes with arsenite (Fig. 3.13) for 
15 min. In addition, there was no significant increase, compared to the basal level, in 
AMPK Thr172 phosphorylation. However, a maximum 1.81 +/- 0.66 fold increase in 
Thr172 phosphorylation occurred after 15 min.  
A23187 
Incubation of 3T3-L1 adipocytes with A23187 (Fig. 3.14) displayed a modest 1.4 increase, 
compared to the basal level, in AMPK activity after 5 min. A significant (p < 0.05) 
maximum 1.61 +/- 0.25 fold increase in AMPK activity occurred at 60 min. There was no 
significant increase, compared to the basal level, in AMPK Thr172 phosphorylation. 
However, a maximum 1.54 +/- 0.73 fold increase in AMPK Thr172 phosphorylation 
occurred at 60 min.  
Rosiglitazone 
A significant (p < 0.05) increase, compared to the basal level, in AMPK activity was 
obtained after incubation of 3T3-L1 adipocytes in rosiglitazone (Fig. 3.15) for 5 min, 15 
min and 60 min. A maximum 2.27 +/- 0.75 fold increase in AMPK activity occurred after 
30 min, although this did not reach statistical significance. There was no significant  
increase, compared to the basal level, in AMPK Thr172 phosphorylation. However, 
rosiglitazone displayed a tendency to increase Thr172 phosphorylation after 15 min, and 
reached a maximum 1.53 +/- 0.41 fold increase after 30 min.  
Metformin 
Metformin (Fig. 3.16) stimulated a subtle significant (p < 0.05) 1.30 +/- 0.07 fold increase, 
compared to the basal level, in AMPK activity after 5 min in 3T3-L1 adipocytes. A 
maximum 1.35 +/- 0.35 fold increase was observed after 30 min, although this did not 
reach statistical significance (p < 0.05). There was no significant increase, compared to the 
basal level, in AMPK Thr172 phosphorylation. However, a maximum 1.79 +/- 0.51 fold 
increase in Thr172 phosphorylation was obtained after 5 min. 
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Figure  3-13: Effect of 100 µM arsenite on AMPK activity and Thr172 phosphorylation. 
3T3-L1 cells were incubated in 100 µM arsenite for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti- AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum +/- 
S.E.M of three independent experiments performed in duplicate. Basal AMPK activity (nmol 32P 
incorporated into the SAMS substrate peptide/min/mg protein) is 0.14 +/- 0.01 (mean +/- S.E.M). 
Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to nitrocellulose, and probed with 
anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) Representative blots are shown, from 
three independent experiments in duplicate. (C) Quantification of AMPKα Thr172 phosphorylation 
was determined by comparison with total AMPK using densitometric analysis. Data shown 
represents the mean % maximum +/- S.E.M of three independent experiments performed in 
duplicate. 
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Figure  3-14: Effect of 5 µM A23187 on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 5 µM A23187 for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and 
α2 antibodies and assayed for AMPK activity. . Data shown represents the mean % maximum +/- 
S.E.M of three independent experiments performed in duplicate, *p < 0.05 (1-tail t-test). Basal 
AMPK activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) is 0.30 +/- 
0.13 (mean +/- S.E.M).  Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) 
Representative blots are shown, from three independent experiments in duplicate. (C) 
Quantification of AMPKα Thr172 phosphorylation was determined by comparison with total AMPK 
using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments performed in duplicate. 
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Figure  3-15: Effect of 100 µM rosiglitazone on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 100 µM rosiglitazone for various times and lysates prepared. (A) 
Total AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 
and α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum 
+/- S.E.M of three independent experiments performed in duplicate, *p < 0.05 (1-tail t-test). Basal 
AMPK activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) is 0.32 +/- 
0.04 (mean +/- S.E.M). Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti- AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) 
Representative blots are shown, from three independent experiments in duplicate. (C) 
Quantification of AMPKα Thr172 phosphorylation was determined by comparison with total AMPK 
using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments performed in duplicate. 
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Figure  3-16: Effect of 1 mM metformin on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 1 mM metformin for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum +/- 
S.E.M of three independent experiments performed in duplicate, *p < 0.05 (1-tail t-test). Basal 
AMPK activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) is 0.27 +/- 
0.02 (mean +/- S.E.M). Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) 
Representative blots are shown, from three independent experiments in duplicate. (C) 
Quantification of AMPKα Thr172 phosphorylation was determined by comparison with total AMPK 
using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments performed in duplicate. 
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Isoproterenol 
A significant (p < 0.05) (Fig. 3.17) increase, compared to the basal level, in AMPK activity 
was observed after incubation of 3T3-L1 adipocytes with isoproterenol for 15 min. A 
maximum 1.99 +/- 0.78 fold increase in AMPK activity was obtained after 30 min, 
although this did not reach statistical significance. There was no significant increase, 
compared to the basal level, in AMPK Thr172 phosphorylation. However, a maximum 
subtle 1.18 +/- 0.40 fold increase in Thr172 phosphorylation did occur after 15 min. 
Sodium azide 
Incubation of 3T3-L1 adipocytes with sodium azide (Fig. 3.18) displayed a tendency to 
increase AMPK activity, compared to the basal level. A maximum 3.01 +/- 0.79 fold 
increase was obtained after 30 min, although this did not reach statistical significance. A 
maximum 2.3 +/- 0.37 fold increase, compared to the basal level, in AMPK Thr172 
phoshorylation was observed after incubation of the 3T3-L1 adipocytes with azide for 15 
min. 
Hydrogen peroxide 
Incubation of 3T3-L1 adipocytes with hydrogen peroxide (Fig. 3.19) caused a significant 
increase, compared to the basal level, in AMPK activity after 15 min, 30 min and 60 min. 
A maximum 1.92 +/- 0.17 fold increase in AMPK activity occurred after 30 min, and was 
sustained for a further 30 min. In parallel, hydrogen peroxide displayed a significant 
increase, compared to the basal level, in Thr172 phosphorylation after 5 min, 15 min, 30 
min and 60 min, with a maximum 3.32 +/- 0.33 fold increase in Thr172 phosphorylation 
occurring after 60 min. 
Leptin 
Incubation of 3T3-L1 adipocytes with leptin (Fig. 3.20) displayed a tendency to increase 
AMPK activity, compared to the basal level. A maximum 2.3 +/- 0.72 fold increase in 
AMPK activity occurred after 30 min, although it did not reach statistical significance. 
There was no significant increase, compared to the basal level, in AMPK Thr172 
phosphorylation. However, a maximum 1.55 +/- 0.66 fold increase in Thr172 
phosphorylation was observed at 30 min. 
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A769662 
Incubation of 3T3-L1 adipocytes with the novel direct AMPK activator, A769662, (Fig. 
3.21) caused a significant (p < 0.05) increase, compared to the basal level, in AMPK 
activity after 30 min and 60 min. A maximum 1.9 +/- 0.29 fold increase in AMPK activity 
was observed after 60 min. In parallel, A769662 caused an increase, compared to the basal 
level, in Thr172 phosphorylation after 15 min, 30 min and 60 min, with a maximum 
significant (p < 0.05) 1.92 +/- 0.10 fold increase in Thr172 phosphorylation, occurring 
after 60 min. 
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Figure  3-17: Effect of 1 µM isoproterenol on AMPK activity in 3T3-L1 adipocytes 
3T3-L1 cells were incubated in 1 µM isoproterenol for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum +/- 
S.E.M of three independent experiments performed in duplicate, *p < 0.05 (1-tail t-test). Basal 
AMPK activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) is 0.36 +/- 
0.16 (mean +/- S.E.M). Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) 
Representative blots are shown, from three independent experiments in duplicate. (C) 
Quantification of AMPKα Thr172 phosphorylation was determined by comparison with total AMPK 
using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments performed in duplicate. 
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Figure  3-18: Effect of 5 mM sodium azide on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 5 mM sodium azide for various times and lysates prepared. (A) 
Total AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 
and α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum 
+/- S.E.M of three independent experiments performed in duplicate. Basal AMPK activity (nmol 32P 
incorporated into the SAMS substrate peptide/min/mg protein) is 0.40 +/- 0.04 (mean +/- S.E.M). 
Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to nitrocellulose, and probed with 
anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) Representative blots are shown, from 
three independent experiments in duplicate. (C) Quantification of AMPKα Thr172 phosphorylation 
was determined by comparison with total AMPK using densitometric analysis. Data shown 
represents the mean % maximum +/- S.E.M of two independent experiments performed in 
duplicate. 
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Figure  3-19: Effect of 1 mM hydrogen peroxide on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 1 mM hydrogen peroxide for various times and lysates prepared. 
(A) Total AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK 
α1 and α2 antibodies and assayed for AMPK activity. Data shown represents the mean % 
maximum +/- S.E.M of three independent experiments performed in duplicate, *p < 0.05 (1-tail t-
test). Basal AMPK activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) 
is 0.10 +/- 0.01 (mean +/- S.E.M). Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) 
Representative blots are shown, from three independent experiments in duplicate. (C) 
Quantification of AMPKα Thr172 phosphorylation was determined by comparison with total AMPK 
using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments performed in duplicate, *p < 0.05 (one-way ANOVA). 
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Figure  3-20: Effect of 0.1 µM leptin on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 0.1 µΜ leptin for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum +/- 
S.E.M of three independent experiments performed in duplicate, *p < 0.05 (1-tail). Basal AMPK 
activity (nmol 32P incorporated into the SAMS substrate peptide/min/mg protein) is 0.28 +/- 0.14 
(mean +/- S.E.M). Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to nitrocellulose, 
and probed with anti-AMPKα Thr172 and anti-Pan AMPKα antibodies. (B) Representative blots are 
shown, from three independent experiments in duplicate. (C) Quantification of AMPKα Thr172 
phosphorylation was determined by comparison with total AMPK using densitometric analysis. . 
Data shown represents the mean % maximum +/- S.E.M of three independent experiments 
performed in duplicate. 
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Figure  3-21: Effect of 300 µM A769662 on AMPK activity and phosphorylation. 
3T3-L1 cells were incubated in 300 µМ A769662 for various times and lysates prepared. (A) Total 
AMPK was immunoprecipitated from 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and 
α2 antibodies and assayed for AMPK activity. Data shown represents the mean % maximum +/- 
S.E.M of three independent experiments, *p < 0.05 (1-tail t-test). Basal AMPK activity (nmol 32P 
incorporated into the SAMS substrate peptide/min/mg protein) is 0.25 +/- 0.025 (mean +/- S.E.M). 
Lysates (30 µg) were resolved by 7% SDS-PAGE, transferred to nitrocellulose, and probed with 
anti-AMPKα Thr172 and anti-AMPKα1 antibodies. (B) Representative blots are shown, from three 
independent experiments in duplicate. (C) Quantification of AMPKα Thr172 phosphorylation was 
determined by comparison with total AMPK using densitometric analysis. Data shown represents 
the mean % maximum +/- S.E.M of three independent experiments, *p < 0.05 (one-way ANOVA). 
 
Pamela Jane Logan, 2009   Chapter 3, 119 
3.2.5 Investigation of the molecular mechanism of AMPK 
activation by various stimuli in 3T3-L1 adipocytes 
3.2.5.1 Effect of STO-609 on AMPK activity in response to various stimuli 
To determine whether any of the stimuli activate AMPK via CaMKK in 3T3-L1 
adipocytes, the cells were treated with the different stimuli, in the presence or absence of 
the CaMKK inhibitor STO-609 (Tokumitsu et al 2002). AMPK was immunoprecipitated 
with a mixture of anti-AMPKα1 and anti-AMPKα2 antibodies, and total AMPK activity 
assayed. 
In the presence of STO-609, A23187-stimulated AMPK activity was significantly (p < 
0.05) abrogated. A statistically significant (p < 0.05) increase in AMPK activity was 
obtained from AICAR, sorbitol and azide in the presence and absence of STO-609, 
isoproterenol, metformin, arsenite and A23187 in the absence of STO-609 and 
rosiglitazone in the presence of STO-609. AMPK stimulated activity by all these 
activators, apart from A23187, was not significantly altered in the presence of STO-609. 
Leptin and hydrogen peroxide, in the presence and absence of STO-609, did not cause a 
significant (p < 0.05) increase in AMPK activity compared to basal levels. 
These results suggest these activators, apart from A23187, may activate AMPK via a 
CaMKK independent pathway (Fig. 3.22).  
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Figure  3-22: Effect of STO-609 on AMPK activity, stimulated by different AMPK activators. 
Lysates were prepared from cells pre-incubated in the presence and absence of the CaMKK 
inhibitor STO-609 (25 µM) for 20 min, prior to the addition of 5 mM sodium azide, 0.6 M sorbitol, 2 
mM AICAR, 5 µM A23187, 100 µM rosiglitazone, 1 mM metformin, 1 µM isopreterenol, 1 mM H2O2 
and 0.1 µM leptin for 30 min or 100 µM arsenite for 15 min. Total AMPK activity was 
immunoprecipitated from the 3T3-L1 lysates (200 µg) with a mixture of anti-AMPK α1 and α2 
antibodies and assayed for AMPK activity. Data shown represents the mean % basal +/- S.E.M of 
three independent experiments performed in duplicate, *p < 0.05 (1-tail t-test), increase in AMPK 
activity, relative to control. †p < 0.05 (2-tail t-test), compared to the presence of STO-609. Basal 
AMPK activity was 0.315 +/- 0.03 nmol/min/mg (SEM). 
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3.2.5.2 Effect of various stimuli on the AMP/ATP and ADP/ATP ratios 
HPLC was used to determine whether any of the AMPK activators caused a change in the 
cellular adenine nucleotide ratios (AMP/ATP or ADP/ATP). 
The elution times of AMP, ADP, and ATP are shown below (Fig. 3.23).  
To ensure that other common nucleosides/nucleotides did not have an elution time that 
would mask the AMP, ADP or ATP peaks, the elution times of the candidate molecules; 
adenosine, cAMP and ZMP were determined. It was established that these molecules had 
distinct elution times, as shown below (Fig. 3.24-3.26).  
As AICAR is phosphorylated to the nucleotide ZMP in cells, nucleotide extracts from 
AICAR-treated cells were subjected to HPLC to ensure separation and identification of the 
ZMP/AMP peaks. Analysis (Figs. 3.27 and 3.28) of the chromatogram from the nucleotide 
extract of AICAR treated cells, suggested that the peaks occurring at 4.4 min and 5.4 min 
are ZMP and AICAR respectively.  
3T3-L1 adipocytes were incubated in the presence of various stimuli, prior to nucleotide 
extraction and analysis using HPLC. A significant (p < 0.05) 4.14 +/- 0.38, 4.14 +/- 0.96 
and 2.71 +/- 0.38 fold increase in the ADP/ATP ratio, compared to basal level, was 
observed in cells incubated in the presence of isoproterenol, sodium azide, and 
rosiglitazone respectively (Fig. 3.29).  
None of the AMPK stimuli produced a significant fold increase in the AMP/ATP ratio, 
compared to basal level. However, isoproterenol, sodium azide, rosiglitazone and AICAR 
all displayed a tendency to increase the AMP/ATP ratio compared to basal levels. 
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Figure  3-23: Elution times of AMP, ADP and ATP. 
HPLC analysis, as described in section 2.2.9, of a mixture of 1 nmol each of AMP, ADP and ATP. 
Individual runs of each nucleotide were performed in order to identify the elution time for each 
molecule (data not shown).  
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Figure  3-24: Elution time of adenosine.  
HPLC analysis, as described in section 2.2.9, of (A) a mixture of 2.5 nmol each of AMP, ADP, ATP 
and adenosine, (B) a mixture of 5 nmol each of AMP, ADP and ATP, and (C) 5 nmol adenosine. 
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Figure  3-25: Elution time of cAMP.  
HPLC analysis, as described in section 2.2.9, of (A) a mixture of 5 nmol each of AMP, ADP, ATP 
and cAMP, (B) a mixture of 5 nmol each of AMP, ADP and ATP, and (C) 1 nmol cAMP. 
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Figure  3-26: Elution time of ZMP. 
HLPC analysis, as described in section 2.2.9 of (A) a mixture of 2.5 nmol each of AMP, ADP, ATP 
and ZMP, (B) a mixture of 5 nmol each of AMP, ADP and ATP, and (C) 5 nmol ZMP. 
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Figure  3-27: Identification of a ZMP peak in a nucleotide extract from AICAR treated cells 
using HPLC. 
HPLC analysis, as described in section 2.2.9, of (A) 5 nmol ZMP, (B) a nucleotide extract obtained 
from AICAR treated cells, (C) a nucleotide extract obtained from control cells, spiked with 2.5 nmol 
ZMP and (D) a nucleotide extract obtained from control cells. 
 
 
 
 
 
A 
B 
C 
D 
Pamela Jane Logan, 2009   Chapter 3, 127 
 
5 10 15 20
50100
150200
250
mVolts
2.
80
3
3.
09
9
3.
26
3
3.
58
6
3.
88
0
4.
09
1
4.
40
7
5.
02
8
AI
CA
R
 
(5.
60
4)
6.
76
4
7.
33
9
AM
P 
(7.
90
3)
8.
80
0
9.
43
8
10
.
01
4
11
.
70
0
AD
P 
(13
.
36
1)
16
.
37
1
AT
P 
(18
.
45
1)
20
.
52
0c:\star\data\17thfebaicarcellsam.run
50
100
150
mVolts
2.
72
6
3.
01
1
3.
36
0
3.
59
7
3.
98
4
4.
56
0 5
.
02
4
AI
CA
R
 
(5.
54
2)
6.
72
9
AM
P 
(7.
79
1)
8.
65
2
9.
29
3
9.
88
0
AD
P 
(13
.
24
4)
AT
P 
(18
.
32
3)
c:\star\data\17thfebcontrol+aica.run
Minutes
5.
02
8
AI
CA
R
 
(5.
60
4)
AM
P 
(7.
90
3)
AD
P 
(13
.
36
1)
AT
P 
(18
.
45
1)
5.
02
4
AI
CA
R
 
(5.
54
2)
AM
P 
(7.
79
1)
AD
P 
(13
.
24
4)
AT
P 
(18
.
32
3)
50
100
150
200mVolts 5
.
04
8
AM
P 
(7.
88
1)
AD
P 
(13
.
32
1)
AT
P 
(18
.
37
2)
0
100
200
300mVolts
AI
CA
R
 
(5.
41
4)
c:
-
-
-
2.
80
3
3.
09
9
3.
26
3
3.
58
6
3.
88
0
4.
09
1
4.
40
7
5.
02
8
AI
CA
R
 
(5.
60
4)
6.
76
4
7.
33
9
AM
P 
(7.
90
3)
8.
80
0
9.
43
8
10
.
01
4
11
.
70
0
AD
P 
(13
.
36
1)
16
.
37
1
AT
P 
(18
.
45
1)
20
.
52
0
2.
72
6
3.
01
1
3.
36
0
3.
59
7
3.
98
4
4.
56
0 5
.
02
4
AI
CA
R
 
(5.
54
2)
6.
72
9
AM
P 
(7.
79
1)
8.
65
2
9.
29
3
9.
88
0
AD
P 
(13
.
24
4)
AT
P 
(18
.
32
3)
5.
02
8
AI
CA
R
 
(5.
60
4)
AM
P 
(7.
90
3)
AD
P 
(13
.
36
1)
AT
P 
(18
.
45
1)
5.
02
4
AI
CA
R
 
(5.
54
2)
AM
P 
(7.
79
1)
AD
P 
(13
.
24
4)
AT
P 
(18
.
32
3)
5.
04
8
AM
P 
(7.
88
1)
AD
P 
(13
.
32
1)
AT
P 
(18
.
37
2)
AI
CA
R
 
(5.
41
4)
 
Figure  3-28: Identification of an AICAR peak in a nucleotide extract from AICAR treated cells 
using HPLC. 
HPLC analysis, as described in section 2.2.9, of (A) a nucleotide extract obtained from AICAR 
treated cells, (B) a nucleotide extract obtained from control cells, spiked with 1 nmol AICAR, (C) a 
nucleotide extract obtained from control cells and (D)5 nmol AICAR. 
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Figure  3-29: The effect of various AMPK activators on the ADP/ATP ratio. 
Nucleotide extracts were prepared from cells incubated for 15 min in 100 µM arsenite and 30 min 
in 5 mM sodium azide, 0.6 M sorbitol, 1 µM isoproterenol, 2 mM AICAR, 100 µM rosiglitazone, 1 
mM metformin, 5 µM A23187, 0.1 µM leptin or  1 mM hydrogen peroxide. Analysis of nucleotide 
ratios (ADP/ATP) was performed using HPLC, as described in section 2.2.9. Data shown 
represents the mean ADP/ATP ratio +/- S.E.M of three independent experiments performed in 
duplicate, *p < 0.05 (one-way ANOVA). Basal ADP and ATP concentrations were 2.07 µM +/- 0.14 
and 32 µM +/- 1.82 respectively. 
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Figure  3-30: The effect of various AMPK activators on the AMP/ATP ratio 
Nucleotide extracts were prepared from cells incubated for 15 min in 100 µM arsenite and 30 min 
in 5 mM sodium azide, 0.6 M sorbitol, 1 µM isoproterenol, 5 mM azide, 2 mM AICAR, 100 µM 
rosiglitazone, 1 mM metformin, 5 µM A23187, 0.1 µM leptin or 1 mM hydrogen peroxide. AMP and 
ATP were separated and quantified by HPLC, as described in section 2.2.9. Data shown 
represents the mean AMP/ATP ratio +/- S.E.M of three independent experiments performed in 
duplicate. Basal AMP and ATP concentrations were 3.7 µM +/- 0.21 and 32 µM +/- 1.82 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pamela Jane Logan, 2009   Chapter 3, 130 
3.3 Discussion 
The initial studies reported here investigated the expression of molecules both upstream 
and downstream of AMPK in the AMPK signalling cascade.  
3T3-L1 adipocytes expressed LKB1, CaMKKα and CaMKKβ at the protein level. Tumour 
cell lines have been shown to lack the tumour suppressor LKB1 (Tiainen et al 1999). As 
shown in figure 3.1A LKB1 is expressed in 3T3-L1 adipocytes, which is as expected since 
only tumour cells lack the tumour suppressor LKB1. 
CaMKKα/β are both expressed in brain tissue (Sakagami et al 1998) and in mouse skeletal 
muscle (Witczak et al 2007, Jensen et al 2007, McGee et al 2008). In addition CaMKKα 
has been shown to be expressed in mouse liver and adipose tissue (McGee et al 2008). 
Previous work in 3T3-L1 adipocytes has shown the expression of CaMKKβ at the mRNA 
level (Yamauchi et al 2008) however this study is, to our knowledge, the first to show the 
expression at the protein level of both CaMKK isoforms in 3T3-L1 adipocytes (Fig. 
3.1B/C). 
Downstream of AMPK, ACC catalyses the conversion of acetyl CoA to malonyl CoA. The 
relative levels of expression of the two isoforms of ACC, termed ACC1 and ACC2 are 
tissue specific. ACC1 is primarily expressed in liver and adipose, where as ACC2 is 
primarily expressed in cardiac and skeletal muscle (Ha et al 1996).  
As malonyl-CoA is the substrate for fatty acid synthesis, ACC1 which is predominantly 
expressed in liver and adipose, regulates the biosynthesis of long-chain fatty acids. Thus, 
expression of the lipogenic enzyme ACC1 in 3T3-L1 adipocytes (Fig. 3.2A) is also not 
surprising as 3T3-L1 adipocytes undergo significant lipogenesis. In addition previous work 
has shown the expression of ACC1 in 3T3-L1 adipocytes at the mRNA level (Mizuarai et 
al 2005, Kim et al 2004). 
In contrast, ACC2 which is primarily expressed in cardiac and skeletal muscle (Ha et al 
1996), is reported to primarily regulate fatty acid oxidation, whereby malonyl-CoA inhibits 
CPT1, the rate-limiting step in fatty acid uptake and oxidation by mitochondria. The 
identification of the band in the 3T3-L1 lysate (Fig. 3.2B) corresponding to ACC2 remains 
uncertain. Rat and mouse ACC2 are known to differ from each other by 8 amino acid 
residues, whereby rat ACC2 has 2456 amino acid residues and mouse ACC2 has 2448 
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amino acid residues. This would suggest that mouse ACC2 may run at a slightly lower 
molecular weight than rat muscle ACC2. Thus perhaps the intense lower molecular weight 
band, from the doublet, in the 3T3-L1 lysate lane corresponds to ACC2. However, the 
difference of 8 amino acid residues, approximately 800Da, is probably too small to observe 
any difference in migration between rat and mouse ACC2. Previous work in 3T3-L1 
adipocytes has shown the expression of ACC2 at the mRNA level (Du et al 2008). Thus in 
summary, it is likely that the ACC2 protein is expressed in 3T3-L1 adipocytes, however as 
the antibody appears not to be particularly specific, the band corresponding to mouse 
ACC2 in 3T3-L1 adipocytes remains unclear.  
Investigation of AMPK subunit isoform expression (Fig. 3.3-3.9) revealed changes in all 
subunit isoform expression levels throughout adipogenesis, apart from AMPKα1 subunit 
expression which remained at a constant level throughout adipogenesis. An increase in 
expression throughout development from fibroblasts to adipocytes was observed with the 
α2, β2 and γ1 subunits. In contrast β1, γ2 and γ3 subunit expression decreased throughout 
adipogenesis. As the differentiation process involves treatment of fibroblasts with insulin, 
dexamethasone and IBMX on day 0 and insulin on day 2 it is possible that insulin and / or 
IMBX and / or dexamethasone may suppress or promote the expression levels of the 
different subunit isoforms. 
Both α1 and α2 subunits recognise the *(X,β)XXS/TXXX* motif (where * represents a 
hydrophobic residue and β a basic residue). However, it appears that the subunits exhibit 
differences with respect to preferences for the hydrophobic residues as the P-5 and P+4 
positions (Woods et al 1996b). These subtle differences may confer substrate specificity of 
the two isoforms within the cell. Thus increased expression of the α2 subunit throughout 
adipogenesis may allow phosphorylation of specific substrates, such as lipogeneic proteins, 
which may not be phosphorylated by α1.   
Previous work using recombinant AMPK heterotrimeric complexes (Scott et al 2004) and 
native rat complexes (Cheung et al 2000) found that the different γ isoform complexes 
differed in their degree of stimulation by AMP. γ2 displayed the greatest stimulation by 
AMP, while γ1 displayed an intermediate stimulation by AMP and γ3 the lowest 
stimulation by AMP. In this study during adipogenesis the γ1 subunit expression is 
increased, where as the γ2 and γ3 subunit expression is decreased. There was no significant 
(p < 0.05) difference in total AMPK activity (Fig. 3.10), as determined under a saturating 
AMP concentration (200µМ), between fibroblasts and adipocytes. Thus it would be 
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interesting to investigate the sensitivity to AMP, of AMPK complexes 
immunoprecipitated, from both fibroblasts and adipocytes, given that the expression levels 
of the γ subunit isoforms are altered during adipogenesis.   
Previous work in human adipose tissue (Lihn et al 2004) and rat adipocytes (Daval et al 
2005) found that the α1 catalytic subunit accounts for the major part of basal AMPK 
activity. Interestingly, the α1 subunit was found to account for almost all total basal AMPK 
activity in both fibroblasts and adipocytes throughout adipogenesis, while the α2 subunit 
displayed negligible contribution to total basal AMPK activity (Fig. 3.10). Salt and co-
workers also found that the α1 subunit accounts for the majority of the basal AMPK 
activity in 3T3-L1 adipocytes (Salt et al 2000). However, in contrast to this study, Salt and 
co-workers (Salt et al 2000), also found that the α2 subunit contributed about 20% to the 
total basal AMPK activity. Thus in this current study it was initially thought that the lack 
of α2-specific AMPK activity might be due to the failure of the anti-α2 antibody to 
successfully immunoprecipitate the AMPK complexes containing α2 subunits. However, 
this seems unlikely as α2 is detected in the α2 immunoprecipitates as shown in figure 3.10 
The relative contribution of the α1 and α2 isoforms to total AMPK activity in rat liver is 
approximately equal (Woods et al 1996b). Equal volumes of the rat liver kinase (K) were 
used as a positive control for α1 and α2 subunit expression blots (Fig. 3.3 and 3.4). 
Comparable intensities of the rat liver kinase (K) with expression levels of the α1 and α2 
isoforms suggests there is indeed far less α2 subunit expression in fibroblasts and 
adipocytes compared to α1 i.e the intensity of the α2 band in the purified rat liver kinase 
detected by the anti-α2 antibody is more intense compared to the 3T3-L1 lysate, whereas 
the α1 band detected by the anti-α1 antibody in the purified liver kinase is less intense 
compared to the 3T3-L1 lysates suggesting that α1 expression is far more abundant than α2 
throughout adipogenesis. Thus, in conclusion, it is likely that α1 may account for almost all 
total AMPK activity in this study, due to its predominant expression level. Thus the only 
other possible explanation for the discrepancy is that the 3T3-L1 cell passage number and 
initial source were different in this work compared to the work by Salt and co-workers 
(Salt et al 2000), and that either of these differences altered the contribution of the α2 
subunit to the total basal AMPK activity. 
In this study the kinetics of AMPK activity in response to various activators was assessed, 
in order to determine whether there is a correlation between AMPK activation and various 
downstream effects such as glucose transport. The extent of AMPK activation and Thr172 
phosphorylation in the 3T3-L1 adipocytes varied for each of the different stimuli, as shown 
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in (Figs. 3.11-21). In 3T3-L1 adipocytes sorbitol produced the greatest fold increase in 
AMPK activity compared to basal levels. It should be noted that the direct AMPK activator 
A769662 has been shown to activate only β1 containing AMPK complexes (Scott et al 
2008), whereas it is probable that the other stimuli can activate both β1 and β2 containing 
AMPK complexes. Thus potentially this may account for the very modest increase in 
AMPK activity observed with the direct AMPK activator A769662.  
These results support previous studies reporting the stimulation of AMPK activity by 
various AMPK activators in various tissues; arsenite in rat hepatocytes (Corton et al 1994), 
azide in fao hepatoma cells (Witters et al 1991), rosiglitazone in mouse muscle cells (Fryer 
et al 2002b) and in vivo in rat adipose tissue (Ye et al 2004), metformin in rat hepatocytes 
(Zhou et al 2001) and adipocytes (Huypens et al 2005), sorbitol in mouse muscle cells 
(Fryer et al 2002b), AICAR in rat hepatocytes (Corton et al 1995) and adipocytes (Corton 
et al 1995), hydrogen peroxide in NIH-3T3 cells (Choi et al 2001),  leptin in skeletal 
muscle (Minokoshi et al 2002) and adipose tissue (Orci et al 2004), adiponectin in muscle 
and liver (Yamauchi et al 2002) and adipose (Wu et al 2003) and isoproterenol in isolated 
rat epididymal fat cells (Moule and Denton 1998) and in 3T3-L1 adipocytes (Yin et al 
2003).   
Subsequently, this study investigated the molecular mechanisms by which AMPK is 
activated by each test substance in 3T3-L1 adipocytes. This included using the CaMKK 
inhibitor STO-609 and determining whether there was a change in the nucleotide 
ADP/ATP ratio and AMP/ATP ratio by HPLC.  
As mentioned AICAR is converted into ZMP in the cell which functions as a cellular 
mimetic of AMP. Thus like AMP, ZMP causes allosteric activation of AMPK and protects 
phosphorylation of Thr172, by the constitutively active AMPK kinase LKB1, from 
dephosphorylation. Thus, it was not surprising that STO-609 did not inhibit AICAR 
stimulated AMPK activity (Fig. 3.22), and that AICAR did not significantly alter the 
ADP/ATP ratio (Fig. 3.29) and AMP/ATP (Fig. 3.30) ratio. In contrast, the calcium 
ionophore A23187 stimulates AMPK activity via CaMKK. Therefore in the presence of 
STO-609, A23187 stimulated AMPK activity is significantly (p < 0.05) attenuated (Fig. 
3.22). Thus, this study shows that 3T3-L1 adipocytes express CaMKK and exhibit 
CaMKK-dependent AMPK activation upon A23187 stimulation. These results suggest a 
potential role for CaMKK as an upstream AMPK kinase in 3T3-L1 adipocytes. However, 
Hawley et al 2005 showed that CaMKKβ appears to activate AMPK much more rapidly 
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than CaMKKα in cell-free assays. Further work such as siRNA knockdown of CaMKKα/β, 
is required to determine which CaMKK isoform is most catalytically active in 3T3-L1 
adipocytes. 
This current study found that sorbitol did not significantly increase the ADP/ATP ratio 
(Fig. 3.29) and AMP/ATP ratio (Fig. 3.30). Indeed, previous observations in a mouse 
skeletal muscle cell line (Fryer et al 2002b) have concluded that sorbitol can activate 
AMPK without altering the cellular energy level. Sorbitol has been shown to be able to 
increase intracellular calcium levels in the chicken B cell line DT40 (Qin et al 1997) and 
was recently suggested to stimulate AMPK activity in LKB1 deficient HeLa cells via 
CaMKKβ (Woods et al 2005). However this current study suggests that in 3T3-L1 
adipocytes sorbitol appears to be able to activate AMPK in a CaMKK independent and 
nucleotide independent manner (Fig. 3.22). Thus, sorbitol may stimulate AMPK activity in 
adipocytes via an alternative AMPK kinase. A recent study has suggested that TAK1 
(Momcilovic et al 2006) may function as a novel mammalian AMPK kinase. Furthermore 
it should be noted that there is still residual basal AMPK activity in CaMKKβ knockout 
studies in HeLa cells, which lack LKB1 (Woods et al 2005). This could be explained in 
part by the incomplete knockdown of CaMKKβ protein expression in these cells, however 
the possibility still remains that another unidentified upstream kinase is contributing to 
AMPK activity in these cells. This supports the idea that there may be as yet unidentified 
mammalian AMPK kinases, which may exhibit differential tissue expression. 
The β adrenoreceptor agonist isoproterenol has previously been shown to activate AMPK 
in rat epididymal fat cells (Moule and Denton 1998) and 3T3-L1 adipocytes (Yin et al 
2003, Gauthier et al 2008). In addition incubation of isolated adipocytes with the β 
adrenoreceptor agonists, adrenaline and forskolin, also increased AMPK activity and the 
AMP/ATP ratio (Koh et al 2007) (Gauthier et al 2008). This study showed that ST0-609 
does not perturb the ability of isoproterenol (Fig. 3.22) to stimulate AMPK activity in 3T3-
L1 adipocytes, and that it stimulates a statistically significant (p < 0.05) increase in the 
ADP/ATP ratio (Fig. 3.29), and displays a tendency to increase the AMP/ATP ratio (Fig. 
3.30). This suggests that isoproterenol activates AMPK by a mechanism which is 
independent of CaMKK, and dependent on a decrease in the cellular energy level. Thus, in 
3T3-L1 adipocytes, isoproterenol potentially activates AMPK via LKB1. 
A recent study (Gauthier et al 2008) concluded that the activation of AMPK, and 
subsequent inhibition of lipolysis, in 3T3-L1 adipocytes, by agents (isoproterenol, IBMX 
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and forskoline) that increase cAMP appears to be secondary to an increase in the 
AMP/ATP ratio that accompanies lipolysis and not the direct result of increases in cAMP 
levels and PKA activity, as treatment of cells with orlistat partially inhibited isoproterenol 
induced lipolysis and AMPK activity, yet did not alter cAMP levels or PKA activity. The 
re-esterification of NEFAs back into TG requires their acylation, which is catalysed by 
acyl-CoA synthetase. This process is energy dependent consequently reducing ATP levels 
and increasing AMP levels. Gauthier and co-workers concluded that reduced energy levels 
are possibly due in part to acylation of fatty acids produced during lipolysis, as Triacsin C, 
an acyl-CoA synthetase inhibitor, blunted isoproterenol induced increases in AMPK 
activity and the AMP/ATP ratio.  
Other events may contribute to the reduced energy state which accompanies lipolysis. 
NEFAs cause uncoupling of oxidative phosphorylation which depletes energy levels, 
(Wojtczak et al 1993) and the formation of glycerol-3-phosphate used for the re-
esterification of NEFAs into TG is also energy dependent. 
In addition, NEFAs have been shown to activate AMPK in rat islets, the MIN6 β cell line 
(Wang et al 2007) and  rat L6 skeletal muscle cells (Fediuc et al 2006). Thus, it is possible 
that NEFAs accumulating in adipose tissue following isoproterenol induced lipolysis 
activate AMPK via an AMP/ATP dependent pathway.  
In contrast it has also been shown that activation of AMPK in 3T3-L1 adipocytes by 
isoproterenol stimulates lipolysis (Yin et al 2003). Interestingly, Yin et al 2003, showed 
that cAMP analogues also stimulated AMPK phosphorylation. Furthermore, they showed 
that insulin, which inhibits lipolysis via the activation of PDE3B which breaks down 
cAMP to AMP, antagonized the activation of AMPK by forskolin. Therefore Yin and co-
workers suggested that isoproterenol is activating AMPK via an intermediary rise in cAMP 
levels and not via an increase in AMP levels resulting from degradation by PDE3B (Yin et 
al 2003). 
In this current study the source of this decrease in cellular energy level was not 
investigated. As maximum AMPK activity was observed after 30 min, it is perhaps more 
likely that NEFAs or re-esterification of NEFAs and glycerol to TG may play a role in the 
AMP/ATP dependent stimulation of AMPK activity, rather than elevated AMP levels 
resulting from the degradation of cAMP to AMP by PDE3. To confirm this, a PDE3B 
inhibitor could be used to determine whether isoproterenol is activating AMPK via  
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elevating AMP levels resulting from degradation of cAMP into AMP, or indeed whether 
re-esterification of NEFAs is playing a role in the AMP/ATP dependent stimulation of 
AMPK activity. 
In cells treated with metformin, hydrogen peroxide, leptin and arsenite there was no 
observed increase in the ADP/ATP or AMP/ATP ratio (Fig. 3.29, 3.30). In addition, these 
stimuli did not appear to stimulate AMPK activity in a CAMKK dependent manner (Fig. 
3.22). These results suggest that metformin, hydrogen peroxide, leptin and arsenite all 
activate AMPK via a nucleotide and CAMKK independent manner. However, in general, 
the effect of these activators on AMPK activity is very subtle in 3T3-L1 adipocytes, thus 
potentially masking any alterations in nucleotide levels and effects of STO-609. Leptin, 
hydrogen peroxide and arsenite have previously been shown to activate AMPK, in skeletal 
muscle, NIH-3T3-L1 cells, and rat hepatocytes respectively, and cause an increase in the 
AMP/ATP ratio (Minokoshi et al 2002, Chou et al 2001, Corton et al 1994). Previous 
studies in CHO cells, the rat hepatoma cell line H4IIE and the skeletal muscle cell line H-
2Kb have also reported that metformin activates AMPK without altering the cellular energy 
level (Hawley et al 2002, Fryer et al 2002b). Interestingly, Huypens and co-workers 
showed that prolonged stimulation of 3T3-L1 adipocytes with metformin stimulated 
AMPK activity, as shown by an increase in AMPK Thr172 phosphorylation (Huypens et al 
2005). It has been demonstrated that metformin is transported into liver cells via the 
organic cation transporter 1 (OCT1), stimulating AMPK phosphorylation (Shu et al 2007). 
The same study found that acute treatment of 3T3-L1 adipocytes with metformin did not 
stimulate AMPK Thr172 phosphorylation, and that 3T3-L1 adipocytes exhibited little 
OCT-activity (Shu et al 2007). Thus, it has been suggested (Shu et al 2007) that perhaps 
prolonged metformin treatment results in passive diffusion of metformin into 3T3-L1 
adipocytes which consequently causes an increase in AMPK activity.  
In this study azide and rosiglitazone were both shown to cause a significant (p < 0.05) 
increase in the ADP/ATP ratio (Fig. 3.29), and displayed a tendency to increase the 
AMP/ATP ratio (Fig. 3.30). This supports previous work by Witters and co-workers 
(Witters et al 1991) in fao hepatoma cells and Fryer and co-workers (Fryer et al 2002b) in 
mouse muscle cells that azide and rosiglitazone can both decrease the cellular energy level. 
In addition, in this study these activators did not appear to stimulate AMPK activity in a 
CAMKK dependent manner (Fig. 3.22). Thus, it is possible that both azide and 
rosiglitazone stimulate AMPK activity in 3T3-L1 adipocytes in a LKB1 dependent 
manner. 
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It should be noted that in this study the basal AMP concentration appeared to be greater 
than the basal ADP concentration, which differs from the studies by Fryer and co-workers 
(Fryer et al 2002b) and Luo and co-workers (Luo et al 2007) which reported that the ADP 
concentration was greater than the AMP concentration under basal conditions in muscle 
cells and 3T3-L1 adipocytes respectively. Also, the AMP/ATP ratio in the muscle cells 
under basal conditions was 0.05 and in the 3T3-L1 cells, 0.04, which is lower than the 
AMP/ATP ratio of 0.14 under basal condition in this study. It is possible that another 
molecule not tested in this study such as guanosine monophosphate (GMP), inosine 
monophosphate (IMP), or uridine monophosphate (UMP) may have a similar elution time 
as AMP in this system, which could mask the real AMP peak and account for the 
apparently elevated AMP concentrations. Thus further work is required to determine the 
elution time of other candidates including GMP, IMP and UMP. Furthermore, the 
equilibrium between adenine nucleotides (2ADP ↔ AMP + ATP) refers to free AMP in 
the cell. This study measured the adenine nucleotide ratio using total cellular nucleotide 
concentrations, i.e including AMP bound to proteins. Thus in general these results should 
be taken with caution, given that AMPK is only regulated by the cytosolic AMP/ATP ratio.  
As shown in figure 3.31, there was no simple linear relationship between the fold increase 
in AMPK activity and the ADP/ATP ratio for each stimuli in 3T3-L1 adipocytes. 
 
Figure  3-31: Effects of various stimuli on AMPK activity versus ADP/ATP ratio. 
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Figure 3.32 summarises the proposed mechanisms of AMPK activation in 3T3-L1 
adipocytes. AICAR is converted into ZMP in the cell which functions as a cellular mimetic 
of AMP i.e ZMP causes allosteric activation of AMPK and protects phosphorylation of 
Thr172, by the constitutively active AMPK kinase LKB1, from dephosphorylation. The 
novel direct AMPK activator A769662 activates AMPK by mimicking the effects of AMP. 
The calcium ionophore A23187 is thought to stimulate AMPK activity through CaMKK, 
as A23187 stimulated AMPK activity is perturbed by STO-609. AMPK activation by 
isoproterenol, azide and rosiglitazone caused a significant (p < 0.05) increase in the 
ADP/ATP ratio and displayed a tendency to increase the AMP/ATP ratio. In addition 
AMPK stimulated activity by these activators was not significantly altered in the presence 
of STO-609. Therefore it is possible that these activators are stimulating AMPK via an 
LKB1 dependent pathway. Sorbitol, metformin, arsenite, hydrogen peroxide and leptin 
were found to have no significant (p < 0.05) effect on the nucleotide ratios, and AMPK 
stimulated activity by these activators was not significantly altered in the presence of STO-
609. In summary, these results suggest a role for both LKB1 and CaMKK as AMPK 
kinases in 3T3-L1 adipocytes. However, potentially there exists other as yet unidentified 
AMPK kinases in 3T3-L1 adipocytes, which are both nucleotide and calcium independent.  
 
Figure  3-32: Mechanism of acute AMPK activation in 3T3-L1 adipocytes. 
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Chapter 4 - Role of acute AMPK activation in 
adipocyte insulin action 
4.1 Introduction 
4.1.1 Insulin-stimulated glucose uptake 
Insulin is a polypeptide hormone which is produced in the Islets of Langerhans in the 
pancreas. After feeding, elevated blood glucose levels trigger exocytosis of the insulin 
secretary vesicles and release of insulin into the bloodstream (see 1.2.2). 
Upon insulin signalling (see 1.2.2) in target tissues, glucose transporters which facilitate 
the uptake of glucose into target cells, are transported to the plasma membrane in vesicles. 
In muscle and fat cells the glucose transporter, GLUT4, is responsible for the uptake of 
glucose into the cells where it is stored as glycogen and TG respectively (Saltiel et al 
2001). 
4.1.2 Insulin indepedent glucose uptake 
In muscle, exercise has been reported to stimulate AMPK activity (Winder and Hardie 
1996) and increase glucose transport in an insulin-independent manner, resulting in 
increased translocation of GLUT4 to the plasma membrane from intracellular stores 
(Hayashi et al 1997, Douen et al 1990, Douen et al 1989, Goodyear et al 1991). In 
addition, contraction of isolated rat epitrochlearis muscles via electrical stimulation has 
also been shown to increase AMPK activity and glucose transport in an insulin-
independent manner (Hayashi et al 1998). Like physical exercise, contraction has also been 
reported to increase GLUT4 translocation to the plasma membrane (Goodyear et al 1990, 
Lund et al 1995). 
The AMPK activator AICAR has also been reported to increase glucose transport in L6 
myocytes (Chen et al 2002), isolated rat epitrochlearis muscles (Hayashi et al 1998, 
Hayashi et al 2000, Bergeron et al 1999), perfused rat hindlimbs (Merrill et al 1997) and in 
skeletal muscle of conscious rats (Bergeron et al 1999). In addition, AICAR has been 
shown to potentiate insulin-stimulated glucose transport (Bergeron et al 1999, Hayashi et 
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al 1998) in isolated rat epitrochlearis muscles, and stimulate GLUT4 translocation to the 
plasma membrane in perfused rat hindlimbs (Kurth-Kraczek et al 1999).  
Since exercise, contraction and AICAR all activate AMPK activity and stimulate glucose 
uptake into skeletal muscle independently of insulin-stimulated glucose transport, it has 
been hypothesised that AMPK mediates this effect (Hayashi et al 1998). However 
currently there exists a great deal of confusion as to whether AMPK mediates contraction-
stimulated glucose uptake into muscle due to conflicting studies. Experiments using 
genetically manipulated mice with knockout catalytic (Jørgensen et al 2004) or regulatory 
(Barnes et al 2004) AMPK subunits in skeletal muscles have reported that contraction-
stimulated glucose transport was unaffected. Although AMPK activity was only partially 
reduced in these studies, the AMPK knockouts did inhibit the effect of AICAR on muscle 
glucose transport (Jørgensen et al 2004, Barnes et al 2004). In contrast, another study 
using genetically manipulated mice where AMPK was completely knocked down in 
skeletal muscle by overexpression of functionally inactive AMPK (Mu et al 2001) reported 
that there was a significant reduction in contraction-stimulated glucose transport in fast and 
slow twitch muscles. Interestingly, another study in perfused rat hindlimbs (Derave et al 
2000) showed that there was a significant correlation between AMPK activity and glucose 
transport in contracting fast-twitch muscles, however in slow-twitch muscles glucose 
transport was increased during contraction whereas AMPK activity did not increase. This 
suggests that the role of AMPK may differ between muscle fibre type. 
Interestingly, in adipocytes AICAR was shown to modestly stimulate basal glucose 
transport while demonstrating an inhibitory effect on insulin-stimulated glucose transport 
and GLUT4 translocation to the plasma membrane (Salt et al 2000). Thus the effect of 
AICAR in adipocytes contrasts with the effect of AICAR in skeletal muscle. 
4.1.3 The role of AS160 and TBC1D1 in glucose transport 
AS160 has been identified as a potential target of PKB and AMPK which both mediate 
GLUT4 translocation in response to insulin and AICAR respectively in muscle cells (Bruss 
et al 2005, Thong et al 2007).  
AS160 is a 160kDa Rab GAP which was first discovered using the PAS antibody to 
immunoprecipitate proteins harbouring phosphorylated PKB substrate motifs from insulin-
stimulated adipocytes (Kane et al 2002). In addition to a GAP domain at the C-terminus, 
Pamela Jane Logan, 2009   Chapter 4, 141 
AS160 also contains two phospho-tyrosine binding domains and six potential 
phosphorylation sites (Ser318, Ser341, Ser570, Ser588, Thr642, Ser751) that match the 
criteria for a PKB consensus motif (RXRXXS*/T*) (Sano et al 2003). Quantification of 
the relative amount of phosphopeptides derived from extracts of 3T3-L1 adipocytes in the 
presence or absence of insulin revealed that levels of phosphorylation at five of these 
phosphorylation sites (Ser318, Ser570, Ser588, Thr642, and Thr751) was increased with 
insulin (Sano et al 2003). More recently, in HEK 293 cells, Geraghty and co-workers 
identified two novel AS160 sites Thr568 and Ser666, which lie within a motif which is not 
a consensus sequence for PKB (Geraghty et al 2007).   
AS160 has been implicated in insulin-stimulated GLUT4 trafficking of vesicles to the 
plasma membrane. It has been demonstrated in 3T3-L1 cells that AS160 can retain GLUT4 
vesicles intracellularly by the activity of its GAP domain under basal conditions (Eguez et 
al 2005, Larance et al 2005). It has been proposed that AS160 phosphorylation at PAS 
sites in response to insulin promotes exocytosis of GLUT4 vesicles by reducing the GAP 
activity of the protein towards Rab proteins associated with GLUT4 vesicles, as 
transfection of 3T3-L1 adipocytes and L6 GLUT4-myc myoblasts with a constitutively 
active AS160 incapable of being phosphorylated at PAS regulatory motifs displayed 
reduced insulin-induced GLUT4 translocation (Sano et al 2003, Thong et al 2005). 
Despite the finding that AS160 is thought to integrate signals from both PKB and AMPK 
in muscle cells (Bruss et al 2005, Thong et al 2007), it is possible that this is not the case in 
adipocytes due to the opposing action of AICAR on insulin-stimulated glucose transport 
(Salt et al 2000). In addition, it is thought that the inhibitory effect of AICAR on insulin-
stimulated glucose transport in adipocytes is at a site downstream of PKB in the insulin 
signalling cascade, as AICAR appears to have no effect on IRS-1 tyrosine phosphorylation, 
PI3K recruitment to IRS-1 or PKB activity (Salt et al 2000).   
TBC1D1 is a paralogue of AS160, with a predicted molecular mass of 133kDa (Chen et al 
2008). TBC1D1 and AS160 both contain GAP domains which are highly conserved, but 
display sequence variation at the N-terminus and within the two distinct clusters of 
phosphorylated sites that are located either side of the second phospho-tyrosine binding 
domain. TBC1D1 contains predicted PKB phosphorylation sites at Thr596 and Ser507 
corresponding to Thr642 and Ser570 on AS160, respectively (Roach et al 2007). Mass 
spectrometer analysis of TBC1D1 isolated from HEK 293 cells incubated in medium 
containing serum identified Thr596, Ser507, Ser237, Ser263, Ser565, Ser566 and Ser585 
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as phosphorylation sites on TBC1D1 (Chen et al 2008). Interestingly it has been 
established that Ser237 on TBC1D1 becomes phosphorylated in response to treatments that 
elevate levels of active and phosphorylated AMPK in 3T3-L1 adipocytes, HEK 293 cells 
and rat L6 myotubes (Chavez et al 2008, Chen et al 2008). During the course of this work 
TBC1D1 emerged as a Rab GAP also involved in regulating glucose transport. 
TBC1D1 is expressed in 3T3-L1 adipocytes (Chavez et al 2008), however it appears to be 
only 1/20 as abundant as AS160. Insulin treatment of 3T3-L1 adipocytes has been shown 
to cause phosphorylation of TBC1D1 on Thr596 in the PKB phosphorylation motif 
RRRANTL (Roach et al 2007).  TBC1D1 is thought not to be as important as AS160 in 
3T3-L1 cells as TBC1D1 did not contribute significantly to the total GAP activity towards 
the Rab(s) involved in GLUT4 translocation. This was shown by knockdown of TBC1D1 
which did not increase the amount of GLUT4 at the cell surface in the absence of insulin 
(Chavez et al 2008), whereas knockdown of AS160 did (Eguez et al 2005). Interestingly, 
overexpression of TBC1D1 was shown to markedly inhibit insulin-stimulated GLUT4 
translocation (Roach et al 2007) in 3T3-L1 adipocytes, whereas overexpression of AS160 
did not (Sano et al 2003). It was initially thought that perhaps the endogenous PKB was 
insufficient to phosphorylate ectopic TBC1D1 to the extent required. However, in a 
subsequent study overexpressed TBC1D1 was also shown to inhibit GLUT4 translocation 
elicited by ectopic activated PKB which suggests that the GAP activity of TBC1D1 is not 
suppressed by PKB phosphorylation (Chavez et al 2008), whereas the GAP activity of 
AS160 is suppressed by PKB phosphorylation. Thus, although TBC1D1 is expressed in 
3T3-L1 adipocytes, it is considered unlikely to participate significantly in insulin-
stimulated GLUT4 translocation. Hence, in adipocytes it is thought that insulin signals 
GLUT4 translocation primarily through AS160 and not TBC1D1.  
TBC1D1 is highly expressed in skeletal muscle (Chavez et al 2008, Taylor et al 2008) and 
was shown to be phosphorylated at PAS sites in mouse skeletal muscle in vivo by insulin, 
AICAR and contraction (Taylor et al 2008). However AMPK is thought to be the more 
important regulator as semi-quantitative analysis of spectra suggested that AICAR caused 
greater overall phosphorylation of TBC1D1 sites compared to insulin (Taylor et al 2008). 
Recent work by Chavez and co-workers, showed that AICAR partially reversed the 
inhibition of insulin-stimulated GLUT4 translocation by overexpressed TBC1D1 in 3T3-
L1 cells (Chavez et al 2008). These findings have led to the proposal that TBC1D1 may 
participate in the regulation of GLUT4 translocation in response to contraction and/or 
AMPK activation.  
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Insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes is thought to require insulin-
stimulated association of 14-3-3 proteins with phosphorylated AS160 (Ramm et al 2006). 
In rat L6 myotubes, insulin was shown to promote the phosphorylation of Thr596 on 
TBC1D1 but not the binding of 14-3-3 proteins, whereas AMPK activation by AICAR, 
phenformin and A-769662 was shown to promote the phosphorylation of Ser237 on 
TBC1D1 and binding of 14-3-3 proteins. In contrast, AS160 was shown to be 
phosphorylated on its 14-3-3 binding sites (Ser341 and Thr642) and to bind 14-3-3 
proteins in response to insulin, but not the AMPK activator A-769662 in rat L6 myotubes 
(Chen et al 2008). These findings further support the proposal that TBC1D1 and AS160 
may have complementary roles in regulating vesicle trafficking in response to insulin and 
AMPK activation in skeletal muscle. 
The mechanism by which AS160/TBC1D1/Rabs mediate exocytosis of GLUT4 vesicles 
remains undefined. However, the v-SNARE VAMP2 and the t-SNAREs syntaxin4 and 
SNAP23 have been shown to be involved in GLUT4 exocytosis (Bryant et al 2002, Hou 
and Pessin 2007). In addition, the syntaxin 4-binding proteins, Munc18c, tomosyn and 
synip have also been proposed to regulate SNARE complex assembly and GLUT4 
translocation (Kanda et al 2005,  Widberg et al 2003, Yamada  et al 2005). 
4.1.4 Rab proteins 
Rabs are small G-proteins that in their GTP-bound form participate in vesicle movement 
and membrane fusion (Zerial et al 2001). Rabs are activated by replacement of GDP with 
GTP catalysed by GEFs (guanine nucleotide exchange factors). Active Rabs can interact 
with Rab effector proteins on target membranes, which allows tethering of the vesicle to its 
target membrane and other membrane proteins, including the SNARE proteins, to interact, 
facilitating docking of the vesicle to the plasma membrane. SNARE proteins can be 
classified as either v-SNARES, (SNARES associated with the vesicle) and, t-SNARES, 
(SNARES associated with the target membrane) (Bryant et al 2002). GAP degrades GTP 
to GDP which allows the Rabs to be recycled. GDP dissociation inhibitor (GDI) binds the 
Rab inhibiting the exchange of GDP for GTP, and a Rab escort protein escorts the Rab 
back to its original membrane (Fig. 4.1). 
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Figure  4-1: The Rab GTPase cycle. 
The Rab GTPase switches between GDP- and GTP-bound forms, which have different 
conformations. Conversion from the GDP- to the GTP-bound form is caused by nucleotide 
exchange, catalyzed by a GDP/GTP exchange factor (GEF). Conversion from the GTP-to the 
GDP-bound form occurs by GTP hydrolysis, facilitated by a GTPase-activating protein (GAP). The 
GTP-bound form interacts with effector molecules, whereas the GDP-bound form interacts with 
Rab escort protein (REP) and GDP dissociation inhibitor (GDI). Pi, inorganic phosphate.  
Miinea and co-workers identified specific Rab isoforms (Rab1A, 1B, 2A, 3A, or 3D; Rab 
4B, 5A, 5B, 5C, 6A, or 6B; Rab7, 8A, or 8B; Rab10, 11B, 14, 18, and 35) associated with 
GLUT4 vesicles in 3T3-L1 cells by immunoprecipitation (Miinea et al 2005). Also in 3T3-
L1 adipocytes, Larance and co-workers found that GLUT4 vesicles were associated with 
Rab 10, 11 and 14 (Larance et al 2005). In addition RNAi knockdown of Rab10 was found 
to result in an approximately 80% reduction in GLUT4 translocation in 3T3-L1 adipocytes 
(Sano et al 2007). Thus, Rab 10 is currently thought to be the most likely Rab involved in 
GLUT4 vesicle translocation in 3T3-L1 adipocytes. 
4.1.5 Aims 
Previous work (Salt et al 2000) showed that AICAR inhibits insulin-stimulated glucose 
transport in 3T3-L1 adipocytes, which is in contrast to the effect of AICAR in muscle. In 
order to further characterise the role of AMPK in the inhibition of insulin-stimulated 
glucose transport, this study investigated the effect of various AMPK activators, including 
the direct AMPK activator A769662, on insulin-stimulated glucose transport in 3T3-L1 
adipocytes. The effect of AMPK inhibition and knockdown, on AICAR stimulated basal 
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glucose transport and inhibition of insulin-stimulated glucose transport was also assessed 
to determine whether the effects of AICAR on glucose transport were dependent on 
AMPK activation.  
Previous work by Salt and co-workers showed that AICAR did not alter IRS-1 
phosphorylation, association of PI3K with IRS-1 or PKB activity in 3T3-L1 adipocytes 
(Salt et al 2000). During the course of this project AS160 and TBC1D1 have both emerged 
as Rab GAPs involved in the regulation of glucose transport. Therefore, in this study the 
mechanism by which AICAR inhibits insulin-stimulated glucose transport in adipocytes 
was further investigated, with particular attention being paid to the effect of AICAR on 
basal and insulin-stimulated AS160/TBC1D1 phosphorylation at PAS sites. 
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4.2 Results        
4.2.1 Effect of various AMPK activators on basal and insulin-
stimulated glucose transport 
The effect of various AMPK activators on basal and insulin-stimulated glucose transport 
was investigated using 2-[3H] deoxy-D-glucose. A significant (p < 0.05) 39.7 +/- 2.28 %, 
49 +/- 10.7 %, 73.6 +/- 5.7 %, 38.7 +/- 3.5 % and 67.5 +/- 7.8 % inhibition of insulin-
stimulated glucose transport (Fig. 4.2) was observed in cells pre-treated with AICAR, 
sorbitol, rosiglitazone, isoproterenol and A769662 respectively. A23187 did display an 
apparent tendency to inhibit insulin-stimulated glucose transport, however this effect was 
not statistically significant (Fig. 4.2). In addition, sorbitol produced a significant (p < 0.05) 
5.74 +/- 0.55 fold increase in basal glucose transport, whereas the other stimuli did not 
significantly alter basal glucose transport. 
4.2.2 Investigating whether the inhibition of insulin-stimulated 
glucose transport by AICAR is dependent on AMPK activation 
4.2.2.1 Effect of Compound C on AICAR mediated inhibition of insulin-
stimulated glucose uptake 
The AMPK inhibitor, Compound C, was utilized to determine the effect of AMPK 
inhibition on the inhibition of insulin-stimulated glucose transport by AICAR. Western 
blotting assessing phosphorylation of the AMPK target protein ACC, at Ser79, was 
performed to determine whether AMPK activity was inhibited by Compound C. As shown 
in figure 4.3B/C, AICAR caused a significant (p < 0.05) 2.18 +/- 0.69 and 2.54 +/- 0.49 
fold increase in ACC Ser79 phosphorylation, in non-insulin-stimulated cells and insulin-
stimulated cells respectively. In comparison, AICAR was not found to significantly 
increase ACC Ser79 phosphorylation, under non-insulin-stimulated and insulin-stimulated 
conditions, in 3T3-L1 adipocytes incubated in the presence of Compound C. Incubation of 
3T3-L1 adipocytes in AICAR caused a significant (p < 0.05) 28.4 +/- 3.5 % inhibition of 
insulin-stimulated glucose transport (Fig. 4.3A). However, in the presence of Compound 
C, AICAR did not inhibit insulin-stimulated glucose transport in 3T3-L1 adipocytes (Fig. 
4.3A). In addition, a significant (p < 0.05) 32 +/- 1.2 % reduction in insulin-stimulated 
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glucose transport was observed in 3T3-L1 adipocytes incubated in the presence of 
Compound C.  
4.2.2.2 Effect of a DN AMPK mutant on AICAR mediated inhibition of insulin-
stimulated glucose transport 
Adenovirus-mediated gene transfer was used to overexpress a dominant negative AMPK 
mutant (Ad.α1DN) in 3T3-L1 adipocytes, in order to further investigate the effect of down-
regulation of AMPK on AICAR mediated inhibition of insulin-stimulated glucose 
transport.  
The α1DN mutant protein is based on the entire α1 subunit sequence and contains an N-
terminal myc tag. The expression of α1DN is shown by the presence of a band detected by 
the myc antibody at about 62kDa (Fig. 4.4A). In addition, AICAR stimulated ACC Ser79 
phosphorylation was decreased in Ad.α1DN infected cells, compared to Ad.null infected 
cells. 
AICAR caused a 22.4 +/- 9.2 % and 41 +/- 26.8 % inhibition of insulin-stimulated glucose 
transport in Ad.null and Ad.α1DN infected cells, respectively. In addition, this current 
work also found that both insulin-stimulated and basal glucose transport were exacerbated 
in Ad.α1DN infected cells, compared to Ad.null infected cells (Figure 4.4B). In Ad.null 
infected cells the fold increase in glucose transport upon insulin-stimulation was 8 +/- 0.62 
and 4.38 +/- 0.8 in non-AICAR treated cells and AICAR treated cells respectively. 
However, in Ad.α1DN infected cells the fold increase in glucose transport upon insulin-
stimulation was 4.54 +/- 1.42 and 2.27 +/- 0.8 in non-AICAR treated cells and AICAR 
treated cells respectively. This implies that suppression of AMPK increases basal glucose 
transport, while reducing the extent by which insulin activates glucose transport. 
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Figure  4-2: Effect of various AMPK activators on basal and insulin-stimulated glucose 
transport.  
3T3-L1 adipocytes were pre-incubated for 30 min in the presence of 2 mM AICAR, 0.6 M sorbitol, 
100 µM rosiglitazone, 1 µM isoproterenol, 5 µM A23187or 300 µM A-769662 prior to stimulation 
with 10 nΜ insulin for 15 min. Glucose transport was initiated by the addition of 2-[3H]-deoxy-D-
glucose, and terminated after 3 min. Data shown represents the mean % insulin-stimulated +/- 
S.E.M of three independent experiments, *p < 0.05 (2-tail t-test), compared to insulin-stimulated, •p 
< 0.05 (2-tail t-test), compared to control. Insulin-stimulated glucose transport was 644 +/- 34 
(mean +/- SEM) pmol glucose transported / min / mg protein. 
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Figure  4-3: Effect of Compound C on AICAR mediated inhibition of insulin-stimulated 
glucose transport.  
3T3-L1 adipocytes were pre-incubated for 30 min in the presence of 60 µM Compound C, prior to 
the addition of 2 mM AICAR for 30 min. The cells were then stimulated with 10 nΜ insulin for 15 
min. (A) Glucose transport was initiated by the addition of 2-[3H]-deoxy-D-glucose, and terminated 
after 3 min. Data shown represents the mean % insulin-stimulated +/- S.E.M of three independent 
experiments, *p < 0.05 (one-way ANOVA). Insulin-stimulated glucose transport was 940 +/- 378 
(mean +/- SEM) pmol glucose transported / min / mg protein. 3T3-L1 lysates (10 µg) were resolved 
on 10% polyacrylamide gels, transferred to nitrocellulose and probed with anti-ACC Ser79 and anti-
GAPDH antibodies. (B) Representative blots from three independent experiments. (C) 
Quantification of ACC Ser79 phosphorylation was determined by comparison with total GAPDH 
using densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments, *p < 0.05 (one-way ANOVA). The position of the molecular weight 
markers are shown to the left of the gel.  
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Figure  4-4: Effect of overexpression of a dominant negative AMPK mutant on AICAR 
mediated inhibition of insulin stimulated glucose transport in 3T3-L1 adipocytes 
(A) 3T3-L1 adipocytes were infected (600 ifu/cell) for 48 hr with Ad.α1DN or Ad.null prior to 
stimulation for 30 min with 2 mM AICAR. Cell lysates (25 µg) were resolved by SDS-PAGE, 
transferred to nitrocellulose and probed with anti-ACC Ser79, anti-AMPKα1, anti-c-myc and anti-
GAPDH antibodies. The position of the molecular weight markers are shown to the left of the gel. 
(B) 3T3-L1 adipocytes cultured on 12 well plates were infected (600 ifu/cell) with Ad.α1DN or 
Ad.null. After 48 hr 3T3-L1 adipocytes were pre-incubated  for 30 min in the presence of  2 mM 
AICAR prior to stimulation with 10 nΜ insulin for 15 min. Glucose transport was initiated by the 
addition of 2-[3H]-deoxy-D-glucose, and terminated after 3 min. Data shown represents the mean 
% insulin-stimulated +/- S.E.M of three independent experiments. Insulin-stimulated glucose 
transport in Ad.null cells was 540 +/- 126 (mean +/- SEM) pmol glucose transported / min / mg 
protein. A = AICAR, I = insulin. 
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4.2.3 Investigating the mechanism of AICAR mediated inhibition 
of insulin-stimulated glucose uptake in 3T3-L1 adipocytes. 
4.2.3.1 Specificity of anti-AS160 and anti-TBC1D1 antibodies 
AS160 and TBC1D1 are highly related Rab GAPs. To investigate the specificity of the 
anti-AS160 and anti-TBC1D1 antibodies, AS160 and TBC1D1 were immunprecipitated 
from 3T3-L1 lysates using anti-TBC1D1 and anti-AS160 antibodies. The 
immunoprecipitates and respective supernatants were analysed by western blotting using 
anti-TBC1D1 and anti-AS160 antibodies. As shown in figure 4.5A TBC1D1 is detected in 
the TBC1D1 immunoprecipitate and the supernatants from both TBC1D1 and AS160 
immunoprecipitates. However, it would appear that the anti-AS160 antibody does not 
immunoprecipitate TBC1D1 since TBC1D1 is not detected in the AS160 
immunoprecipitate. Conversely, as shown in figure 4.5B, AS160 is detected only in the 
AS160 immunoprecipitate, suggesting that the anti-TBC1D1 antibody does not 
immunoprecipitate AS160.  
4.2.3.2 Effect of AICAR on basal and insulin-stimulated AS160 
phosphorylation at PAS sites and association of 14-3-3 proteins. 
In order to determine the effect of AICAR on basal and insulin-stimulated AS160 
phosphorylation at PAS sites and association of 14-3-3 proteins with phosphorylated 
AS160, AS160 was immunoprecipitated from 3T3-L1 lysates treated in the presence and 
absence of AICAR, prior to stimulation with insulin. Immunoprecipitates were then 
subjected to western blotting with anti-PAS and anti-14-3-3 antibodies. 
As shown in figure 4.6, AICAR did not significantly alter basal or insulin stimulated 
phosphorylation of AS160 at PAS sites. Interestingly, the amount of proteins that co-
immunoprecipited with AS160 with apparent molecular masses matching those of the 14-
3-3 proteins, did not differ between basal and insulin-stimulated conditions. 
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Figure  4-5: Specificity of anti-AS160 and anti-TBC1D1 antibodies. 
(A) AS160 and TBC1D1 were immunoprecipitated from 3T3-L1 adipocyte lysates (200 µg) using 
anti-TBC1D1 and anti-AS160 antibodies. Immunoprecipitates and respective supernatants were 
then resolved on 10% SDS-PAGE, transferred to nitrocellulose and probed with (A) anti-TBC1D1 
antibody, (B) anti-AS160 antibody.  Representative blots from two independent experiments. The 
position of the molecular weight markers are shown to the left of the gel. IP = immunoprecipitate, 
sup = supernatant. 
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Figure  4-6: Effect of AICAR on basal and insulin-stimulated AS160 phosphorylation at PAS 
sites and association with 14-3-3 proteins. 
AS160 was immunoprecipitated from 3T3-L1 lysates (250 µg) obtained from cells treated in the 
presence and absence of 2 mM AICAR for 30 min, prior to stimulation with 10 nM insulin for 30 
min. Immunoprecipitates were resolved on 10% SDS-PAGE, transferred to nitrocellulose and 
probed with anti-PAS and anti-14-3-3 antibodies. (A) Quantative analysis of AS160 phosphorylation 
at PAS sites. Data shown represents the mean % insulin-stimulated +/- S.E.M of three independent 
experiments with duplicates in each. (B) Representative western blot, from three independent 
experiments with duplicates. C = control, A = AICAR, I = insulin. The position of the molecular 
weight markers are shown to the left of the gel.  
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4.2.3.3 Effect of AICAR on basal and insulin-stimulated TBC1D1 
phosphorylation at PAS sites. 
In order to determine the effect of AICAR on basal and insulin-stimulated TBC1D1 
phosphorylation at PAS sites, TBC1D1 was immunoprecipitated from 3T3-L1 lysates 
treated in the presence and absence AICAR, prior to stimulation with insulin. 
Immunoprecipitates were then subjected to western blotting with anti-PAS antibody. 
As shown below in figure 4.7, there was no detectable levels of PAS phosphorylated 
TBC1D1 in control or AICAR treated 3T3-L1 adipocytes. In addition, AICAR did not 
significantly alter insulin-stimulated TBC1D1 phosphorylation at PAS sites. 
4.2.3.4 Effect of AICAR on PKB substrate phosphorylation  
To determine whether AICAR alters the phosphorylation of any insulin-stimulated PKB 
substrate proteins, lysates from 3T3-L1 adipocytes pre-incubated for 30 min in the 
presence of 2 mM AICAR, prior to stimulation with 10 nΜ insulin for 15 min, were 
resolved by SDS-PAGE and western blotted with the anti-PAS antibody. As shown in 
figure 4.8, AICAR does not appear to perturb insulin-stimulated phosphorylation of any 
proteins. However, AICAR does appear to increase PAS phosphorylation, compared to 
basal levels, of two proteins * with molecular masses of about 40kDa and 48kDa. 
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Figure  4-7: Effect of AICAR on basal and insulin-stimulated TBC1D1 phosphorylation at PAS 
sites. 
TBC1D1 was immunoprecipitated from 3T3-L1 lysates (200 µg) obtained from cells treated in the 
presence and absence of 2 mM AICAR for 30 min, prior to stimulation with 10 nM insulin for 30 
min. Immunoprecipitates were resolved on 10% SDS-PAGE, transferred to nitrocellulose and 
probed with anti-PAS and anti-TBC1D1 antibodies. (A) Quantification of TBC1D1 phosphorylation 
was determined by comparison with total TBC1D1 using densitometric analysis. Data shown 
represents the mean % insulin-stimulated +/- S.E.M of two independent experiments. (B) 
Representative western blot, from two independent experiments. C = control, A = AICAR, I = 
insulin. The position of the molecular weight markers are shown to the left of the gel.  
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Figure  4-8: Effect of AICAR on PKB substrate phosphorylation.  
3T3-L1 adipocytes were pre-incubated for 30 min in the presence of 2 mM AICAR, prior to 
stimulation with 10 nΜ insulin for 15 min. Lysates (25 µg) were then resolved on 10% SDS-PAGE 
gels, transferred to nitrocellulose and probed with the anti-PAS antibody. Representative blot from 
four independent experiments with duplicates. C = control, A = AICAR, I = insulin. The position of 
the molecular weight markers are shown to the left of the gel. * = AICAR increases basal PAS 
phosphorylation of the indicated proteins. 
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4.3 Discussion 
The key findings of this chapter are that multiple AMPK stimuli inhibited insulin-
stimulated glucose transport, that in the presence of the AMPK inhibitor Compound C the 
inhibitory effect of AICAR on insulin-stimulated glucose transport was no longer apparent, 
and that inhibition of insulin-stimulated glucose transport by AICAR was not associated 
with altered PKB-mediated phosphorylation of AS160/TBC1D1. 
AMPK and glucose transport 
AICAR 
In muscle cells, AICAR stimulates basal glucose transport and potentiates insulin-
stimulated glucose transport (Bergeron et al 1999). In contrast this study showed that 
AICAR significantly (p < 0.05) inhibits insulin-stimulated glucose uptake in 3T3-L1 
adipocytes, which supports previous work by Salt and co-workers (Salt et al 2000). 
AICAR has also been shown to inhibit insulin-stimulated glucose transport in isolated rat 
adipocytes (Gaidhu et al 2006), and rat cardiomyocytes (Segalen et al 2008). Salt and co-
workers also reported that AICAR inhibited insulin-stimulated GLUT4 translocation to the 
plasma membrane in 3T3-L1 adipocytes by assay of plasma membrane lawns (Salt et al 
2000). In contrast, Chavez and co-workers measured the amount of GLUT4 at the cell 
surface by the quantitative single-cell fluorescence assay that employs the reporter 
construct of GLUT4 with a haemagglutinin (HA) tag in the amino-terminal extracellular 
loop and green fluorescent protein (GFP) fused to the carboxyl terminus (HA-GLUT4-
GFP), and reported that AICAR did not alter insulin-stimulated GLUT4 translocation to 
the plasma membrane (Chavez et al 2008). Potentially the tagged GLUT4 construct may 
behave differently to endogenous GLUT4 in the 3T3-L1 adipocytes, which could explain 
the contrasting results. For example AICAR may increase the rate at which endogenous 
GLUT4 is trafficked from the plasma membrane into intracellular storage vesicles, which 
would deplete the amount of GLUT4 at the plasma membrane, whereas potentially the 
tagged GLUT4 maybe retained at the plasma membrane. 
Sorbitol 
This study found that sorbitol caused a significant (p < 0.05) 5 fold increase in basal 
glucose transport and significantly (p < 0.05) inhibited insulin-stimulated glucose uptake. 
Previous studies have also shown that sorbitol stimulates basal glucose transport in rat 
adipocytes, L6 myotubes and 3T3-L1 adipocytes (Sajan et al 2002, Chen et al 1997, Chen 
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et al 1999). In 3T3-L1 adipocytes, signalling pathways downstream of Grb2-associated 
binding protein 1 (Gab1), and specifically the Gab1 / CT10 sarcoma oncogene cellular 
homolog II (CrkII) / GTP binding protein TC10 (TC10) signalling pathway, are thought to 
play a crucial role in osmotic-stress induced glucose transport (Janez et al 2000, Gual et al 
2002). It has also been reported that hyperosmotic stress activates the proline-rich tyrosine 
kinase 2 (PYK2) / extracellular signal-regulated kinase (ERK) / phospholipase D (PLD) / 
aPKC pathway in 3T3-L1 adipocytes and rat adipocytes, leading to GLUT4 translocation 
and glucose uptake (Sajan et al 2002). 
In muscle overexpression of a dominant-negative form of AMPK blocked the stimulation 
of GLUT4 translocation by hyperosmotic stress (Fryer et al 2002a), suggesting a role for 
AMPK activation in hyperosmotic-induced glucose uptake. In skeletal muscle, 
hyperosmotic stress was shown to stimulate AMPK activity and increase insulin-stimulated 
glucose transport (Smith et al 2005). In addition, the increase in insulin-stimulated glucose 
transport caused by hyperosmotic stress was prevented by inclusion of the AMPK inhibitor 
Compound C, suggesting that AMPK activation may mediate the synergistic effect of 
hyperosmotic stress on insulin-stimulated glucose transport (Smith et al 2005). This is in 
stark contrast to the findings of this study and a previous study in 3T3-L1 adipocytes 
(Chen et al 1999), which found that hyperosmotic stress induced by sorbitol inhibited 
insulin-stimulated glucose transport in 3T3-L1 adipocytes. Similarly, in rat epididymal 
adipose cells, hyperosmotic stress was shown to markedly reduce insulin-induced glucose 
transport (Komjati et al 1998). The proposed modes of action of hyperosmotic stress 
induced inhibition of insulin-stimulated glucose transport in 3T3-L1 adipocytes include; 
inactivation of PKB (Chen et al 1999) serine phosphorylation of IRS1 (Gual et al 2003) 
and enhanced degradation of IRS proteins (Gual et al 2003). 
Rosiglitazone 
This study showed that acute treatment of 3T3-L1 adipocytes with the anti-diabetic drug, 
rosiglitazone, significantly (p < 0.05) inhibited insulin-stimulated glucose transport. It 
should be noted that using concentrations of 100µM rosiglitazone in this study was merely 
a tool to stimulate activation of AMPK, and that this acute inhibition of insulin-stimulated 
glucose transport with 100µM rosiglitazone has no clinical significance as the maximum 
concentration of rosiglitazone reached in patients is approximately 1µM. Indeed previous 
work, showed that chronic (48hr) treatment of 3T3-L1 adipocytes with increasing 
concentrations (1nМ-10µM) of rosiglitazone resulted in progressive increases in both basal 
and insulin-stimulated 2-deoxyglucose uptake (Standaert et al 2002). Interestingly, a recent 
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study showed that long-term TZD treatment enhanced AMPK-stimulated glucose uptake 
into muscle and adipose tissue in insulin-resistant states in rats (Ye et al 2006).  
Isoproterenol 
This current study showed that isoproterenol significantly (p < 0.05) inhibited insulin-
stimulated glucose transport. Previously, isoproterenol was shown to induced a two fold 
increase in glucose transport (Smith et al 1984) and inhibit insulin-stimulated glucose 
uptake in rat adipose cells (Smith et al 1984, Joost et al 1986, Kirsch et al 1983, Kashiwagi 
et al 1983, Yang et al 2002).  
A23187 
It has been reported that calcium is involved in insulin signalling in muscle (Clausen et al 
1974) and adipose (Clausen et al 1974, Draznin et al 1987, Yang et al 2000). Calcium is  
thought to be involved in at least two different steps of the insulin-dependent recruitment 
of GLUT4 to the plasma membrane. One involves the translocation step. The second 
involves the fusion of GLUT4 vesicles with the plasma membrane (Whitehead et al 2001). 
In this study the calcium ionophore A23187 displayed a modest tendency to inhibit insulin-
stimulated glucose transport, however this was not statistically significant. Previous work 
by Draznin and co-workers also showed that another calcium ionophore, ionomycin, 
inhibited insulin-stimulated glucose transport in isolated rat adipocytes (Draznin et al 
1987). Draznin and co-workers proposed that high and/or sustained levels of intracellular 
calcium may function as a postreceptor feedback sensor to diminish cellular 
responsiveness to insulin (Draznin et al 1987). Potentially elevated intracellular calcium 
levels by the two ionophores may activate AMPK via CaMKK, which in turn may mediate 
inhibition of insulin-stimulated glucose transport. 
A769662 
Interestingly, this current study also found that the novel, direct AMPK activator, 
A769662, significantly (p < 0.05) inhibited insulin-stimulated glucose transport. Given that 
A769662 is a direct AMPK activator, these results provide the best evidence so far that 
activation of AMPK inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. 
As AICAR, sorbitol, rosiglitazone, isoproterenol and the direct AMPK activator, A769662, 
have all been shown to stimulate AMPK activity (Figs. 3.11-3.21), and inhibit insulin-
stimulated glucose transport in 3T3-L1 adipocytes (Fig. 4.1), it is possible that activation 
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of AMPK inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. In addition, 
there did appear to be a correlation between the % inhibition of insulin-stimulated glucose 
transport and fold increase in AMPK activity in 3T3-L1 adipocytes (Fig. 4.9) i.e 
rosiglitazone displayed a large % inhibition of insulin-stimulated glucose transport and 
stimulated a large fold increase in AMPK activity, isoproterenol and AICAR displayed a 
lower % inhibition of insulin-stimulated glucose transport and stimulated a lower fold 
increase in AMPK activity compared to rosiglitazone, and A23187 displayed the lowest % 
inhibition of insulin-stimulated glucose transport and stimulated the lowest fold increase in 
AMPK activity. The exceptions were the direct AMPK activator A769662, which 
displayed the second greatest % inhibition of insulin-stimulated glucose uptake, despite 
only modestly stimulating AMPK activity, and sorbitol which displayed the third highest 
% inhibition of insulin-stimulated glucose transport, despite stimulating the greatest fold 
increase in AMPK activity. The direct AMPK activator, A769662, has been reported to 
activate only β1 containing AMPK complexes (Scott et al 2008), which is likely to account 
for the modest increase in AMPK activity observed in cells incubated with A769662. Since 
sorbitol, is not a direct AMPK activator it is possible that through non-AMPK mediated 
pathways sorbitol is having additional effects on insulin-stimulated glucose transport.  
 
Figure  4-9: Fold increase in AMPK activity versus % inhibition of insulin-stimulated glucose 
transport. 
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It should also be noted that the most potent AMPK activator, sorbitol, displayed a highly 
significant (p < 0.05) five fold increase in basal glucose transport, whereas all the other 
stimuli did not significantly alter basal glucose transport. This suggests that the 
exceptionally high increase in basal glucose transport by sorbitol may be mediated by both 
AMPK-dependent and -independent mechanisms. 
Interestingly in isolated hepatocytes and heart, insulin has been shown to inhibit AMPK 
activity (Witters and Kemp 1992, Gamble and 1997). However, in the liver cell line H4IIE 
insulin was found to have no effect on AMPK activity (Lochhead et al 2000). In this 
current work insulin did not significantly alter AMPK activity as assessed by ACC Ser79 
phosphorylation (Fig. 4.3). In addition, previous work in our lab showed that insulin did 
not alter AMPK activity, as assessed by AMPK assays, in 3T3-L1 adipocytes (personal 
correspondence with Dr. I.P Salt). 
In order to investigate whether the effect of AICAR on insulin-stimulated glucose transport 
is mediated by AMPK activation, the effect of AICAR on insulin-stimulated glucose 
transport was assessed in the presence of the AMPK inhibitor Compound C (Fig. 4.3). This 
study found that in the presence of Compound C, AICAR did not inhibit insulin-stimulated 
glucose transport. This suggests that AMPK activation in 3T3-L1 adipocytes inhibits 
insulin-stimulated glucose transport. However, it is difficult to conclude whether 
Compound C is rescuing the inhibition of insulin-stimulated glucose transport by AICAR, 
given the fact that Compound C itself significantly inhibits insulin-stimulated glucose 
transport. 
In general the results obtained using Compound C should be interpreted with caution as 
Compound C is not a specific AMPK inhibitor. It has been shown to also inhibit a number 
of other protein kinases in vitro including; ERK 8, MAP kinase-interacting kinase 1 
(MNK1), phosphorylase kinase (PHK), maternal embryonic leucine zipper kinase 
(MELK), dual specificity tyrosine phosphorylation and regulated kinase (DYRK) isoforms, 
homeodomain-interacting protein kinase2 (HIPK2), sarcoma kinase (Src) and lymphocyte 
cell-specific protein-tyrosine kinase (Lck) (Bain et al 2007). Bain and co-workers also 
found that the CaMKK inhibitor STO-609 was a more potent AMPK inhibitor than 
Compound C in vitro (Bain et al 2007). In the previous chapter, 25 µМ STO-609 was used 
to inhibit CaMKK in 3T3-L1 adipocytes. However, 25 µМ STO-609 did not appear to 
inhibit AMPK since AICAR stimulated AMPK activity was not perturbed in the presence 
of STO-609. Potentially a higher concentration of STO-609 could be used to inhibit 
Pamela Jane Logan, 2009   Chapter 4, 162 
AMPK and assess the role of AMPK in AICAR mediated inhibition of insulin-stimulated 
glucose transport.  
Interestingly, Fryer and co-workers, showed that Compound C can inhibit the adenosine 
transporter, which is the main transport system used by cells in the uptake of AICAR 
(Fryer et al 2002c). Thus, the reduction in AICAR stimulated ACC Ser79 phosphorylation 
in the presence of Compound C could have resulted from the inhibition of AMPK 
activation by AICAR and/or inhibition of AICAR uptake into the cell.  
Adenoviral DN AMPK was also used to investigate whether the effect of AICAR on 
insulin-stimulated glucose transport is mediated by AMPK activation (Fig. 4.4). Although 
inhibition of insulin-stimulated glucose transport by AICAR did not reach statistical 
significance in Ad.null and Ad.α1DN infected cells, the results do suggest that the effect of 
AICAR on insulin-stimulated glucose transport is not dependent on AMPK activation. This 
is in contrast to results obtained using the AMPK inhibitor Compound C. However, 
perhaps in this current study Compound C inhibited a greater proportion of total AMPK in 
3T3-L1 adipocytes compared to Ad.α1DN, which could explain the discrepancy between 
the results. In addition, this study found that both basal and insulin-stimulated glucose 
transport were exacerbated in Ad.α1DN infected cells, compared to Ad.null infected cells. 
However, the fold increase in glucose transport upon insulin-stimulation was reduced in 
Ad.α1DN infected cells compared to Ad.null infected cells. These results suggest that long 
term suppression of AMPK improves glucose transport while reducing the extent by which 
insulin increases glucose transport. The increase in glucose transport may be due to the 
inhibition of endogenous AMPK activity, which if the case, supports the possibility that 
AMPK activation may inhibit insulin-stimulated glucose transport. In addition, long-term 
treatment of adipocytes with Ad.α1DN maybe increasing glucose transport by altering the 
expression level of key insulin-signalling molecules such as SNARES, AS160 and PKB. 
Previous work in muscle showed that prolonged AMPK activation increased expression 
levels of GLUT4 (Holmes et al 1999). However, currently the effect of prolonged AMPK 
activation on GLUT4 expression in adipocytes has yet to be determined. 
Interestingly, Sakoda and co-workers found that overexpression of α1DN abolishes AMPK 
activation, without affecting the increase in basal glucose uptake by AICAR, thereby 
suggesting that AICAR-induced glucose uptake in 3T3-L1 adipocytes is independent of 
AMPK activation (Sakoda et al 2002). However, in this current study AICAR did not 
significantly increase basal glucose transport in Ad.null infected cells. 
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Since the inhibition of insulin-stimulated glucose transport by AICAR is rescued in cells 
incubated in Compound C, but not in Ad.α1DN, further work is required to determine 
whether AMPK activation inhibits insulin-stimulated glucose transport. This might involve 
investigating the effect of Compound C and Ad.α1DN on the inhibition of insulin-
stimulated glucose transport by other AMPK stimuli. In particular, sorbitol and 
rosiglitazone which both displayed a large % inhibition of insulin-stimulated glucose 
transport, and the novel AMPK activator A769662 which differs from the other AMPK 
stimuli including AICAR, in that it directly activates AMPK. 
Mechanism of AICAR mediated inhibition of insulin-stimulated glucose transport 
The mechanism by which AICAR inhibits insulin-stimulated glucose transport in 3T3-L1 
adipocytes was explored. This study (Fig. 4.6) found that in 3T3-L1 adipocytes AICAR 
does not appear to alter AS160 phosphorylation at PAS sites compared to basal levels, 
which is in contrast to observed effects in skeletal muscle where AICAR has been shown 
to increase AS160 phosphorylation at PAS sites (Bruss et al 2005). Figure 4.6 also shows 
that concomitant incubation of AICAR with insulin does not alter insulin-stimulated 
AS160 phosphorylation at PAS sites, thus it is unlikely that AMPK inhibits insulin-
stimulated glucose transport by inhibiting insulin-stimulated AS160 phosphorylation.  
In addition, this study found that the anti-AS160 antibody did not appear to 
immunoprecipitate TBC1D1, which has an apparent molecular weight of 130kDa (Fig. 
4.5). Thus the intense dark band present at approximately 140kDa in the AS160 IP’s (Fig. 
4.6) detected with the PAS antibody is most likely to be a short splice variant of AS160 or 
another PKB substrate molecule which co-immunoprecipitates with AS160, and not 
TBC1D1. 
Ramm and co-workers previously showed that in 3T3-L1 adipocytes, insulin-stimulated a  
4 fold increase in the amount of 14-3-3 associated with AS160 (Ramm et al 2006).  This 
current study also looked at whether AICAR altered insulin-stimulated AS160 binding to 
14-3-3 proteins. The several protein bands detected by the anti-14-3-3 antibody with 
apparent molecular masses matching those of the 14-3-3 proteins were thought to 
correspond to the various 14-3-3 protein isoforms (Fig. 4.6). However, the intense band, 
recognised by the anti-14-3-3 antibody, which resolves at about approximately 27kDa is 
most likely to correspond to the AS160 antibody light chain (Fig 4.6). The identity of the 
14-3-3 proteins and antibody light chain could be confirmed by comparison with a 
negative control i.e antibody and protein G beads, which is lacking in this experiment. In 
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contrast to the work by Ramm and co-workers, in this current study the amount of proteins 
that co-immunoprecipitated with AS160 with apparent molecular masses matching that of 
the 14-3-3 proteins, did not differ between basal and insulin-stimulated conditions. Chen 
and co-workers, used cross linking to stabilize the insulin-stimulated 14-3-3 interactions 
with TBC1D1 (Chen et al 2008), thus perhaps the interaction between 14-3-3 proteins and 
AS160 in this study were lost during the immunoprecipitation process.  
TBC1D1 was shown to be phosphorylated at PAS sites in mouse skeletal muscle in vivo by 
insulin, AICAR and contraction (Taylor et al 2008). Although, insulin was shown to 
stimulate TBC1D1 phosphorylation at PAS sites, this current study could not detect any 
TBC1D1 phosphorylation at PAS sites in AICAR treated 3T3-L1 cells (Fig. 4.7). The 
current study also found that AICAR did not alter insulin-stimulated PAS phosphorylation 
of TBC1D1 (Fig. 4.7). Interestingly, anti-TBC1D1 appears to immunoprecipitate a protein 
with a molecular weight of about 160kDa, which is PAS phosphorylated. A likely 
candidate was thought to be AS160. However, western blotting of TBC1D1 and AS160 
immunoprecipitates, with the anti-AS160 antibody, suggested that anti-TBC1D1 does not 
immunoprecipitate AS160. However, this experiment remains inconclusive, as unlike 
TBC1D1, AS160 was not detected in the immunoprecipitation supernatants, suggesting 
that the AS160 antibody is relatively weak. Thus potentially anti-TBC1D1 may 
immunoprecipitate small quantities of AS160 which are detected by the more sensitive 
anti-PAS antibody, but not by the anti-AS160 antibody. 
It should be noted that AMPK may be altering insulin-stimulated AS160/TBC1D1 
phosphorylation at PAS sites which are not primarily recognized by the anti-PAS antibody 
in 3T3-L1 adipocytes which may alter AS160/TBC1D1 activity. Indeed in HEK 293 cells 
the anti-PAS antibody was found to primarily detect phospho-Thr642 on AS160 (Geraghty 
et al 2007). Furthermore AMPK activation in 3T3-L1 adipocytes may result in 
phosphorylation of AS160/TBC1D1 at non-PAS sites, and such phosphorylations may 
have additional effects on AS160/TBC1D1 function and GLUT4 trafficking. 
Antibodies against specific phosphorylation sites on AS160 and TBC1D1 could be used in 
order to determine whether AICAR alters phosphorylation of these Rab GAP proteins at 
PAS sites not primarily detected by the anti-PAS antibody and/or stimulates 
phosphorylation at non-PAS sites. Site directed mutagenesis of any such sites could be 
used to investigate whether AICAR inhibits insulin-stimulated glucose transport, by 
altering phosphorylation of AS160 /TBC1D1 at a specific site.  
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Finally this study found that AICAR did not appear to perturb insulin-stimulated 
phosphorylation of any PKB target proteins. However, interestingly it appears that AICAR 
stimulates phosphorylation at PAS sites, compared to basal levels, of two proteins with 
molecular weights of approximately 37kDa and 50kDa. However, the identity of these 
bands remains unknown. Potentially, mass spectrometry could be used to identify the 
proteins. 
Interestingly, intracellular acidification shown to be induced by the AMPK stimuli AICAR 
and isoproterenol, has been proposed to mediate the inhibition of insulin-stimulated 
glucose transport by these reagents (Segalen et al 2008, Yang et al 2002, Civelek et al 
1996).  
Exposure of cells to insulin has been shown to cause an increase in intracellular pH in rat 
adipocytes (Civelek et al 1996), 3T3-L1 cells (Klip et al 1988), muscle (Fidelman et al 
1982, Klip et al 1986), and liver (Peak et al 1992). This alkalinization of cells by insulin is 
reported to be required for optimal glucose transport. 
Inhibition of insulin-induced glucose uptake by AICAR in rat cardiomyocytes is reported 
to occur via the inhibition of the Na+/H+ exchanger-1 (NHE-1), which subsequently 
decreases the insulin mediated increase in intracellular pH (Segalen et al 2008). In addition 
AICAR is thought to exert these effects independently of AMPK activation (Segalen et al 
2008). Although the Na+/H+ exchanger 1 is ubiquitously expressed (Fliegel 2005), it is 
possible that this is a cell type specific mechanism of inhibition by AICAR, and that the 
mechanism of inhibition of insulin-stimulated glucose transport by AICAR in 3T3-L1 
adipocytes is different. This may well be the case given that the effect of AICAR on basal 
glucose transport differs between the two cell types i.e AICAR inhibits basal glucose 
transport in rat cardiomyocytes, while modestly stimulating basal glucose transport in 3T3-
L1 adipocytes (Salt et al 2000).  
Civelek and co-workers have suggested that treatment of adipocytes with isoproterenol 
induces acidification in adipocytes due to the lipolytic release of free fatty acids (Civelek et 
al 1996). Thus it has been proposed that the inhibition of insulin-stimulated glucose 
transport by isoproterenol may occur through cytosol acidification, which essentially 
reverses the alkalinizing effects of insulin required for optimum glucose transport (Yang et 
al 2002). 
Pamela Jane Logan, 2009   Chapter 4, 166 
Overall this current work suggests that acute AMPK activation by AICAR in adipocytes 
inhibits insulin-stimulated glucose uptake, yet this is not associated with altered PKB-
mediated phosphorylation of AS160/TBC1D1. As discussed (1.1.2) glucose is taken up 
into adipocytes in the fed state and stored as TG. Therefore inhibition of glucose uptake 
into adipocytes would subsequently reduce fatty acid and TG synthesis. Thus, it could be 
reasoned that AMPK activation inhibits insulin-stimulated glucose uptake in adipocytes in 
order to reduce the ATP-dependent synthesis of fatty acids and TG in adipocytes. 
Furthermore, the inhibition of glucose transport would allow glucose to be used by other 
tissues as a source of energy, rather than adipocytes, which would start using the stored 
triglyceride. 
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Chapter 5 - Effect of sustained AMPK activation on 
adipocyte insulin action  
5.1 Introduction 
In chapter 4 it was reported that acute treatment of 3T3-L1 adipocytes with various AMPK 
stimuli inhibited insulin-stimulated glucose transport. Furthermore, in the presence of the 
AMPK inhibitor, Compound C, the inhibitory effect of AICAR on insulin-stimulated 
glucose transport was no longer apparent. However, AICAR still displayed a tendency to 
inhibit insulin-stimulated glucose transport in Ad.α1DN infected cells. In addition, 
sustained AMPK knockdown in Ad.α1-DN infected cells appeared to enhance both basal 
and insulin-stimulated glucose transport. Currently, the effect of sustained AMPK 
activation on insulin-stimulated glucose transport in adipocytes has still to be determined.  
As discussed in section 1.4.12, previous studies have reported that sustained AMPK 
activation by AICAR inhibits differentiation of 3T3-L1 preadipocytes (Habinowski and 
Witters 2001, Giri et al 2006, Tong et al 2008). In contrast other studies suggest that 
AMPK may not play a role in regulating adipocyte differentiation in vivo (Villena et al 
2004, Giri et al 2006). Huypens and co-workers showed that long term treatment with the 
AMPK activators metformin and AICAR reduced adiponectin protein expression and 
release in 3T3-L1 adipocytes (Huypens et al 2005). A recent study by Gaidhu and co-
workers showed that prolonged AICAR-induced AMPK activation promotes energy 
dissipation in white adipocytes by preventing TG storage and by activating pathways that 
promote energy dissipation within the adipocyte, such as fatty acid oxidation (Gaidhu et al 
2008). Interestingly, Gaidhu and co-workers also reported that lipolysis was first 
suppressed, but then increased both in vitro and in vivo with prolonged AICAR treatment 
in rat epididymal adipocytes (Gaidhu et al 2008). However, in general the effect of 
prolonged AMPK activation in mature adipocytes remains poorly characterized, 
particularly with respect to glucose transport and insulin signalling. 
5.1.1 Aims 
The principal aim of this study was, therefore, to investigate the effect of sustained AMPK 
activation on glucose transport and insulin signaling in 3T3-L1 adipocytes. In addition, the 
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effects of sustained AMPK activation on insulin signaling in human adipose tissue was 
investigated. 
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5.2 Results 
5.2.1 Effect of sustained AMPK activation on basal and insulin-
stimulated glucose transport in 3T3-L1 adipocytes.  
5.2.1.1 Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with AICAR 
on AMPK expression, ACC expression, AMPK Thr12 phosphorylation and 
ACC Ser79 phosphorylation 
As shown in figure 5.1 a significant (p < 0.05) 2.02 +/- 0.36 and 2.08 +/- 0.57 fold increase 
in AMPK Thr172 phosphorylation was obtained in 3T3-L1 adipocytes incubated with 
AICAR for 24 hr and 48 hr, respectively, in insulin-stimulated cells. These significant (p < 
0.05) increases in Thr172 phsophoryaltion were not associated with altered AMPK α1 
protein expression. In addition, a significant (p < 0.05) 3.1 +/- 0.69 and 2.84 +/- 0.73 fold 
increase in phosphorylation of the AMPK downstream target ACC at Ser79 was obtained 
in 3T3-L1 adipocytes incubated with AICAR for 24 hr and 48 hr respectively, in insulin-
stimulated cells. These significant increases were also not associated with altered ACC 
protein expression (Fig. 5.1). 
5.2.1.2 Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with 
metformin on AMPK expression, ACC expression, AMPK Thr12 
phosphorylation and ACC Ser79 phosphorylation 
As shown in figure 5.2, AMPK Thr172 phosphorylation, ACC Ser79 phosphorylation, 
AMPK protein expression and ACC protein expression were not significantly altered in 
non-insulin-stimulated and insulin-stimulated 3T3-L1 adipocytes incubated with 
metformin for 24 hr and 48 hr. 
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Figure  5-1: Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with AICAR on AMPK 
expression, ACC expression, AMPK Thr172 phosphorylation and ACC Ser79 
phosphorylation. 
3T3-L1 lysates (15 µg) obtained from cells incubated for 24 hr and 48 hr with 1mМ AICAR were 
resolved by 10% SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK α1, anti-
AMPK Thr172, anti-ACC Ser79, anti-ACC1 and anti-GAPDH antibodies. (A) Quantification of 
AMPK Thr172 phosphorylation and AMPK α1 expression were determined by comparison with 
GAPDH by densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of 
three independent experiments, *p < 0.05 (one-way ANOVA). (B) Quantification of ACC Ser79 
phosphorylation and ACC1 expression were determined by comparison with GAPDH by 
densitometric analysis. Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments, *p < 0.05 (one-way ANOVA). (C) Representative blots from three 
independent experiments. The position of the molecular weight markers are shown to the left of the 
gel.  A = AICAR, I = insulin. 
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Figure  5-2: Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with metformin on 
AMPK expression, ACC expression, AMPK Thr172 phosphorylation and ACC Ser79 
phosphorylation. 
3T3-L1 lysates (15 µg) obtained from cells incubated for 24 hr and 48 hr with 1mМ metformin were 
resolved by 10% SDS-PAGE, transferred to nitrocellulose, and probed with anti-AMPK α1, anti-
AMPK Thr172, anti-ACC Ser79, anti-ACC1 and anti-GAPDH antibodies. (A) Quantification of 
AMPK Thr172 phosphorylation and AMPK α1 expression. Data shown represents the mean % 
maximum +/- S.E.M of three independent experiments. (B) Quantification of ACC Ser79 
phosphorylation and ACC1 expression were determined by comparison with GAPDH by 
densitometric analysis.  Data shown represents the mean % maximum +/- S.E.M of three 
independent experiments. (C) Representative blots from three independent experiments. The 
position of the molecular weight markers are shown to the left of the gel.  M = metformin, I = insulin 
 
. 
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5.2.1.3 Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with AICAR 
on insulin-stimulated glucose transport 
The effect of sustained incubation of 3T3-L1 adipocytes with AICAR, on basal and 
insulin-stimulated glucose transport was investigated. As shown in figure 5.3 a significant 
(p < 0.05) 73 +/- 11.3 % and 67 +/- 27 % inhibition of insulin-stimulated glucose transport 
was observed in cells incubated with AICAR for 24 hr and 48 hr respectively. However, 24 
hr and 48 hr treatment of 3T3-L1 adipocytes with AICAR did not significantly alter basal 
glucose transport. 
5.2.1.4 Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with 
metformin on insulin-stimulated glucose transport 
As shown in figure 5.4, basal and insulin-stimulated glucose transport were not 
significantly altered in 3T3-L1 adipocytes incubated with metformin for 24 hr and 48 hr.  
5.2.1.5 Effect of overexpression of a constitutively active AMPK mutant on 
basal and insulin-stimulated glucose transport in 3T3-L1 adipocytes. 
Adenovirus-mediated gene transfer was used to overexpress a constitutively active (CA) 
AMPK mutant (α1312) in 3T3-L1 adipocytes in order to investigate the effects of sustained 
AMPK activation on basal and insulin-stimulated glucose transport.  
The α1312 mutant protein is based on the first 312 amino acid residues of the AMPK α1 
subunit and contains an N-terminal myc tag. Therefore the expression of the α1312 mutant 
in 3T3-L1 adipocytes was confirmed by the presence of a band detected by the myc 
antibody at about 35kDa (Fig. 5.5A). As expected the AMPK activator sorbitol increased 
ACC Ser79 phosphorylation in control infected cells (Ad.null). In addition, basal ACC 
Ser79 phosphorylation was increased in Ad.α1312 infected cells, compared to Ad.null 
infected cells.  
Interestingly, in Ad.α1312 infected cells there appears to be a reduction in insulin-
stimulated glucose transport compared to Ad.null infected cells (Fig. 5.5B).  
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Figure  5-3: Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with AICAR on basal 
and insulin-stimulated glucose transport. 
3T3-L1 adipocytes were incubated for 24 hr and 48 hr in the presence of 1 mM AICAR prior to 
stimulation with 10 nΜ insulin for 15 min. Glucose transport was initiated by the addition of 2-[3H]-
deoxy-D-glucose, and terminated after 3 min. Data shown represents the mean % insulin-
stimulated +/- S.E.M of three independent experiments, *p < 0.05 (2-tail), compared to insulin-
stimulated. Insulin-stimulated glucose transport was 3366 +/- 3173 (S.E.M) pmol transported / min / 
mg protein.  
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Figure  5-4: Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with metformin on 
basal and insulin-stimulated glucose transport. 
3T3-L1 adipocytes were incubated for 24 hr and 48 hr in the presence of 1 mM metformin prior to 
stimulation with 10 nΜ insulin for 15 min. Glucose transport was initiated by the addition of 2-[3H]-
deoxy-D-glucose, and terminated after 3 min. Data shown represents the mean % insulin-
stimulated +/- S.E.M of three independent experiments. Insulin-stimulated glucose transport was 
519 +/- 357 (S.E.M) pmol transported / min / mg protein. This work was performed by Dr.I.Salt 
(FBLS, University of Glasgow). 
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Figure  5-5: Effect of overexpression of a constitutively active AMPK mutant on basal and 
insulin stimulated glucose transport in 3T3-L1 adipocytes. 
(A) 3T3-L1 adipocytes were infected (600 ifu/cell) for 48 hr with Ad. α1312 or Ad.null prior to 
stimulation for 30 min with 0.6M sorbitol. Cell lysates (25 µg) were resolved by SDS-PAGE, 
transferred to nitrocellulose and probed with anti-ACC Ser79, anti-AMPKα1, anti-c-myc and anti-
GAPDH antibodies. The position of the molecular weight markers are shown to the left of the gel. 
(B) 3T3-L1 adipocytes cultured on 12 well plates were infected (600 ifu/cell) with Ad. α1312 or 
Ad.null. After 48 hr 3T3-L1 adipocytes were incubated for 30 min in the presence of  2 mM AICAR 
prior to stimulation with 10 nΜ insulin for 15 min. Glucose transport was initiated by the addition of 
2-[3H]-deoxy-D-glucose, and terminated after 3 min. Data compiled from one experiment. A = 
AICAR, I = insulin. 
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5.2.1.6 Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with AICAR 
on PKB expression and insulin-stimulated PKB phosphorylation 
Stimulation of 3T3-L1 adipocytes with insulin caused a significant (p < 0.05) 13.38 +/- 
3.16, 12.46 +/- 2.73 and 13.8 +/- 2.59 fold increase in PKB Ser473 phosphorylation under 
control conditions and incubation of adipocytes with AICAR for 24 hr and 48 hr 
respectively (Fig. 5.6). Insulin-stimulated PKB Ser473 phosphorylation was not altered in 
3T3-L1 adipocytes incubated in AICAR for 24 hr and 48 hr. In addition, in non-insulin-
stimulated cells and insulin-stimulated cells PKB protein expression was not significantly 
altered in 3T3-L1 adipocytes incubated with AICAR for 24 hr or 48 hr.  
5.2.1.7 Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with 
metformin on PKB expression and insulin-stimulated PKB phosphorylation 
Stimulation of 3T3-L1 adipocytes with insulin caused a significant (p < 0.05) 6.35 +/- 
1.07, 6.28 +/- 0.64 and 5.64 +/- 1.06 fold increase in PKB Ser473 phosphorylation under 
control conditions and pre-treatment of adipocytes with metformin for 24 hr and 48 hr 
respectively (Fig. 5.7). Insulin-stimulated PKB Ser473 phosphorylation was not altered in 
3T3-L1 adipocytes incubated in metformin for 24 hr and 48 hr. In addition, in non-insulin-
stimulated cells and insulin-stimulated cells PKB protein expression was not significantly 
altered in 3T3-L1 adipocytes incubated with metformin for 24 hr or 48 hr.  
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Figure  5-6: Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with AICAR on PKB 
expression and insulin-stimulated PKB phosphorylation. 
3T3-L1 lysates (15 µg) obtained from cells incubated for 24 hr and 48 hr with 1mМ AICAR prior to 
stimulation for 15 min with 10nМ insulin were resolved by 10% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-PKB, anti-PKB Ser473 and anti-GAPDH antibodies.  (A) 
Quantification of PKB expression was determined by comparison with GAPDH, and quantification 
of PKB phosphorylation was determined by comparison with PKB by densitometric analysis. Data 
shown represents the mean % maximum +/- S.E.M of three independent experiments, *p < 0.05 
(one-way ANOVA) compared to non-insulin stimulated cells. (B) Representative blots from three 
independent experiments. The position of the molecular weight markers are shown to the left of the 
gel. A = AICAR, I = insulin. 
Pamela Jane Logan, 2009   Chapter 5, 178 
 
Figure  5-7: Effect of 24 hr and 48 hr incubation of 3T3-L1 adipocytes with metformin on PKB 
expression and insulin-stimulated PKB phosphorylation. 
3T3-L1 lysates (15 µg) obtained from cells incubated for 24 hr and 48 hr with 1mМ metformin prior 
to stimulation for 15 min with 10nМ insulin were resolved by 10% SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-PKB, anti-PKB Ser473 and anti-GAPDH antibodies.  (A) 
Quantification of PKB expression was determined by comparison with GAPDH, and quantification 
of PKB phosphorylation was determined by comparison with PKB by densitometric analysis. Data 
shown represents the mean % maximum +/- S.E.M of three independent experiments, *p < 0.05 
(one-way ANOVA) compared to non-insulin-stimulated cells. (B) Representative blots from three 
independent experiments. The position of the molecular weight markers are shown to the left of the 
gel. M = metformin, I = insulin. 
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5.2.2 Effect of chronic AMPK activation in human adipose tissue 
5.2.2.1 Effect of prolonged treatment of type 2 diabetic subjects with 
metformin on AMPK activity in human adipose tissue. 
In a separate study undertaken by others in the laboratory, the effect of metformin on 
adipose tissue AMPK activity was assessed in subjects with type 2 diabetes. 20 men (aged 
50-70, BMI 27-33) with type 2 diabetes, treated with diet or monotherapy were recruited 
for the study. The study was a double-blinded crossover design, randomised to gliclazide 
(80 mg twice a day) or metformin (500 mg once a day) for 10 weeks with a 6 week 
washout period. Subjects were treated with gliclazide in order to try to match glycaemic 
control at the end of each treatment phase. The clinical and metabolic parameters of test 
subjects after each treatment phase are shown below (Table 5.1). There was no significant 
difference in BMI, total serum adiponectin concentration, total cholesterol concentration, 
HDL cholesterol concentration or triglyceride concentration after each phase of therapy. 
However, gliclazide therapy was more effective at lowering HbA1c than metformin (7.8 
+/- 1.73 % versus 8.3 +/- 1.7 %, p < 0.001). This was complemented by significantly lower 
fasting blood glucose with gliclazide versus metformin therapy (10.3 +/- 3.2 mM versus 
12.1 +/- 4.7 mM). Furthermore LDL cholesterol concentration was significantly lower 
after gliclazide therapy compared with metformin therapy (2.42 +/- 0.74 mM versus 2.79 
+/- 0.74 mM, p = 0.022).  
 Metformin 
mean (SD) 
Gliclazide 
mean (SD) 
p-value 
BMI (Kg/m2) 31.0 (4.3) 31.0 (4.5) 0.80 
Adiponectin (ng/ml) 4193 (2670) 4648 (3291) 0.054 
HbA1c (%) 8.34 (1.70) 7.82 (1.74) <0.001 
Fasting blood glucose (mM) 12.1 (4.7) 10.3 (3.2) 0.005 
Insulin (U/L) 15.6 (13.8) 14.3 (6.0) 0.69 
Cholesterol (mM) 5.16 (1.16) 4.75 (1.59) 0.054 
HDL-C (mM) 1.25 (0.24) 1.20 (0.24) 0.13 
LDL-C (mM) 2.79 (0.74) 2.42 (0.73) 0.022 
Triglycerides (mM) 2.78 (3.76) 2.94 (4.80) 0.58 
Table  5-1: Clinical and metabolic parameters of test subjects 
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As shown in figure 5.8, metformin did not alter AMPK expression levels, but did cause an 
approximate 2 fold significant (p < 0.01) increase in AMPK activity in adipose tissue in 
type 2 diabetic subjects. 
 
 
Figure  5-8: Effect of prolonged treatment of type 2 diabetic subjects with metformin on 
AMPK activity and expression in human adipose tissue. 
Total AMPK was immunoprecipitated from the adipose biopsies (100 µg) with a mixture of anti- 
AMPK α1 and α2 antibodies and assayed for AMPK activity. (A) AMPK activity in each experiment 
was standardized against the activity of purified rat liver AMPK kinase (K). Data shown represents 
the mean +/- 95% confidence intervals of the mean, of 20 subjects, each treated for 10 weeks with 
gliclazide (80 mg) and 10 weeks with metformin (500 mg), *p < 0.01. The values given for the 
means and 95% confidence intervals were calculated using logarithmic transformed data, and back 
transformed for purposes of presentation. Adipose tissue (80 µg) was resolved on 10% SDS-
PAGE, transferred to nitrocellulose and probed with anti-Pan AMPKα antibody. (B) Quantification of 
AMPK expression. Data shown represents the mean +/- 95% confidence intervals of the mean, of 
19 subjects, each treated for 10 weeks with gliclazide (80 mg) and 10 weeks with metformin (500 
mg).This work was performed by Dr Jim Boyle (FBLS, University of Glasgow). 
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5.2.2.2 Effect of prolonged treatment of type 2 diabetic subjects with 
metformin on the expression of GAPDH in human adipose tissue 
As the human adipose tissue lysates used in the study described in 5.2.2.1 represent 
sustained activation of AMPK by metformin in vivo, the expression of several key insulin 
signalling molecules was assessed. As shown below in figure 5.9, prolonged treatment of 
type 2 diabetic subjects with metformin did not significantly alter the expression of 
GAPDH in adipose tissue. Thus, GAPDH was used as a loading control in subsequent 
blotting which assessed the expression of the PI3K p85 subunit, PKB, IRS-1 and FAS. 
5.2.2.3 Effect of prolonged treatment of type 2 diabetic subjects with 
metformin on the expression of PI3K in human adipose tissue. 
As shown below in figure 5.10, prolonged treatment of type 2 diabtic subjects with 
metformin did not significantly alter the expression of the PI3K subunit p85 in adipose 
tissue. 
5.2.2.4 Depletion of albumin from human adipose tissue samples. 
Subsequent western blotting of the adipose tissue samples with anti-PKB antibody, anti-
IRS-1 antibody and anti-FAS antibody was problematic, as they produced unclear data 
even after numerous high salt washes. Albumin is an abundant protein in these samples. 
Thus in an attempt to improve the quality of the western blots, an albumin depletion kit 
was used to remove albumin from the adipose tissue samples.  As shown below in figure 
5.11, the kit was efficient at removing most of the albumin (albumin depletion column). 
Elution of the unbound proteins, which included proteins of interest, did cause elution of 
some bound albumin, however the amount of albumin in this elution fraction was an 
improvement compared to the amount in the initial starting material.  
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Figure  5-9: Effect of prolonged treatment of type 2 diabetic subjects with metformin on 
GAPDH expression in human adipose tissue. 
Adipose tissue (80 µg) was resolved on 10% SDS-PAGE, transferred to nitrocellulose and probed 
with anti-GAPDH antibody. (A) Quantification of GAPDH expression, relative to an internal control 
(subject 14). Data shown represents the mean +/- 95% confidence intervals of the mean, of 19 
subjects, each treated for 10 weeks with gliclazide (80 mg) and 10 weeks with metformin (500 mg). 
(C) Representative western blot (subject 13). The position of the molecular weight markers are 
shown to the left of the gel. G = gliclazide, M = metformin.  
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Figure  5-10: Effect of prolonged treatment of type 2 diabetic subjects with metformin on the 
expression of the PI3K p85 subunit in adipose tissue. 
Adipose tissue (80 µg) was resolved on 10% SDS-PAGE, transferred to nitrocellulose and probed 
with anti-PI3K p85 antibody. (A) Quantification of PI3K p85 subunit expression, relative to an 
internal standard (subject 14) and GAPDH. Data shown represents the mean +/- 95% confidence 
intervals of the mean, of 19 subjects, each treated for 10 weeks with gliclazide (80 mg) and 10 
weeks with metformin (500 mg). The values given for the means and 95% confidence intervals 
were calculated using square root transformed data, and back transformed for purposes of 
presentation. (C) Representative western blot (subject 13). The position of the molecular weight 
markers are shown to the left of the gel. G = gliclazide, M = metformin.  
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Figure  5-11: Albumin depletion from adipose tissue sample. 
Equal equivalent volumes from samples obtained at various points throughout the albumin 
depletion process, from one adipose tissue sample (subject 13), were resolved by 10% SDS-
PAGE. Proteins were visualized by Coomassie stain. 
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5.2.2.5 Effect of prolonged treatment of type 2 diabetic subjects with 
metformin on the expression of IRS-1 and PKB in human adipose tissue. 
The albumin depleted samples were then subjected to western blotting to investigate the 
effect of prolonged treatment of type 2 diabetic subjects with metformin on IRS-1 and 
PKB expression in adipose tissue. As shown below in figure 5.12 and 5.13, IRS-1 
expression and PKB expression, respectively, were not significantly altered by metformin.  
5.2.2.6 Effect of prolonged treatment of type 2 diabetic subjects with 
metformin on FAS expression in human adipose tissue. 
As the AMPK assays were performed on adipose biopsies obtained from subjects treated 
with metformin which contain other cells such as endothelial and fibroblasts, it is possible 
that AMPK activation is occuring in another cell type different from that of adipocytes.  
To determine whether AMPK activation was occurring in adipocytes within adipose tissue 
the effect of metformin on the expression of the late adipogenic marker FAS, whose 
expression has previously been shown to be reduced during differentiation of 3T3-L1 
preadipocytes by AMPK activation (Habinowski and Witters 2001), was investigated. As 
shown in figure 5.14 prolonged treatment of type 2 diabetic subjects with metformin did 
not appear to significantly alter the expression of FAS in adipose.  
The expression of the transcription factors C/EBPα and PPARγ have also previously been 
shown to be reduced by AMPK activation during differentiation of 3T3-L1 preadipocytes 
(Habinowski and Witters 2001, Giri et al 2006, Tong et al 2008) and in fully differentiated 
3T3-F442A adipocytes (Dagon et al 2006). In addition AMPK activation in muscle has 
been shown to increase the expression level of GLUT4 (Holmes et al 1999). Thus the 
effect of metformin on the expression of C/EBPα, PPARγ and GLUT4 were also 
investigated. Unfortunately it was not possible to reliably determine expression by western 
blotting (data not shown). 
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Figure  5-12: Effect of prolonged treatment of type 2 diabetic subjects with metformin on the 
expression of IRS-1 in adipose tissue. 
Albumin depleted adipose tissue (80 µg) was resolved on 10% SDS-PAGE, transferred to 
nitrocellulose and probed with anti-IRS-1 antibody. (A) Quantification of IRS-1 expression, relative 
to an internal standard (subject 14) and GAPDH. Data shown represents the mean +/- 95% 
confidence intervals of the mean, of 19 subjects, each treated for 10 weeks with gliclazide (80 mg) 
and 10 weeks with metformin (500 mg). (B) Representative western blot (subject 9). The position of 
the molecular weight markers are shown to the left of the gel. G = gliclazide, M = metformin.  
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Figure  5-13: Effect of prolonged treatment of type 2 diabetic subjects with metformin on the 
expression of PKB in adipose tissue. 
Albumin depleted adipose tissue (80 µg) was resolved on 10% SDS-PAGE, transferred to 
nitrocellulose and probed with anti-PKB antibody. (A) Quantification of PKB expression, relative to 
an internal standard (subject 14) and GAPDH. Data shown represents the mean +/- 95% 
confidence intervals of the mean, of 19 subjects, each treated for 10 weeks with gliclazide (80 mg) 
and 10 weeks with metformin (500 mg). The values given for the means and 95% confidence 
intervals were calculated using logarithmic transformed data, and back transformed for purposes of 
presentation. (B) Representative western blot (subject 13). The position of the molecular weight 
markers are shown to the left of the gel. G = gliclazide, M = metformin.  
 
 
 
 
 
Pamela Jane Logan, 2009   Chapter 5, 188 
 
 
 
Figure  5-14: Effect of prolonged treatment of type 2 diabetic subjects with metformin on the 
expression of FAS in adipose tissue. 
Albumin depleted adipose tissue (80 µg) was resolved on 10% SDS-PAGE, transferred to 
nitrocellulose and probed with anti-FAS antibody. (A) Quantification of FAS expression, relative to 
an internal standard (subject 14) and GAPDH. Data shown represents the mean +/- 95% 
confidence intervals of the mean, of 13 subjects, each treated for 10 weeks with gliclazide (80 mg) 
and 10 weeks with metformin (500 mg). The values given for the means and 95% confidence 
intervals were calculated using logarithmic transformed data, and back transformed for purposes of 
presentation. (B) Representative western blot (subject 13). The position of the molecular weight 
markers are shown to the left of the gel. G = gliclazide, M = metformin. 
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5.3 Discussion 
The principal findings of this study are that prolonged treatment of 3T3-L1 adipocytes with 
AICAR, but not metformin, increased AMPK Thr172 phosphorylation and inhibited 
insulin-stimulated glucose transport. Inhibition of insulin-stimulated glucose transport by 
AICAR in 3T3-L1 adipocytes was not associated with altered PKB protein expression or 
insulin-stimulated PKB Ser473 phosphorylation. Chronic AMPK activation in adipose 
tissue was observed in metformin treated type 2 diabetic subjects, and was not associated 
with altered expression of three key insulin signalling molecules; PKB, the PI3K p85 
subunit and IRS-1.  
Incubation of 3T3-L1 adipocytes with AICAR for 24 hr and 48 hr was shown to 
significantly (p < 0.05) increase AMPK Thr172 phosphorylation in insulin-stimulated cells 
(Fig. 5.1), and significantly (p < 0.05) inhibit insulin-stimulated glucose transport (Fig. 
5.3). Total AMPK expression was not altered in 3T3-L1 adipocytes incubated with AICAR 
for 24 hr and 48 hr (Fig. 5.1), suggesting that it is the specific activity of AMPK that is 
increasing rather than an increase in AMPK protein expression. However it should be 
noted that only AMPK α1 protein expression levels were assessed. Thus, it is possible that 
incubation of 3T3-L1 adipocytes with AICAR for 24 hr and 48 hr may increase AMPK α2 
protein expression which could account for the increase in AMPK Thr172 
phosphorylation. In addition, this study also found that incubation of 3T3-L1 adipocytes 
with AICAR for 24 hr and 48 hr displayed a significant increase in phosphorylation of the 
AMPK downstream target ACC at Ser79 in insulin-stimulated cells (Fig. 5.1). Habinowski 
and Witters, previously showed that prolonged AMPK activation by AICAR during 
differentiation of 3T3-L1 preadipocytes decreased the expression level of ACC 
(Habinowski and Witters 2001). However, in contrast this current study found that 
prolonged treatment of 3T3-L1 adipocytes with AICAR did not significantly alter ACC1 
expression (Fig. 5.1). Thus, perhaps the effect of AICAR on ACC expression differs 
between fibroblasts and fully differentiated adipocytes. In addition to assessing ACC1 
protein expression it would have been interesting to have also investigated the effect of 
AICAR on ACC2 protein expression, as it is possible that the effect of AICAR on ACC 
expression observed by Habinowski and Witters was ACC2 specific. 
In contrast, incubation of 3T3-L1 adipocytes with metformin for 24 hr and 48 hr did not 
significantly alter AMPK Thr172 phosphorylation (Fig. 5.2), nor alter insulin-stimulated 
glucose transport (Fig. 5.4). It should be noted that this work is in contrast to a previous 
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study (Huypens et al 2005) which showed that treatment of 3T3-L1 adipocytes with 1mM 
metformin for 48 hr did not alter AMPK protein expression levels, but did increase AMPK 
Thr172 phosphorylation. Since this current study found that treatment of 3T3-L1 
adipocytes with metformin for 24 hr and 48 hr did not significantly alter AMPK Thr172 
phosphorylation, it was not surprising that phosphorylation of the AMPK downstream 
target ACC at Ser 79 was also not found to be significantly altered (Fig. 5.2). In addition, 
ACC1 protein expression was also found not to be significantly altered (Fig. 5.2).  
In hepatocytes and intestinal cells metformin is transported into the cell by the organic 
cation transporter1 (OCT1) (McKinney and Hosford 1992, Wang et al 2002). However, 
there was no detectable level of OCT1 mRNA expression in 3T3-L1 adipocytes (Helen M 
McLeod, University of Glasgow personal communication). However, as mentioned 
previously, Huypens and co-workers (Huypens et al 2005) have suggested that metformin 
may be taken up into 3T3-L1 adipocytes via another transporter or by diffusion, although 
this does not appear to be the case in this current study.  
A preliminary experiment showed that in Ad.α1312 infected cells there appeared to be a 
reduction in insulin-stimulated glucose transport compared to Ad.null infected cells (Fig. 
5.5). This suggests that prolonged AMPK activation in 3T3-L1 adipocytes does indeed 
inhibit insulin-stimulated glucose transport. However, it is important to stress that this was 
a preliminary experiment (n=1), thus further repetitions are required in order to confirm 
this observation.  
Collectively, these results suggest that prolonged AMPK activation in adipocytes inhibits 
insulin-stimulated glucose transport. This is in stark contrast to the effect of chronic 
AMPK activation by AICAR in skeletal muscle. Long-term activation of AMPK with 
AICAR increases glycogen content, hexokinase activity, and total GLUT4 protein content 
in rat skeletal muscle (Holmes et al 1999, Ojuka et al 2000). In addition, long term 
treatment of rats with AICAR was shown to induce a pronounced increase in insulin-
stimulated glucose uptake and GLUT4 cell surface content in rat skeletal muscle (Buhl et 
al 2001).  
This current work showed that long-term AMPK activation by AICAR in 3T3-L1 
adipocytes did not alter PKB protein expression levels, nor alter insulin-stimulated PKB 
phosphorylation at Ser473 (Fig. 5.6). However, it is highly possible that prolonged AMPK 
activation in 3T3-L1 adipocytes may inhibit insulin-stimulated glucose transport by 
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altering the expression level of other key insulin-signalling molecules, as prolonged 
AMPK activation has previously been demonstrated to alter protein expression. Activation 
of AMPK by AICAR during differentiation of 3T3-L1 preadipocytes has been shown to 
reduce the expression of the early adipogenic transcription factors C/EBPα, C/EBPβ and 
PPARγ (Habinowski and Witters 2001, Giri et al 2006, Tong et al 2008), and the late 
adipogenic markers FAS and ACC (Habinowski and Witters 2001). Incubation of rat 
hepatocytes with AICAR was also found to inhibit glucose activated FAS gene expression 
(Foretz et al 1998). In addition the expression of the genes for the gluconeogenic enzyme 
phosphoenolpyruvate carboxy kinase and glucose-6-phosphatase were also shown to be 
reduced in hepatoma cells by activating AMPK using AICAR (Lochhead et al 2000). In 
muscle, AMPK activation by AICAR, was shown to increase both GLUT4 and hexokinase 
gene transcription (Holmes et al 1999, Zheng et al 2001, Ojuka et al 2000). AMPK has 
been proposed to regulate gene expression by directly phosphorylating certain transcription 
factors and co-activators including; p53, p300, TRIP6, and TORC2 (Leff 2003, Imamura et 
al 2001, Solaz-Fuster et al 2006, Shaw et al 2005). 
The biguanide metformin, used in the treatment of type 2 diabetes, works primarily by 
reducing hepatic glucose release from hepatic glycogen stores (Kirpichnikov et al 2002). 
Metformin is thought to mediate its effects on hepatic glucose production via AMPK 
activation in cultured primary rat and human hepatocytes (Zhou et al 2001). This AMPK 
dependent mechanism has been further investigated and recent work suggests that 
metformin increases the expression of the nuclear receptor gene, SHP, via AMPK 
activation and that this in turn inhibits the expression of the hepatic gluconeogenic genes 
PEPCK and G6Pase (Kim et al 2008). Metformin has also been shown to increase AMPK 
activity in human muscle of subjects with Type 2 diabetes (Musi et al 2002). Furthermore 
this metformin-induced increase in AMPK activity in muscle is associated with higher 
rates of glucose disposal (Musi et al 2002). Prolonged treatment of 3T3-L1 adipocytes with 
metformin has previously been reported to stimulate AMPK activity (Huypens et al 2005), 
in contrast to the data presented here, yet metformin increases adipose AMPK activity in 
vivo in adipose tissue of subjects with type 2 diabetes compared with gliclazide (Fig. 5.8). 
The increase in adipose AMPK activity was not associated with an increase in AMPK 
protein expression. This suggests that the change in AMPK activity is due to an increase in 
the specific activity of AMPK rather than simply a difference in the total amount of AMPK 
between phases. The study design aimed to match glycaemic control at the end of each 
phase but this, in the event, proved not to be possible. Metformin increased AMPK activity 
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when compared to gliclazide despite better glycaemic control with the latter, supporting a 
glucose-independent mechanism for this metformin effect. 
Prolonged AMPK activation in vivo in adipose tissue could occur under other conditions. 
The β adrenoreceptor agonists isoproterenol and adrenaline have both previously been 
shown to stimulate acute AMPK activity in adipocytes (Moule and Denton 1998, Yin et al 
2003, Koh et al 2007). Thus it is feasible that sustained isoproterenol or adrenaline levels 
could result in prolonged AMPK activation in vivo in human adipose tissue. Leptin (Orci et 
al 2004) has been shown to acutely activate AMPK in adipose tissue. Given that leptin 
secretion increases with adipose tissue mass (Maffei et al 1995), it is possible that 
prolonged AMPK activation may occur in vivo in adipose tissue in obese individuals. 
Hypoxia/ischaemia has previously been shown to stimulate AMPK activity (Marsin et al 
2000, Kudo et al 1995) in rat hearts. Thus, sustained ischemia in vivo in adipose tissue may 
also cause prolonged AMPK activation given that it is well established that adipose tissue 
is highly susceptible to ischemia (Kovach et al 1976, Coban et al 2005).   
The TZD’s are another class of drugs used in the treatment of type 2 diabetes. They 
stimulate PPARγ mediated adipocyte differentiation and increase the number of small 
adipocytes (Okuno et al 1998). This is associated with reduced serum NEFAs and reduced 
TNFα expression, which increases insulin sensitivity in liver and skeletal muscle (Quinn et 
al 2008). In addition, TZDs can also elevate levels of adiponectin. This is achieved in part 
via the generation of the small adipocytes which abundantly express and secrete 
adiponectin (Yamauchi et al 2001) and by the up-regulation of adiponectin via direct 
effects of TZDs on adiponectin gene transcription (Iwaki et al 2003). Adiponectin has 
previously been demonstrated to activate AMPK in muscle, liver and adipocytes 
(Yamauchi et al 2002, Wu et al 2003). In addition, Yamauchi and co-workers have shown 
that adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-
activated protein kinase in liver and muscle (Yamauchi et al 2002). Thus TZDs are able to 
activate AMPK indirectly via adiponectin. In addition, the TZD, rosiglitazone has been 
shown to stimulate AMPK activity after 30 min in H-2Kb muscle cells suggesting an 
adiponectin independent effect (Fryer et al 2002b). Saha and co-workers showed that 
prolonged treatment of rats with pioglitazone increased the activity of AMPK in rat 
adipose and liver tissue, however, it is unclear whether it does so by a direct effect and/or 
by increasing plasma levels of adiponectin (Saha et al 2004). Therefore rosiglitazone may 
directly or indirectly, via adiponectin, cause sustained AMPK activation in vivo in human 
adipose tissue. 
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Metformin has also been shown to reduce the expression of various genes involved in the 
endocrine system in adipocytes; i.e inhibition of resistin (Rea and Donnelly 2006) leptin 
(Klein et al 2004) and adiponectin (Huypens et al 2005). The study by Huypens and co-
workers is one of the few that effectively links metformin’s suppression of gene expression 
with AMPK activation. In this current study the effect of chronic AMPK activation by 
metformin on the expression of key insulin signalling molecules in the human adipose 
biopsies was investigated. In summary, this study found that chronic AMPK activation by 
metformin in human adipose tissue did not appear to significantly alter the expression of 
IRS-1 (Fig. 5.12), the PI3K p85 subunit (Fig. 5.10) and PKB (Fig. 5.13). However, it still 
remains to be determined whether metformin alters the insulin sensitivity of these 
molecules in adipose tissue of type 2 diabetic subjects. 
It should be noted that potentially metformin may not be having a direct effect on adipose 
tissue in vivo. Perhaps another molecule secreted from the liver, the primary site of 
metformin action, may be activating AMPK in vivo in human adipose tissue. 
Adiponectin is secreted exclusively from adipocytes and has been shown to activate 
AMPK in isolated rat adipocytes (Wu et al 2003). Thus potentially metformin, via a direct 
or indirect effect on adipose tissue, could increase the adiponectin expression level in 
plasma and/or locally in adipose tissue in type 2 diabetic subjects which could 
subsequently result in adiponectin-mediated AMPK activation in adipose tissue. However, 
this seems unlikely since the data (Table 5.1) presented in this study shows that the 
increase in adipose AMPK activity after metformin treatment was not associated with any 
difference in the serum adiponectin level. This is in agreement with other previous studies 
which also found that metformin did not alter serum adiponectin concentration in type 2 
diabetic subjects (Phillips et al 2003, Tiikkainen et al 2004). In addition it has also been 
reported that treatment of type 2 diabetic subjects with metformin does not alter 
adiponectin mRNA concentration in adipose tissue or the adipocyte adiponectin protein 
content (Tiikkainen et al 2004, Phillips et al 2003). However it should also be noted that 
measuring the total serum adiponectin level does not discriminate between adiponectin 
trimeric, hexameric and higher order polymeric structures which all exist in plasma 
(Pajvani et al 2003). The biological activity of adiponectin depends on its structure, with 
different oligomeric complexes activating different pathways. For example only globular 
and trimeric adiponectin were found to activate AMPK in myocytes (Tasao et al 2003, 
Tomas et al 2002). 
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Adipose tissue is constructed of different components including; adipocytes, connective 
tissue matrix, nerve tissue, stromovascular cells and immune cells. Thus potentially 
metformin may not be directly or indirectly activating AMPK in adipocytes within human 
adipose tissue. This current study found that the expression of FAS, whose expression has 
previously been shown to be reduced by AMPK activation during differentiation of 3T3-
L1 preadipocytes (Habinowski and Witters 2001) was not significantly altered (Fig. 5.14) 
in adipose tissue from type 2 diabetic subjects treated with metformin. This suggests that 
metformin, either directly or indirectly, may be stimulating an increase in AMPK activity 
in non-adipocyte cells within adipose tissue. Prolonged AMPK activation by AICAR 
during differentiation of 3T3-L1 preadipocytes has also been reported to block the 
expression of the early adipogenic transcription factors C/EBPα, C/EBPβ and PPARγ, and 
of the late adipogenic marker ACC (Habinowski and Witters 2001, Giri et al 2006, Tong et 
al 2008). In addition, 24 hr AICAR treatment has also been shown to inhibit the expression 
of C/EBPα and PPARγ in fully differentiated 3T3-F442A cells (Dagon et al 2006). 
Therefore it would be useful to determine whether the expression of these adipogenic 
transcription factors and adipogenic markers in metformin treated type 2 diabetic subjects 
is altered in order to establish whether chronic AMPK activation by metformin in type 2 
diabetic subjects activates AMPK in adipocytes within adipose tissue. However it is 
possible that the effect of AMPK activation on the expression of the adipogenic 
transcription factors and adipogenic markers may differ in mature adipocytes. In addition, 
adipocytes could be isolated from the adipose tissue biopsies and AMPK activity assessed. 
However, this would take several hours which may result in any non-genomic effects of 
metformin on the AMPK activity being lost.  
Overall the findings of this study suggest that prolonged AMPK activation in 3T3-L1 
adipocytes inhibits insulin-stimulated glucose transport and that this is not associated with 
altered PKB protein expression or insulin-stimulated PKB Ser473 phosphorylation. This 
study also reported that prolonged treatment of type 2 diabetic subjects with metformin 
increased AMPK activity in adipose tissue and that this was not associated with altered 
expression of three key insulin signalling molecules; PKB, the PI3K subunit p85 and IRS-
1. The very modest effect of acute metformin treatment on AMPK activity in 3T3-L1 
adipocytes, the lack of effect of prolonged metformin treatment on AMPK activity in 3T3-
L1 adipocytes and the lack of effect of metformin on FAS expression in human adipose 
tissue suggests metformin’s effects in adipose may not represent direct effects on the 
adipocytes within that tissue. 
195 
Chapter 6 – Final discussion 
The principal findings of this study were that AMPK activity in 3T3-L1 adipocytes is 
sensitive to multiple stimuli that act via different mechanisms, did not alter substantially 
during adipogenesis and is associated with reduced insulin-stimulated glucose transport. 
AMPK has been proposed to be a therapeutic target for patients with type 2 diabetes and 
the metabolic syndrome due to its beneficial effects on metabolic parameters. In skeletal 
muscle AMPK stimulates glucose uptake and fatty acid oxidation, whereas in liver it 
inhibits gluconeogenesis, fatty acid synthesis and cholesterol synthesis (Hardie 2004a). 
Overall the beneficial metabolic effects of AMPK activation in muscle and liver have been 
well-studied. However, despite the importance of adipose tissue in energy homeostasis the 
potential role of AMPK in the regulation of adipocyte biology was poorly characterised 
prior to this study.   
Work in this current study showed that AMPK can be acutely activated in 3T3-L1 
adipocytes by a variety of different stimuli; sorbitol, AICAR, arsenite, A23187, 
rosiglitazone, metformin, isopreterenol, sodium azide, H2O2, leptin and A769662. The 
mechanism of AMPK activation differs for the different stimuli (Fig. 6.1). AICAR is 
converted into ZMP in the cell which functions as a cellular mimetic of AMP i.e ZMP 
causes allosteric activation of AMPK and protects phosphorylation of Thr172, by the 
constitutively active AMPK kinase LKB1, from dephosphorylation. The novel direct 
AMPK activator A769662 activates AMPK by mimicking the effects of AMP. The 
calcium ionophore A23187 elevates intracellular calcium concentrations, thereby 
stimulating AMPK activity via a CaMKK dependent pathway. AMPK activation by 
isoproterenol, azide and rosiglitazone was not significantly altered in the presence of the 
CaMKK inhibitor STO-609. In addition these stimuli caused a significant increase in the 
ADP/ATP ratio which suggests that these stimuli activate AMPK via an LKB1-dependent 
pathway. Sorbitol, metformin, arsenite, hydrogen peroxide and leptin were found to have 
no significant effect on the nucleotide ratios, and AMPK stimulated activity by these 
activators was not significantly altered in the presence of STO-609. This suggests that 
these stimuli may be activating AMPK via novel AMPK kinases which are both nucleotide 
and calcium independent. One potential candidate is TAK1, which has recently been 
identified as a possible novel AMPK kinase in mammalian cells (Momcilovic et al 2006), 
however there may also exist other currently unidentified AMPK kinases. 
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Previous work by Salt and co-workers reported that stimulation of AMPK is associated 
with reduced insulin-stimulated glucose transport in 3T3-L1 adipocytes (Salt et al 2000), 
which is in contrast to the effect in muscle.  
Acute stimulation of AMPK activity by sorbitol, rosiglitazone, isoproterenol, AICAR and 
A769662 in 3T3-L1 adipocytes significantly (p < 0.05) inhibited insulin-stimulated 
glucose transport. Although AICAR still displayed a tendency to inhibit insulin-stimulated 
glucose transport in Ad.α1DN infected cells, in the presence of the most effective AMPK 
inhibitor available, compound C, the inhibitory effect of AICAR on insulin-stimulated 
glucose transport was no longer apparent. Taken together these results provide strong 
evidence that acute AMPK activation does inhibit insulin-stimulated glucose transport. 
Results from this current study also showed that AMPK activation does not impair insulin-
stimulated phosphorylation of AS160 or TBC1D1 at PAS sites. Thus, the molecular 
mechanism by which AMPK elicits the inhibition of insulin-stimulated glucose uptake still 
remains to be determined, but may potentially occur at a site downstream of 
AS160/TBC1D1 in the insulin signalling cascade. These findings are summarized below 
(Fig. 6.1). 
 
Figure  6-1: Proposed mechanism of acute AMPK activation and subsequent inhibition of 
insulin-stimulated glucose transport in 3T3-L1 adipocytes. 
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This current work also investigated the long-term effects of AMPK activation on insulin-
stimulated glucose transport. Prolonged treatment of 3T3-L1 adipocytes with AICAR was 
found to activate AMPK activity and dramatically inhibit insulin-stimulated glucose 
transport. In addition a preliminary experiment showed that infection of 3T3-L1 adipocytes 
with Ad.α1312 also inhibited insulin-stimulated glucose transport. Collectively, these results 
suggest that prolonged AMPK activation also inhibits-insulin-stimulated glucose transport 
in 3T3-L1 adipocytes. The mechanism of inhibition of insulin-stimulated glucose transport 
by prolonged AMPK activation in adipocytes was also investigated in this current study. 
However prolonged treatment of 3T3-L1 adipocytes was not associated with altered PKB 
expression or insulin-stimulated PKB phosphorylation. Furthermore chronic AMPK 
activation by metformin in adipose tissue of type 2 diabetic subjects was not associated 
with altered expression of three key insulin signalling molecules; PKB, the PI3K p85 
subunit and IRS-1.  
Overall this study suggests that both acute and prolonged AMPK activation in adipocytes 
inhibits insulin-stimulated glucose uptake. As discussed (1.1.2) glucose is taken up into 
adipocytes in the fed state and is stored as TG. Therefore inhibition of glucose uptake into 
adipocytes would subsequently reduce fatty acid and TG synthesis. The synthesis of fatty 
acids and TG from glucose is an energy dependent process. Thus, it could be reasoned that 
AMPK activation inhibits insulin-stimulated glucose uptake in adipocytes in order to 
reduce the ATP-dependent synthesis of fatty acids and TG in adipocytes. Furthermore, the 
inhibition of glucose transport would allow glucose to be used as an energy source by other 
tissues, rather than adipocytes, which would start using the stored triglyceride. 
Although this current work reported that there was no change in total AMPK activity, as 
determined under a saturating AMP concentration (200µМ), between fibroblasts and 
adipocytes throughout adipogenesis, there was an observed change in the expression levels 
of the γ subunit isoforms throughout adipogenesis i.e there was an increase in the γ1 
isoform expression level and a reduction in the expression level of the γ2 and γ3 isoforms. 
Previous studies using native rat complexes and recombinant AMPK heterotrimeric 
complexes (Cheung et al 2000, Scott et al 2004) reported that different γ isoform 
complexes differed in their degree of stimulation by AMP i.e γ2 displayed the greatest 
stimulation by AMP, while γ1 displayed an intermediate stimulation by AMP and γ3 the 
lowest stimulation by AMP. Since the expression level of the different γ isoforms is altered 
during adipogenesis it would be interesting to investigate the sensitivity of AMPK 
complexes immunoprecipitated from fibroblasts and adipocytes to AMP, as it is possible 
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that during adipogenesis the sensitivity of adipocytes to energy balance changes may be 
altered.  
Currently the mechanism by which AMPK activation in 3T3-L1 adipocytes inhibits 
insulin-stimulated glucose transport remains to be elucidated. This current work reported 
that AMPK activation did not impair insulin-stimulated phosphorylation of 
AS160/TBC1D1 at PAS sites. AS160 contains six potential PKB phosphorylation sites 
(Ser318, Ser341, Ser570, Ser588, Thr642, Ser751) (Sano et al 2003), and TBC1D1 
contains two potential PKB phosphorylation sites (Thr596 and Ser507) (Roach et al 2007). 
The anti-PAS antibody only gives a measure of total phosphorylated AS160/TBC1D. Thus 
although the total PAS phosphorylation is unaltered, the actual extent of phosphorylation at 
each PAS site may be altered, with consequent effects on AS160/TBC1D1 activity. Since 
AMPK (*(Xβ)XX(S/T)XXX*); *= Met, Val, Leu, Ile, or Phe, and β = Arg, Lys, or His) 
(Dale et al 1995) and PKB (RXRXX(S/T) (Yaffe et al 2001) have subtly different substrate 
specificities it is feasible that AICAR would preferentially cause phosphorylation of some 
PAS sites, and insulin (via PKB) of different ones. This could result in a different 
phosphorylation pattern on AS160/TBC1D1 with the same phosphorylation stoichiometry. 
It is not known precisely which PAS sites are important for regulating activity in vivo, thus 
it is possible that AICAR/PKB may cause phosphorylation at different PAS sites with 
corresponding changes in AS160/TBC1D1 activity, without altering total AS160/TBC1D1 
PAS phosphorylation. 
In HEK 293 cells the anti-PAS antibody was found to primarily detect phospho-Thr642 on 
AS160 (Geraghty et al 2007). Thus potentially AMPK may be altering insulin-stimulated 
AS160/TBC1D1 phosphorylation at PAS sites which may not be primarily recognized by 
the anti-PAS antibody in 3T3-L1 adipocytes. 
In addition activation of AMPK in 3T3-L1 adipocytes may result in phosphorylation of 
AS160/TBC1D1 at non-PAS sites which may subsequently alter the activity of 
AS160/TBC1D1. Since the AMPK phosphorylation sites on AS160 lie within the PAS 
sites, and are thus detected by the PAS antibody, it is more likely that AMPK activation 
may result in the subsequent activation of a downstream kinase which may then 
phosphorylate AS160 at non-PAS sites, rather than AMPK directly phosphorylating 
AS160 at non-PAS sites. Thr568 and Ser666 have previously been identified as 
phosphorylation sites on AS160 which do not lie within a PKB consensus phosphorylation 
motif, and have been shown to be phosphorylated by RSK1 and SGK1 in vivo in HEK 
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cells (Geraghty et al 2007). Thus it is feasible that AMPK activation in adipocytes may 
result in activation of downstream kinases which may subsequently phosphorylate 
Thr568/Ser666 or novel sites on AS160. 
Ser237, which lies within an AMPK consensus phosphorylation motif on TBC1D1, has 
been shown to be phosphorylated in response to treatments that elevate levels of active and 
phosphorylated AMPK in HEK 293 cells and rat L6 myotubes (Chen et al 2008). As 
previously mentioned overexpression of TBC1D1 was shown to markedly inhibit insulin-
stimulated GLUT4 translocation in 3T3-L1 adipocytes (Roach et al 2007). Furthermore, 
this inhibition was reported to be partially reversed by AICAR (Chavez et al 2008). 
Interestingly, phosphorylation at Ser237 did not appear to underlie the effect of AICAR to 
relieve in part TBC1D1 inhibition of the insulin-stimulated increase in cell surface GLUT4 
in 3T3-L1 adipocytes (Chavez et al 2008). In addition to Ser237, human TBC1D1 contains 
three other Ser/Thr residues that conform to the AMPK consensus phosphorylation 
sequence at amino acid residues 69, 372, and 565 (Chavez et al 2008). Thus in 3T3-L1 
adipocytes it is possible that AMPK may phosphorylate TBC1D1 at non-PAS sites, which 
may subsequently alter the activity of TBC1D1. 
Mass spectrometer analysis of TBC1D1 isolated from HEK 293 cells incubated in medium 
containing serum also identified Ser263, Ser566 and Ser585 as phosphorylation sites on 
TBC1D1 (Chen et al 2008). Thus, as discussed with regards to AS160, AMPK activation 
in 3T3-L1 adipocytes may result in the activation of downstream kinases which may 
subsequently phosphorylate TBC1D1 at non-PAS sites and alter its activity. 
Although antibodies against specific phosphorylation sites could be used to further 
investigate the effect of AMPK activation on AS160/TBC1D1 phosphorylation, it is 
currently not possible to directly assess endogenous AS160/TBC1D1 Rab-GAP activity or 
Rab activation in adipocytes. 
It is also possible that AICAR inhibits insulin-stimulated glucose transport at a site 
downstream of AS160/TBC1D1. It has been established that the SNARE complex 
VAMP2/SNAP23/syntaxin4 is involved in insulin-stimulated GLUT4 translocation to the 
plasma membrane (Bryant et al 2002). In addition, the accessory proteins, munc18c, synip 
and tomosyn, have also been proposed to regulate SNARE complex assembly and GLUT4 
translocation (Kanda et al 2005, Widberg et al 2003, Yamada et al 2005). 
Pamela Jane Logan, 2009   Chapter 6, 200 
Since the known molecular machinery (VAMP2/SNAP23/syntaxin4, munc18c, synip, 
tomosyn) that regulates GLUT4 exocytosis, downstream of AS160/TBC1D1, is common 
to muscle and adipocytes (Foster and Klip 2000, Randhawa et al 2000, Olson et al 1997, 
Widberg et al 2003, Yang et al 2001, Kanda et al 2005, Spurlin et al 2003, Yamada et al 
2005, Min et al 1999), it is possible that the inhibition of insulin-stimulated glucose 
transport by AMPK activation in adipocytes is mediated by an effector specific to 
adipocytes that is absent or not functioning in muscle. 
Thus the aim of future experiments would be to determine the molecular mechanism by 
which AMPK suppresses insulin-stimulated glucose transport in adipocytes. There a few 
potential mechanisms by which AMPK may be mediating inhibition of insulin-stimulated 
glucose transport in adipocytes; 1. AMPK may alter the subcellular location of key 
components of the insulin-stimulated GLUT4 trafficking pathway, subsequently altering 
their function, 2. AMPK may phosphorylate a currently unidentified protein which may 
inhibit insulin-stimulated glucose transport at a site downstream of AS160/TBC1D1, 3. 
AMPK may increase the rate at which GLUT4 is trafficked from the plasma membrane 
into intracellular storage vesicles, thus effectively reducing the amount of GLUT4 at the 
plasma membrane under insulin-stimulated conditions, 4. AMPK could potentially be 
altering the Cbl-TC10 pathway which is required for insulin-stimulated glucose transport. 
In order to determine the effect of AMPK activation on the subcellular localization of key 
insulin-signalling molecules, cell lysates obtained from 3T3-L1 adipocytes incubated in the 
presence or absence of insulin and AMPK activators, could be subjected to subcellular 
fractionation. Proteins from the cytosolic, plasma membrane and microsomal fractions 
could then be subjected to immunoblotting with specific antibodies to insulin signalling 
and GLUT4 trafficking proteins.  
In order to try to identify the AMPK effector proteins that inhibit insulin-stimulated 
glucose transport, 3T3-L1 adipocytes would be labelled with 33PO43- and incubated in the 
presence or absence of insulin and AMPK activators.  Incorporation of 33PO43- into any 
proteins in the presence of AMPK activators could be detected by autoradiography, with 
target protein bands being subsequently excised and identified by sequencing. The effect of 
knockdown of the potential AMPK effector proteins in 3T3-L1 adipocytes, using siRNA, 
on AMPK mediated inhibition of insulin-stimulated glucose transport would help identify 
the AMPK effector mediating inhibition of insulin-stimulated glucose transport.  
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In the absence of insulin, GLUT4 is sequestered away from the cell surface plasma 
membrane, and stored in GLUT4 storage vesicles, available for rapid mobilisation upon 
insulin binding (Bryant et al 2002). To determine whether AMPK activation in 3T3-L1 
adipocytes accelerates internalization and sequestration of GLUT4 from the plasma 
membrane under insulin-stimulated conditions, the rate of reversal of insulin-stimulated 
glucose transport could be determined by washing away insulin, as previously described 
(Proctor et al 2006), in the presence and absence of AMPK activators. If a change in 
trafficking was observed, 3T3-L1 adipocytes transfected with a GLUT4 tagged with an HA 
on the extracellular loop (HA-GLUT4) could be utilized to permit the precise 
determination of GLUT4 internalisation under basal and insulin-stimulated conditions.  
The Cbl-TC10 pathway is a parallel insulin-signalling pathway which has been reported to 
contribute to GLUT4 translocation. Insulin-stimulated phosphorylation of Cbl activates the 
small GTP-binding protein TC10, which functions to stimulate trafficking of GLUT4 
vesicles due to actin rearrangement (Saltiel and Pessin 2002). To determine the effect of 
AMPK activation on the Cbl-TC10 pathway, Cbl phosphorylation could be assessed by 
western blotting using phospho-specific antibodies in lysates obtained from 3T3-L1 
adipopcytes incubated in the presence or absence of insulin and AMPK activators. In 
addition, analysis of TC10 activity (GTP-loading) could also be determined in cell lysates. 
Impaired insulin-stimulated glucose transport in muscle and adipose contributes to 
hyperglycaemia in patients with diabetes. Thus elucidation of the molecular mechanisms 
which mediate the regulation of insulin-stimulated glucose transport in adipocytes, may 
uncover potential novel therapeutic targets, which may lead to the development of novel 
therapies for treating type 2 diabetes. 
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